Company Code: 688271 Company Abbreviation: United Imaging Healthcare

Shanghai United Imaging Healthcare Co., Ltd.
2025 Half-year Report Summary

Section I Management Discussion and Analysis

I Description of the company's industry and main business during the reporting period

(I) Overview of the company's main business

United Imaging Healthcare is committed to providing global clients with high-performance medical imaging equipment, radiation therapy products, and life science instruments. The company is headquartered in Shanghai, with regional headquarters and R&D centers established in the United States, the Netherlands, the UAE, Malaysia, Colombia, and other locations. It has also set up production capacity in Shanghai, Changzhou, Wuhan, and Houston, USA, forming a global R&D, production, and service network.

Since its establishment, the company has consistently invested heavily in R&D, committed to overcoming core technologies in the field of large-scale medical equipment such as medical imaging devices and radiotherapy products. After years of effort, the company has established a comprehensive product line layout, including medical imaging devices, radiotherapy products, and life science instruments. As of the end of the reporting period, the company had launched over 140 products to the market, including magnetic resonance imaging systems (MR), X-ray computed tomography systems (CT), X-ray imaging systems (XR), molecular imaging systems (PET/CT, PET/MR), medical linear accelerator systems (RT), and life science instruments.

During the reporting period, the company achieved steady growth in its operating performance, with operating revenue reaching 6.02 billion CNY, a year-on-year increase of 12.79%. Net profit attributable to shareholders of the parent company was 998 million CNY, up 5.03% year-on-year, while net profit attributable to ordinary shareholders of the Company after deducting non-recurring profit or loss was 966 million CNY, a 21.01% increase year-on-year, reflecting continuous improvement in profitability. The company persistently made breakthroughs in core technologies, continuously introduces innovative products, establishes a solid customer base, consistently strengthens brand recognition, and earning a strong market reputation.

(II) Industry Overview

a) The development stage, fundamental characteristics, main technical barriers, and changes in the industry

According to the *Industrial Classification for National Economic Activities* (GB_T4754-2017) issued by the National Bureau of Statistics, the industry in which the company operates falls under the 35th major category "Special Purpose Equipment Manufacturing (Classification Code C35)" within "Medical Equipment and Instrument Manufacturing (Classification Code C358)" and specifically under "Medical Diagnostic, Monitoring, and Treatment Equipment Manufacturing (Classification Code C3581)."

(1) Development Stage

Global aging, the increase in chronic diseases, and rising healthcare expenditures have led to the expansion of the global medical device market, while global public health emergencies have accelerated this market growth. According to data from CIC, the global medical device market size exceeded $480 billion USD in 2021 and is projected to reach $848 billion USD by 2030, with a compound annual growth rate (CAGR) of 6.4% from 2021 to 2030, indicating stable growth potential in the global market.

Compared to the global medical device market, China's medical device market has developed relatively more rapidly. Due to constraints in the level of productivity development, China's medical device industry started relatively late. However, driven by factors such as the improvement of living standards, an aging

population, China's medical device market has grown rapidly. From 2015 to 2020, the market size of China's medical device industry grew from 312.55 billion CNY to 778.93 billion CNY, with a compound annual growth rate of approximately 20%. In the future, with increasing market demand and industrial upgrades driven by technological advancements in the medical device sector, the industry is expected to maintain rapid growth. It will also transition from mid-to-low-end products to high-end import substitutions. By 2030, the market size of medical devices is projected to reach 2,492.40 billion CNY, with a compound annual growth rate of 11.9% from 2021 to 2030.

Based on different functions and roles, medical devices can be categorized into medical imaging equipment, surgical-related equipment, in-vitro diagnostic equipment, and others. Medical imaging equipment refers to devices that utilize various physical signals such as visible light, X-rays, ultrasound, and strong magnetic fields to record the distribution of signal feedback from the human body, forming images that enable doctors to interpret anatomical structures and pathological information for diagnostic or treatment guidance purposes. Based on their purposes, medical imaging equipment can be categorized into diagnostic imaging devices and therapeutic imaging devices. Diagnostic imaging devices are further divided by signal type into magnetic resonance imaging (MR) devices, X-ray computed tomography (CT) devices, X-ray imaging (XR) devices, molecular imaging (MI) devices, and ultrasound (US) devices. Therapeutic imaging devices primarily include digital subtraction angiography (DSA) devices and directional radiation equipment (such as orthopedic C-arms).

Medical imaging equipment represents the segment with the highest technological barriers in the medical device industry. With China's rapid economic growth, the increasing aging population, and rising public health awareness, the demand for healthcare services continues to rise, leading to a corresponding rapid growth in the domestic market's need for high-quality medical imaging. Driven by market demand, China's medical imaging equipment market will continue to grow. The market size reached 53.70 billion CNY in 2020 and is expected to approach 110.00 billion CNY by 2030, with an estimated compound annual growth rate of 7.30%.

(2) Basic Characteristics

The high-end medical equipment industry is a high-tech sector characterized by interdisciplinary integration, talent intensity, knowledge intensity, and innovation intensity. Compared to the global market, China's medical imaging equipment industry has long been characterized by low industry concentration, relatively small company sizes, and a low market share of domestic products in the mid-to-high-end segments. In recent years, with the overall advancement in R&D capabilities of domestic medical equipment, core technologies have been gradually mastered, and product quality and reputation have risen. Some domestic companies have achieved leapfrogging through technological innovation, reshaping the market landscape long monopolized by multinational enterprises (MNEs). The domestic medical imaging equipment industry is progressively advancing toward parity with leading international brands.

(3) Key Technical Barriers

The R&D of high-end medical devices faces extremely high technical barriers, as it is a multidisciplinary, knowledge-intensive, and innovation-intensive industry. The development of a single device often involves numerous fields such as biomedical engineering, mechanical engineering, algorithms, electronic information, materials science, and medical imaging technology, resulting in high R&D thresholds and lengthy development cycles.

The main technical barriers in the field of magnetic resonance imaging include superconducting magnet technology, gradient technology, radiofrequency technology, spectrometer design technology, and application technology. The company possesses the capability to develop superconducting magnets with field strengths of 1.5T, 3.0T, 5.0T, and higher, and has pioneered the industry's first 75cm large-bore 3.0T

and 5.0T whole-body MR products, as well as the first domestically produced 3.0T MR and 9.4T animal MR products. It has the ability to develop multi-size, high-performance gradient coils and has mastered the technology for high-precision, high-power gradient power amplifiers. The company also owns the design and manufacturing technology for high-channel radiofrequency receive coils suitable for various human body parts and can design and manufacture multi-channel radiofrequency transmit coils for human use at field strengths ranging from 1.5T to 3.0T and above, along with the technology for multi-channel high-power radiofrequency amplifiers. Additionally, it has independently developed a distributed spectrometer system featuring multi-channel transmission, ultra-high-channel parallel radiofrequency data acquisition, nanosecond-level synchronization, and round-the-clock component monitoring. The company boasts extensive research and clinical application technologies and is a leader in the industry in AI-powered innovative applications.

The main technical barriers in the field of X-ray computed tomography (CT) imaging include detector technology, X-ray tube and high-voltage generator technology, and reconstruction algorithms. The company's self-developed spatiotemporal detectors have been applied to its CT product series, supporting multiple spatiotemporal detector configurations with a minimum slice thickness of 0.5mm. The company has independently mastered bipolar CT tube technology and high-voltage generator technology. It has developed correction reconstruction algorithms based on CT products, delivering excellent CT image quality and enhancing system dynamic scanning capabilities. Additionally, the company has researched and developed an artificial intelligence-based full-model iterative reconstruction algorithm, which maximizes dose reduction while ensuring the images meet clinical diagnostic requirements.

The main technical barriers in the field of X-ray imaging include high-voltage generator technology, image reconstruction and post-processing technology, and automated electromechanical control technology. The company has developed metal implant recognition and image denoising technologies based on deep learning, enabling precise detection of metal implant regions in medical images. It has pioneered a full-field scanning trajectory and reconstruction algorithm, expanding the reconstruction field of view of cone-beam CT on DSA systems to 431mm. The company has mastered high-voltage generator technology for XR, and this component has now achieved mass production and is used in some products. The self-developed high-voltage generator reduces product size through high-frequency inverter technology to meet end-user space requirements, minimizes output ripple to optimize exposure dosage and improve image quality, and enhances kV output pulse switching speed to reduce the radiation dose received by patients.

The main technical barriers in the field of molecular imaging include scintillators, detector technology, and more. The company's detectors, through SiPM-based digital detector modules and a large axial field-of-view overall design, achieve high sensitivity that effectively enhances image quality, scanning speed, and reduces scanning dose. The company's high-resolution detectors, combined with high-bandwidth data acquisition and transmission technology, enable lossless recording and processing of data generated by high-definition digital detectors. The company is also one of the few enterprises in the industry capable of designing and manufacturing long-axis PET products.

The main technical barriers in the field of radiotherapy include accelerator tubes, dynamic multi-leaf collimator technology, etc. The company's integrated CT imaging system technology can combine imaging systems with treatment systems, achieving a coaxial and same-bed design for CT and medical linear accelerators. This enables clearer visualization of tumors through high-quality diagnostic imaging, enhancing the precision of clinical treatments. Additionally, the core algorithms of the company's independently developed TPS treatment planning system, including dose calculation and optimization algorithms, improve the speed and accuracy of dose calculations, thereby increasing the efficiency of clinical physicists. The company's self-developed 6MV accelerator tube achieves an industry-leading

maximum dose rate (600 MU/min@1m in flattened mode, 1400 MU/min@1m in unflattened mode) and ensures precise control over each dose pulse. The company's proprietary dynamic multi-leaf collimator technology facilitates the clinical application of efficient and precise volumetric modulated arc therapy, reducing the radiation dose to healthy tissues through accurate dose modulation.

(4) Industry Development and Policy Changes

China's high-end medical imaging equipment market was long dominated by foreign companies. For instance, GE Healthcare, Siemens Healthineers, and Philips once held over 90% of the market share in high-end products such as PET/CT, MR, and CT. For example, as the core equipment for interventional diagnosis and treatment, DSA is used in over 1 million coronary interventional procedures annually in China, ranking first globally. Despite the enormous clinical demand, market data shows that China has only 6.4 DSA units per million people, compared to 45.5 in the U.S., indicating significant market substitution potential for domestic brands in this field. Currently, domestic DSA brands hold approximately 10% of the market share. With the continuous development of domestic medical imaging equipment technology, the independent innovation capabilities of domestic manufacturers have been continuously enhanced, and the trend of import substitution has become increasingly evident.

Meanwhile, the core concept of modern medicine continues to evolve, with precision medicine gradually becoming mainstream. Traditional treatment methods often lack personalization and precision, whereas precision medicine emphasizes providing more accurate diagnosis and treatment plans based on the patient's specific condition and biomarkers, thereby improving therapeutic outcomes and reducing side effects. For example, in cancer treatment, PET imaging technology has become a crucial tool for enhancing treatment precision and effectiveness. In the field of neuroscience, molecular imaging technology plays a crucial role. Recently, several FDA-approved Alzheimer's disease treatments were evaluated based on PET imaging results, which played a key role in the early detection and intervention of Alzheimer's disease.

Medical imaging diagnosis not only enhances the precision of treatment but also significantly improves the overall efficiency of healthcare services. Taking orthopedic surgery as an example, doctors can use imaging results from CT or XR devices to accurately measure patients' joints, thereby better determining surgical plans. Against the backdrop of high costs for personalized medical devices, advanced medical imaging equipment that provides precise diagnostics before surgery can not only assist in the surgical process but also avoid unnecessary consumables and surgical expenses.

In terms of integrated diagnosis and treatment, the medical imaging equipment industry must not only provide high-performance devices to medical institutions but also assist doctors in developing integrated diagnostic and therapeutic solutions. The ultimate goal is to reduce patients' treatment costs and improve treatment efficiency. Therefore, multimodal fusion and integrated diagnosis and treatment will become the main direction of industry development, and more medical imaging diagnostic and therapeutic devices with multimodal capabilities will be introduced to the market. Taking MR-guided linear accelerators as an example, radiotherapy is one of the important means of cancer treatment. However, traditional image-guided accelerator systems often lack effective imaging guidance for soft tissues, making it impossible to locate tumors in real-time during treatment. This greatly limits the precision and effectiveness of radiotherapy for tumors in various parts of the body, particularly evident in the treatment of thoracic and abdominal tumors. Although the radiotherapy industry has been committed to integrating magnetic resonance systems with medical linear accelerators, true integration still faces many challenges due to numerous technical hurdles in the design principles of these two devices.

In the future, United Imaging Healthcare will continue to focus on cutting-edge technologies in the field of medical imaging, tackling key core technologies and accelerating innovative breakthroughs. The

company will further introduce innovative devices featuring multimodality, precision, intelligence, and integrated diagnosis and treatment to meet clinical needs across various scenarios and diseases, significantly improving the accuracy, effectiveness, and accessibility of clinical disease diagnosis and treatment.

The global healthcare sector is also facing numerous significant challenges, which not only impact individual health and well-being but also profoundly affect the stability and development of society as a whole. The first major challenge is the increasingly severe aging population worldwide. With the changing demographic structure, the proportion of the elderly population continues to rise. According to the United Nations' *World Population Prospects 2022* data, the population aged 65 and above is growing faster than the population group under 65. The proportion of the population aged 65 and above is growing faster than that under 65. By 2050, the global proportion of people aged 65 and over is projected to rise from 10% in 2022 to 16%. By then, the global population aged 65 and above will be twice that of children under 5, nearly equivalent to the number of children under 12. The rapid increase in the proportion of the elderly population, coupled with insufficient growth in the labor force, will further exacerbate the imbalance between supply and demand for medical resources. The elderly population typically suffers from more chronic and degenerative diseases, which will lead to a significant increase in future healthcare demands. However, many countries worldwide currently face strained healthcare resources, including overworked and burnt-out medical staff, resulting in increased medical safety risks and declining service quality. Secondly, the threat of infectious diseases on a global scale cannot be ignored. In recent years, various new infectious diseases have emerged, such as the outbreak of the COVID-19 pandemic, which has posed severe challenges to global healthcare systems. Infectious diseases spread rapidly and widely, posing a serious threat to public health security. The prevention and control of infectious diseases require substantial investment in medical resources, including medical equipment, pharmaceuticals, and human resources. Furthermore, the global healthcare sector also faces the issue of uneven distribution of medical resources. In developing countries and impoverished regions, the scarcity of medical resources and the low standard of healthcare services leave many people unable to access timely and effective medical treatment. This imbalance in resource allocation not only exacerbates social inequality but also hinders the overall development of global healthcare. Moreover, with the continuous advancement of medical technology, people have higher expectations for the quality and efficiency of healthcare services. However, some existing healthcare systems still suffer from issues such as cumbersome medical service processes, lack of transparency, and poor communication, causing inconvenience and distress to patients.

In response to these challenges, medical technology is undergoing profound changes and innovations to meet the demands and developments of global healthcare. First is the development of intelligence and personalization. By integrating advanced technologies such as artificial intelligence, big data, and large models, medical equipment can often achieve precise analysis of patient conditions and the formulation of personalized treatment plans. This not only improves the efficiency and quality of medical services but also reduces the waste of medical resources, alleviating the issue of strained medical resources. Secondly, telemedicine and mobile healthcare are receiving increasing attention. With the continuous advancement of communication technologies such as 5G, doctors can overcome geographical barriers through remote connectivity, providing more timely and higher-quality medical services to patients in areas with insufficient healthcare resources. The rise of the Internet of Things and mobile healthcare technologies enables patients to access medical information and health management services anytime and anywhere, significantly improving the accessibility and convenience of healthcare services. Furthermore, with the advancement of medical and technological levels, coupled with advanced technologies such as AI and large models, medical equipment is increasingly being utilized in prevention and health management. This enables early intervention and effective management of chronic diseases, reducing the incidence and recurrence rates of illnesses. This not only alleviates the burden on the healthcare system but also enhances people's quality of life and health standards.

With the implementation and advancement of the aforementioned multi-level domestic and international policies, the demand in the global medical market will be fully unleashed, and the trend of steady growth in the medical equipment industry will become further clarified.

b) Analysis of the company's industry position and its changes

The company's product line covers high-end medical imaging diagnostic products and radiotherapy products, achieving an integrated diagnosis and treatment layout. A comparison of the company's product line with major market participants domestically and internationally is as follows:

Device type	United Imaging Healthcare	GE Healthcare	Siemens Healthineers	Philips	Elekta	Wandong Medical	Neusoft Medical
MR products							
5.0T and above	▲	▲	▲				
3.0T	▲	▲	▲	▲		▲	▲
1.5T and below	▲	▲	▲	▲		▲	▲
CT products							
Photon-counting spectral CT	▲		▲				▲
320 rows/640 layers	▲						
256-row/512-slice		▲	▲				▲
128 rows and below	▲	▲	▲	▲		▲	▲
XR products							
DSA	▲	▲	▲	▲		▲	▲
Mammo	▲	▲	▲			▲	▲
Conventional/Mobile DR	▲	▲	▲	▲		▲	▲
Small and medium C	▲	▲	▲	▲		▲	▲
MI products							
PET/CT							
AFOV>120cm	▲						

Device type	United Imaging Healthcare	GE Healthcare	Siemens Healthineers	Philips	Elekta	Wandong Medical	Neusoft Medical
AFOV50-120cm	▲	▲	▲				
AFOV<50cm	▲	▲	▲	▲			▲
PET/MR	▲	▲	▲				
Ultrasound products		▲	▲	▲		▲	▲
RT product							
Linear accelerator	▲		▲		▲		▲
Image-guided radiotherapy	▲		▲		▲		▲
Life science instruments	▲						

As shown in the table above, in the field of high-end medical imaging and radiotherapy products, the company's product line coverage is essentially on par with international manufacturers such as GE Healthcare, Siemens Healthineers, and Philips. In the industry where the company operates, the mid-to-low-end product market has gradually achieved domestic substitution. Although the high-end and ultra-high-end product markets are still dominated by imported brands, the company has gained a leading edge in certain areas and continues to expand its market share in competition with international manufacturers. According to the statistics of the domestic new market amount in the first half of 2025, the company's product lines all rank among the top in the industry.

(3) Main products and their uses

As of the end of the reporting period, the company has launched over 140 products to the market, including magnetic resonance imaging systems (MR), X-ray computed tomography systems (CT), X-ray imaging systems (XR), molecular imaging systems (PET/CT, PET/MR), medical linear accelerator systems (RT), and life science instruments.

The company's specific product categories and their uses are as follows:

Serial number	Category	Product	Product Usage
1	Medical imaging equipment	Magnetic Resonance Imaging System (MR)	MR offers advantages such as no radiation, rich contrast, and high soft tissue resolution. It is widely used in various clinical scenarios including disease diagnosis, health checkups, surgical navigation, and provides critical diagnostic information for cutting-edge research in fields like basic medicine, neuroscience, and molecular biology.
		X-ray computed tomography system (CT)	CT features fast scanning speed and high spatial resolution, making it suitable for medical institutions at all levels, capable of providing the necessary information for physical examinations, diagnosis, and treatment.
		X-ray imaging system (XR)	XR includes conventional DR, mobile DR, mammography machines, C-arm X-ray machines, DSA, etc., and can be used for screening and diagnosis of various diseases as well as image guidance for surgical and interventional procedures.
		Molecular Imaging System (MI)	Includes PET/CT and PET/MR, which combine molecular metabolic activity images from PET scans with morphological and functional information from CT or MR scans. It has extensive clinical value in diagnosing systemic tissues, particularly in oncology, cardiovascular, and neurological fields, and is also highly valuable in research and translational medicine.

Serial number	Category	Product	Product Usage
2	Radiotherapy products	Medical linear accelerator system (RT)	Radiation therapy is currently an important treatment modality in oncology, and medical linear accelerators, with their broad range of indications and moderate operational difficulty, are the mainstream radiation therapy equipment.
3	Life Science Instruments	Animal MR	It can present the structural and functional information of live animals, aiding pathological and pharmacological research in animal models, and providing support for translational medicine.
		Animal PET/CT	Enables real-time monitoring of physiological, pathological, and drug metabolism processes in various animal models at the dynamic molecular level, facilitating drug development and supporting translational medicine.

Note 1: Animal MR and animal PET/CT refer to magnetic resonance imaging systems (MR) and molecular imaging systems (MI) applied in the field of animal model imaging. Sales data for life science instruments are combined with medical imaging equipment.

Note 2: During the reporting period, the company sold part of its medical internet software assets (including patent ownership/application rights and software copyrights related to products such as medical imaging data archiving and transmission systems and medical electronic cloud films) for RMB 1,030.00 million (excluding tax). The transferee in this transaction was Shanghai Zhiyuan. Upon completion of this transaction, the Company will no longer engage in businesses related to medical imaging data archiving and transmission systems or medical electronic cloud film, and there will be no newly arisen competition within the same industry . The aforementioned related-party transaction has been reviewed and approved by the company's general manager's office meeting and does not require submission to the board of directors for review. The assets being sold exhibit significant differences from medical imaging equipment and radiotherapy products in terms of product form, core functionality, underlying technology, application scenarios, operational models, cost structure, and development trends. This transaction will help optimize the company's asset structure and concentrate superior resources for forward-looking deployment in high-performance medical imaging equipment and radiotherapy products.

1. Medical Imaging Diagnosis

(1) Magnetic Resonance Imaging System

Magnetic Resonance Imaging (MRI) is a device that utilizes the magnetic resonance signals of atomic nuclei (primarily hydrogen protons) in water molecules within the human body under a strong magnetic field to reconstruct images of tissues or organs.

The company possesses the capability to independently design, develop, and manufacture high-field superconducting magnets, high-performance gradient coils, high-density radiofrequency coils, multi-channel distributed spectrometers, as well as MRI imaging software and advanced applications. The company has launched a range of superconducting MR products including 1.5T, 3.0T, and 5.0T models, catering to diverse market segments from basic clinical diagnosis to high-end research.

Several of these products are industry-first or domestically first-of-their-kind.

The uMR Jupiter 5T is the industry's first 5.0T MR system capable of whole-body imaging, achieving ultra-high-field whole-body clinical imaging. The uMR Max, a next-generation 3.0T MR, features a high-performance gradient system, a new online ecosystem platform, and a full-process AI-assisted system, significantly improving examination efficiency and diagnostic consistency. The uMR 770 is the first domestically developed 3.0T MR system. The uMR 780, equipped with the uCS(united compressed sensing) technology platform, is the first domestic device to integrate three acceleration technologies—compressed sensing, parallel imaging, and half-Fourier—and achieves rapid 3D dynamic high-resolution imaging at 0.5 seconds per phase. The uMR 790 is the first high-performance research-oriented 3.0T MR system in China. The uMR 890, featuring a high-performance gradient system with single-axis field strength and slew rate reaching 120mT/m and 200T/m/s respectively, supports brain science research. The uMR Omega is the industry's first 75cm ultra-wide-bore 3.0T MR system, better supporting intraoperative and radiotherapy positioning, and meeting the diagnostic needs of special populations such as pregnant women and overweight individuals. The uMR 600 is the industry's first silicon carbide (SiC) MR system, equipped with a third-generation semiconductor SiC gradient power amplifier (GPA). Empowered by the uAIFI platform, it enhances image quality and scanning speed while significantly reducing energy consumption.

The company's main MR products are as follows:

Serial number	Product model	Schematic diagram	Product introduction and highlights
1	uMR Jupiter 5T		• The industry's first 5.0T superconducting MR system, supporting clinical and research applications for all body parts • The first 8-channel volume transmit coil, solving the challenge of ultra-high field RF excitation uniformity and achieving precise whole-body imaging • Equipped with a 3.5MW gradient power amplifier, supporting ultra-high gradient performance of 120mT/m & 200T/m/s, facilitating cutting-edge brain science research. • Innovative magnet design requires only the installation space of a traditional 3.0T MR, significantly enhancing the accessibility of ultra-high field systems.
2	uMR Max		• The innovative gradient control system breaks through traditional limitations, achieving significant improvements in precise imaging and scanning efficiency. • Leveraging the online ecosystem platform, it supports real-time access to a wealth of cutting-edge technologies and diverse clinical solutions. • End-to-end AI empowerment enhances the intelligence level of magnetic resonance imaging, significantly improving examination efficiency and diagnostic consistency
3	uMR Omega		• The industry's first 75cm large-bore 3.0T MR, meeting the diagnostic and treatment needs of pregnant women and overweight individuals, with support for surgical navigation and radiotherapy simulation positioning. • Equipped with a high-uniformity large-bore superconducting magnet, achieving 60cm industry-leading wide-range high-definition scanning imaging. • Equipped with a 3.5MW gradient power amplifier to meet the demands of high-speed scanning and high-resolution imaging in clinical settings • Silent mode scanning significantly reduces acoustic noise during MR examinations

Serial number	Product model	Schematic diagram	Product introduction and highlights
4	uMR NX		• Ultra-high-performance 3.0T MR for scientific research, suitable for high-end research scenarios • Equipped with a 3.5MW gradient power amplifier, an ultra-high-performance gradient system (single-axis field strength of 120mT/m, slew rate of 200T/m/s), and a 64-channel ultra-high-density head research coil, it is suitable for brain science research. • Equipped with a fully digital RF system and Light-Speed imaging technology, it enhances scanning speed and image quality.
5	uMR 880		• A full-body high-performance 3.0T MR for research and advanced clinical applications • Equipped with a 3.5MW gradient power amplifier and a high-performance gradient system (single-axis field strength of 80mT/m, slew rate of 200T/m/s), it is widely suitable for research and high-end clinical applications in various regions. • Features ultra-high-density super-flexible coils and a millimeter-wave radar respiratory motion detection system, comprehensively enhancing image quality and workflow efficiency. • Achieving comprehensive advanced clinical and research applications in neurology, body, and cardiology
6	uMR 870		• Whole-body 3.0T MR for both clinical and research applications, suitable for scenarios that prioritize both clinical and scientific research. • Equipped with a high-density super-flexible coil and a millimeter-wave radar respiratory motion detection system, comprehensively improving image quality and workflow efficiency • Whole-body, full-sequence silent scanning enhances patient experience

Serial number	Product model	Schematic diagram	Product introduction and highlights
7	uMR 790		• The first domestically produced high-performance research-oriented 3.0T MR, suitable for high-end research scenarios • Equipped with an ultra-high-performance gradient system (single-axis field strength 100mT/m, slew rate 200T/m/s), enhancing scanning speed and imaging quality to meet neuroscience research needs
8	uMR 780		• China's first uCS 3.0T MR, suitable for scenarios that emphasize both clinical and research applications. • Equipped with uCS(united compressed sensing) technology platform and paired with a high-performance Light Spiral Reconstruction Engine, it achieves rapid scanning at 0.5 seconds per phase. • Clinical solutions cover static and dynamic application scenarios for all body parts, while also being suitable for clinical scientific research.
9	uMR 680		• The 3.0T-class large-bore flagship research-oriented 1.5T magnetic resonance imaging system is suitable for scenarios that prioritize both clinical and research applications. • 3.0T-level performance hardware system: single-axis gradient field strength of 45mT/m, gradient slew rate of 200T/m/s • Equipped with high-definition noise reduction technology, delivering 3.0T-level high signal-to-noise ratio and higher-resolution images • Equipped with dual millimeter-wave radar remote sensing life detection technology, enabling non-contact acquisition of physiological signals • Full-sequence ultra-fast silent imaging system, delivering an exceptional scanning experience • Comprehensive clinical and research applications at the 3.0T level

Serial number	Product model	Schematic diagram	Product introduction and highlights
10	uMR 670		• Large-aperture image fidelity 1.5T MR, suitable for clinical scenarios • Equipped with high-definition noise reduction technology, achieving 3.0T-level high signal-to-noise ratio and higher-resolution images • Equipped with dual millimeter-wave radar remote sensing life detection technology, enabling non-contact acquisition of physiological signals • Full-sequence ultra-fast silent imaging system, delivering an excellent scanning experience
11	uMR 660		• 1.5T MR with image fidelity, suitable for clinical scenarios • Equipped with high-definition noise reduction technology for higher signal-to-noise ratio and higher resolution images. • Equipped with a fully digital RF system for high-fidelity, low-noise imaging. • Equipped with Light Shuttle Imaging Technology, effectively enhancing clinical scanning speed
12	uMR 600		• The industry's first silicon carbide MRI, paired with the new uAIFI platform, achieves both efficiency and energy savings. • Equipped with the pioneering silicon carbide (SiC) gradient power amplifier (GPA) featuring high electrical energy utilization efficiency, the SiC GPA reduces device losses by over 60% compared to traditional silicon GPAs at the same power level. Combined with a full set of low-carbon energy-saving solutions, it can save more than 57% of electrical energy. • The uCS&DeepRecon Hybrid dual-drive system combines image quality and scanning speed, achieving a reduction of up to 60% in scan time. It supports dedicated low-carbon sequences and Qscan silent scanning technology.

Serial number	Product model	Schematic diagram	Product introduction and highlights
13	uMR 585e		• Fully digital 1.5T MR, suitable for clinical scenarios • Equipped with industry-leading compressed sensing imaging and AI image reconstruction technology, it achieves higher resolution and higher signal-to-noise ratio without sacrificing scan time • Features a more comprehensive AI positioning workflow: covers intelligent positioning for multiple commonly used body parts. Reduces the technician's manual positioning time, improves standardized scanning and image quality control, covering 2D/3D scanning, quantitative analysis, functional and metabolic imaging technologies. • Equipped with high-performance RF and integrated high-density phased array coil sets, achieving higher signal transmission efficiency for comprehensive clinical applications
14	uMR 588		• Fully digital 1.5T MR, suitable for clinical scenarios • Equipped with fully digital RF transmission technology, achieving high-fidelity, low-noise imaging • Automated inspection process to enhance operational efficiency • Equipped with uCS(united compressed sensing) technology platform, effectively improving clinical scanning speed
15	uMR 580		• Fully digital 1.5T MR, suitable for clinical scenarios • Equipped with fully digital RF transmission technology, achieving high-fidelity, low-noise imaging • Automated inspection process enhances operational efficiency • Providing comprehensive clinical solutions

(2) X-ray computed tomography system

The X-ray computed tomography (CT) system emits X-rays from the tube, which penetrate human tissues and are then received by the detector and converted into digital signals. These signals are processed by a computer to generate cross-sectional or three-dimensional images of the examined area, thereby detecting abnormalities in human tissues or organs.

The company has mastered the R&D and production capabilities of detectors, tubes, high-voltage generators, high-speed rotating gantries, and advanced applications for image processing used in CT. The company's CT product line covers clinical economical models and high-end research-oriented products, meeting diverse needs such as disease screening, clinical diagnosis, and scientific research. The company has successively launched CT products ranging from 16-slice to 320-slice, including the domestically first photon-counting spectral CT uCT Ultima, pioneering whole-body ultra-high-resolution imaging and precise spectral imaging for domestic photon-counting spectral CT, suitable for high-end clinical diagnosis and integrated research scenarios; the new-generation ultra-high-end CT uCT Atlas Pro, the domestically first 320-slice ultra-high-end CT product uCT 960+, and the domestically first 80-slice CT product uCT 780. Among them, uCT Atlas Pro, as the latest ultra-high-end 320-slice 640-layer CT released by United Imaging Healthcare, is equipped with the all-new AIIR Pro dual-engine supercomputing imaging platform, achieving a revolutionary dual-engine reconstruction algorithm architecture while maintaining advantages in optical, noise, anatomical, and system models—accurately preserving anatomical and pathological features while incorporating deep learning denoising technology and natural image texture advantages. The innovative CardioBoost dedicated cardiac deep learning algorithm technology, meticulously developed for cardiac reconstruction, significantly enhances image resolution and eliminates artifact interference using deep learning, while effectively reducing radiation dose and noise, maintaining natural and realistic image texture, and notably improving the accuracy of cardiac diagnosis. uCT 960+ features a self-developed spatiotemporal detector, enabling a gantry rotation speed of 0.25s/rotation and an 82cm large bore, capable of single-heartbeat cardiac imaging for any heart rate, single-organ perfusion, and rapid large-scale vascular imaging, along with low-dose imaging and spectral imaging with tube voltage switching, offering significant clinical diagnostic and research value in cerebrovascular diseases, tumors, emergency care, and pediatric examinations. uCT Orion Plus/Pro/Elite, the new-generation 40-slice practical CT: an integrated imaging chain with self-developed and self-produced detectors, tubes, and high-voltage generators, ensuring accurate data and stable systems to meet high-throughput, multi-site combined scanning, and other complex clinical needs. Orion series AI precision quality control: enhances quality through standardized and safe scanning, supports 8-position AI recognition, including one-click positioning and parameter setting, avoiding artifacts and safety incidents, ensuring image quality and patient safety, and improving grassroots scanning capabilities. Equipped with an AI intelligent clinical application platform: integrates functions such as AI for cerebral hemorrhage and lung nodule screening, facilitating efficient and precise diagnosis and treatment.

The company's main CT products are as follows:

Serial number	Product Model	Schematic Diagram	Product Introduction and Highlights
1	uCT Ultima		• China's first photon-counting spectral CT, pioneering ultra-high resolution and precise spectral imaging for multiple body regions, suitable for integrated high-end clinical diagnosis, treatment, and research scenarios. • In ultra-high-resolution imaging, it breaks through the size limitations of traditional detectors, reducing the pixel area to 1/9 of the conventional size, revealing subtle lesion structures, significantly enhancing spatial resolution, and aiding in precise diagnosis. • Major breakthroughs have been achieved in core areas such as system design, reconstruction algorithms, and spectral applications, enabling full-collimation high-resolution imaging, particularly suitable for high-definition imaging of large organs like the heart.
2	uCT Atlas Pro		• Designed for high-end integrated clinical and research applications, it is equipped with the new-generation AIIR Pro Dual-Engine Supercomputing Imaging Platform. This not only achieves a revolutionary dual-engine reconstruction algorithm architecture, maintaining advantages in optical, noise, anatomical, and system models to accurately preserve anatomical and pathological features but also incorporates deep learning denoising technology and the advantage of natural image texture. • The innovative CardioBoost dedicated cardiac deep learning algorithm technology is meticulously developed for cardiac reconstruction algorithms. It utilizes deep learning to significantly enhance image resolution, eliminate artifact interference, effectively reduce radiation dose and noise, and maintain the natural and realistic texture of images, markedly improving the accuracy of cardiac diagnosis. • The all-new digital intelligent post-processing engine, uOmnispace platform, delivers second-level work efficiency and ultra-realistic rendering technology, offering an exceptional imaging experience.

Serial number	Product Model	Schematic Diagram	Product Introduction and Highlights
3	uCT Atlas Elite		• Designed for high-end integrated clinical and research applications, as a new generation of ultra-high-end CT, the uCT Atlas Elite features ECG Free deep learning technology for non-ECG scanning, eliminating ECG constraints, free from gating limitations and heart rate restrictions. It precisely captures cardiac rhythms for coronary CTA scans, paving the way for clear diagnosis in patients with complex heart rhythms. • Comprehensive innovation in the CT-AI intelligent agent solution, achieving full-domain coverage for second-level recognition in neurological emergencies, detailed analysis of musculoskeletal lesions, and intelligent acceleration of emergency processes, reshaping clinical solutions with digital intelligence. • Powered by the uOmnispace digital intelligence engine platform, a new architecture drives research collaboration, integrating multimodal data and big data connectivity, expanding the depth of clinical exploration. From breakthroughs in cardiac examinations to the intelligent upgrade of comprehensive system diagnostics, and the innovation in research experiences, uCT Atlas Elite cuts through diagnostic barriers with its cutting-edge performance, leading medical imaging into a new era of precision and efficiency.

Serial number	Product Model	Schematic Diagram	Product Introduction and Highlights
4	uCT 968		• A new-generation wide-body CT product designed for high-end clinical and research scenarios, fully integrating deep learning AI technology to provide innovative solutions for CT morphological and functional diagnostics as well as cutting-edge research. • The fifth-generation CT imaging technology—AIIR deep learning full-model iterative algorithm—offers new solutions for whole-body low-radiation-dose and ultra-high-definition imaging. • One-stop cardiac multimodal imaging technology integrates coronary morphology, coronary blood flow, and myocardial microcirculation functional assessment, providing comprehensive information for clinical treatment pathway decisions. Deep learning-based head motion artifact removal and AIIR. • The integration of deep learning full-model iterative algorithms addresses the challenges of head motion artifacts and whole-brain perfusion dosage in emergency stroke patients, enabling lower examination doses, higher image matching accuracy, and significantly improving diagnostic and treatment efficiency.
5	uCT 960+		• China's first domestically produced 320-slice ultra-high-end CT product • A wide-body CT product designed for high-end clinical and research scenarios • Equipped with a self-developed 320-row wide-body spatiotemporal detector, featuring a gantry rotation speed of 0.25s/rotation, capturing 640 high-definition slices per rotation to enhance the success rate of cardiac examinations • It can enhance the scanning speed and imaging quality of the heart and large-scale blood vessels, improving the success rate of cardiac scans. It has the capability for large-scale whole-organ perfusion and dynamic imaging, such as whole-brain and whole-liver scans.

Serial number	Product Model	Schematic Diagram	Product Introduction and Highlights
6	uCT 868		• A wide-body CT product designed for high-end clinical and research scenarios • Equipped with extreme hardware such as a 0.25s/rotation gantry speed, 34MHU high-capacity tube, and 82cm gantry aperture • Equipped with the uSense active sensing platform, which incorporates deep learning algorithms in various aspects such as operation, scanning, dose control, image quality, and artifact suppression, significantly enhancing image quality, diagnostic efficiency, and operational consistency.
7	uCT 860		• A wide-body CT product designed for high-end clinical and research scenarios • Equipped with a self-developed 160-row wide-body detector and a gantry rotation speed of 0.25s/rotation, significantly improving the success rate of cardiac scans • 30MHU high heat capacity tube, capable of meeting clinical demands for high-throughput patient examinations
8	uCT 820		• CT products suitable for clinical and research-oriented scenarios • The extra-large 82cm gantry bore provides a more comfortable examination experience for high-end physical examinations, emergency situations, and other special environments • Equipped with a self-developed detector, the system's rotation speed can reach 0.25s per revolution, comprehensively enhancing cardiac scanning capability and success rate.

Serial number	Product Model	Schematic Diagram	Product Introduction and Highlights
9	uCT 788		• CT products suitable for clinical and research-oriented scenarios • Equipped with Deep Recon deep learning algorithm for whole-body low-dose CT imaging; 0.3s/rotation speed combined with adaptive speed change technology, expanding new scenarios for complex coronary examinations; spectral functional imaging, providing more quantitative information for clinical diagnosis
10	uCT 780		• China's first 80-slice CT product • CT products suitable for clinical and research-oriented scenarios • Equipped with a self-developed detector and a 7.5MHU high-capacity tube, the system rotation speed can reach 0.3s/rotation, significantly improving cardiac scan success rates. It also features a maximum system power of 100kW, making it suitable for examinations of individuals with a higher body weight.
11	uCT 768		• Industry-leading 160-slice CT, equipped with United Imaging's ultra-high-end CT uSense perception platform, enabling full-process AI empowerment • Suitable for 17 cm wide-range whole-brain perfusion imaging, assisting stroke centers in comprehensive patient assessment. • Equipped with ePhase intelligent heart-finding technology to improve coronary scanning success rate. • Equipped with Sky Eye AI technology, it provides an intelligent CT scanning experience, enhancing scanning efficiency.

Serial number	Product Model	Schematic Diagram	Product Introduction and Highlights
12	uCT 760		• CT products suitable for clinical and research-oriented scenarios • Equipped with self-developed detectors • Equipped with a 7.5MHU large heat capacity tube, the system rotation speed reaches 0.35s/rotation, while boasting a maximum system power of 80kW, comprehensively meeting clinical applications such as cardiac scanning and angiography.
13	uCT Orion Plus/Pro/Elite		• The new-generation 40-slice practical CT features an integrated imaging chain, with fully self-developed and self-produced detectors, tubes, and high-voltage generators. It ensures precise data acquisition and stable, reliable system performance, while effortlessly meeting complex clinical needs such as high-throughput scanning, multi-site combined scanning, spectral scanning, and multi-phase enhanced scanning. • The Orion series features exclusive AI precision quality control, enhancing the scanning process from two dimensions: standardization and safety. It supports AI recognition for 8 body positions, equipped with one-click AI precise positioning, AI scanning parameter settings, AI metal foreign object detection, AI motion detection, AI breathing artifact detection, integrated AI collision alerts, AI lead garment recognition, and an AI aperture detection system. These features help avoid metal artifacts, motion artifacts, and safety incidents, ensuring standardized, safe, and high-definition image quality for examinations. This promotes image interoperability and mutual recognition, safeguards patient health and safety, prevents medical disputes, and elevates the scanning capabilities of primary healthcare imaging. • Equipped with a comprehensive AI intelligent clinical application platform, it integrates a one-stop AI for cerebral hemorrhage, intelligent lung nodule screening, intelligent lung parenchyma analysis, intelligent rib and spine

Serial number	Product Model	Schematic Diagram	Product Introduction and Highlights
			analysis, and intelligent dental analysis, among other functions. This provides intelligent and efficient support for clinical diagnosis, improving diagnostic efficiency and accuracy.

Serial number	Product Model	Schematic Diagram	Product Introduction and Highlights
14	uCT Orion Eco/Era/Extra		• The next-generation 20-slice CT utilizes deep learning technology to achieve AI-powered precision quality control, supports AI recognition for 8 body positions, and features one-click AI-assisted precise positioning, AI scan parameter settings, as well as integrated AI collision alerts, AI metal foreign object detection, AI lead garment wear recognition, and AI bore inspection system. This effectively avoids metal artifacts, motion artifacts, and safety incidents, ensuring standardized, safe, and high-definition imaging quality. • Independently developed and produced integrated imaging chain, equipped with the second-generation spatiotemporal detector, a high-heat-capacity 3.8MHU tube, and a 48kW self-developed high-voltage generator, achieving a comprehensive upgrade of core CT components for precise data acquisition and stable, reliable system performance. It also effortlessly meets complex clinical needs such as high-throughput scanning, multi-region combined scanning, and multi-phase contrast-enhanced scanning. • Equipped with a comprehensive AI-assisted diagnostic platform, integrating one-stop AI-assisted diagnosis for cerebral hemorrhage, intelligent lung nodule screening, lung parenchyma analysis, intelligent rib and spine analysis, and intelligent dental analysis, providing intelligent and efficient support for clinical diagnosis, enhancing diagnostic efficiency and accuracy.
15	uCT 550/550+		• Equipped with self-developed detectors • Suitable for a wide range of clinical applications, achieving a 0.55mm acquisition slice thickness to provide clearer and more detailed images for the diagnosis of tiny lesions, thereby obtaining more diagnostic information. • The 5.3MHU tube heat capacity balances scanning speed and image precision, meeting the clinical needs for continuous and large-scale scanning.

Serial number	Product Model	Schematic Diagram	Product Introduction and Highlights
			• Utilizing the KARL3D iterative denoising algorithm, uDose intelligent mA adjustment technology, and 70kV scanning mode, low-dose imaging can be achieved.
16	uCT 530/530+		• Suitable for a wide range of clinical applications • Equipped with a self-developed detector • Achieves a 0.55mm acquisition slice thickness, making tiny lesions clearly visible • 5.3MHU tube heat capacity enables powerful continuous exposure capability, with an ultra-long service life, meeting the clinical demands for continuous and large-scale scanning • Equipped with cutting-edge hardware and software such as KARL3D iterative reconstruction technology and an intelligent management platform, it achieves a triple breakthrough in image precision, ultra-low dose, and scanning speed, effectively restoring image details.

Serial number	Product Model	Schematic Diagram	Product Introduction and Highlights
17	uCT 520/528		• Suitable for routine clinical scenarios • Paired with the self-developed "Space-Time Detector," it achieves a 0.55mm acquisition slice thickness, providing clearer and more detailed images for diagnosing tiny lesions and obtaining more diagnostic information. It can achieve a 22mm detector coverage width, effectively improving examination speed and reducing respiratory motion artifacts. • Equipped with an AI navigation system for patient scanning and positioning, enabling contactless and precise CT scans, significantly simplifying clinical workflows, and effectively enhancing the standardization and normalization of scanning procedures. • Utilizing the KARL3D iterative noise reduction algorithm, uDose intelligent mA adjustment technology, and 70kV scanning mode, low-dose imaging can be achieved.
18	uCT 610 Sim		• A brand-new ultra-large bore CT system integrating diagnostic CT scanning, radiotherapy simulation and positioning, and image-guided interventional puncture procedures. • 87cm ultra-large bore provides ample patient positioning space, accommodating various large-sized positioning accessories for radiotherapy scenarios; offers greater operational freedom for image-guided interventional procedures. • With an ultra-large scanning field of view of 63cm, compared to conventional 70cm aperture CT systems, the scanning field of view is increased by 26%, providing more complete anatomical structures for special patients such as those with large body weight or off-center positioning during simulation and positioning scans. • Supports preoperative planning, intraoperative scanning (single-slice scanning, single helical scanning, continuous slice scanning, and continuous fluoroscopic scanning to meet different interventional puncture application scenarios),

Serial number	Product Model	Schematic Diagram	Product Introduction and Highlights
			postoperative evaluation, and provides a comprehensive and professional interventional suite. • A comprehensive 4D CT solution that can be flexibly used by departments for different clinical scenarios, laying a solid foundation for treating moving tumors.
19	uCT 830 Hybrid		• Equipped with 80 rows of detectors, it can perform scans of the whole body, including the heart and other areas, maximizing its application across all departments and organs. • Featuring the industry's largest bore diameter of 82cm, the diagnostic-grade large bore offers greater advantages in complex intraoperative scenarios, such as increased flexibility in handling surgical setups like head frames, drapes, and anesthesia breathing tubes. • Equipped with powerful core components, including 0.5mm thin-slice scanning capability and a precision flying focal spot liquid metal tube, it ensures tiny lesions in the lungs and liver are clearly visible, and even the smallest distal blood vessels in the brain can be distinctly seen.
20	Vehicle-mounted CT		• CT products for mobile scenarios • Equipped with a contactless scanning navigation system and a dual-channel body design for medical staff and patients, avoiding cross-infection. • Enhanced stability through the CT reinforcement system, ensuring system reliability under long-term and varying distance transportation conditions. • The remote data transmission and processing system ensures the effective and stable operation of the entire system.

(3) X-ray imaging system

The X-ray imaging system (abbreviated as XR) works by emitting X-rays from a tube, which penetrate human tissues and are then captured by a detector to generate images of the body. Depending on clinical applications, it offers various imaging modes, including 2D static imaging, 2D dynamic imaging, and 3D tomographic imaging. XR examinations can be applied for screening, diagnosis, and image guidance in surgical and interventional procedures.

Depending on clinical applications, XR products can be categorized into Digital Radiography (DR), Digital Mammography X-ray Imaging Systems (Mammo), Mobile C-arm X-ray Imaging Systems (Mobile C-arm), and Angiography X-ray Imaging Systems (DSA), among others. Among these, DR is widely used for routine health check-ups and clinical disease diagnosis, making it the most extensively applied radiological imaging device in clinical practice. Mammo is primarily employed for screening and diagnosing various breast diseases. Mobile C-arms are commonly utilized to provide imaging guidance for surgical procedures, while DSA is frequently used for imaging guidance in various interventional surgeries such as cardiac, neurological, and oncological procedures.

Since launching its first XR product in 2016, the company has successively introduced the intelligent bionic minimally invasive interventional surgery system uAngio 960, the intelligent bionic aerial robotic angiography system uAngio AVIVA, and the uAID full-process intelligent imaging platform. Leveraging industry-leading AI technology to empower clinical applications, it has developed the uDR Aurora, the industry's first fully intelligent ceiling-mounted DR system covering 'positioning-imaging-processing-diagnosis-quality control,' the domestically first 3D tomosynthesis mammography system uMammo 890i, the next-generation low-dose large flat-panel mobile C-arm uMC Reveal, the computer vision-powered fully automatic ceiling-mounted DR product uDR 780i Pro, and the domestically first mobile DR product with visual exposure control capability uDR 380i, among other representative products.

The company's main XR products are as follows:

Serial Number	Product Model	Schematic diagram	Product introduction and highlights
1	uAngio 960/960X		• The uAngio 960/960X Intelligent Bionic Minimally Invasive Interventional Surgery System, equipped with the industry-first uSpace digital twin space system, enhances interventional surgery efficiency through computer vision technology, intelligently optimizing device movement, image acquisition, and dose control, delivering a comprehensive intelligent operation experience. • With ultra-high flexibility, it breaks through movement limitations, delivering an unparalleled user experience across all departments with the industry's largest aperture, maximum angle, and widest field of view. • Equipped with the innovative uVera platform, it deeply empowers imaging with digital intelligence, supporting precise diagnosis and treatment in

Serial Number	Product Model	Schematic diagram	Product introduction and highlights
			clinical departments such as neurology, cardiology, oncology, and surgery with exceptional image quality and superior dose control. • Equipped with the industry's first zero-noise imaging technology, by optimizing the imaging chain platform and combining advanced Burst Denoise technology, it increases the signal-to-noise ratio by 4 times while reducing radiation dose by 40-86%. • The system leads the evolution and advancement of hybrid operating rooms, comprehensively promoting interdisciplinary integration and clinical exploration and innovation.
2	uAngio AVIVA CE/CX		• The eight-axis aerial robot design is equipped with the industry-first uSpace digital twin space system, enhancing interventional surgery efficiency through computer vision technology. It intelligently optimizes equipment movement, image acquisition, and dose control, delivering a comprehensive smart control experience. • Equipped with the industry-first uLingo intelligent voice system, supporting 10,000+ high-frequency clinical commands, enabling full-scenario free dialogue, truly freeing doctors' hands. • The industry-leading 8-axis tandem aerial robot unlocks lateral movement to achieve full coverage of any position in the operating room, with extreme flexibility making complex surgeries simpler. • Equipped with the innovative uVera platform, it deeply empowers imaging with digital intelligence, delivering exceptional image quality and superior dose control to support precise diagnosis and treatment in clinical departments such as neurology, cardiology, oncology, and surgery. • Featuring the industry's first zero-noise imaging technology, it optimizes the imaging chain platform and combines advanced Burst Denoise technology to increase the signal-to-noise ratio by 4 times while reducing radiation dose by 40-86%.

Serial Number	Product Model	Schematic diagram	Product introduction and highlights
3	uMammo 890i		• China's first high-definition low-dose 3D digital Mammo, suitable for medical institutions at all levels • Three-dimensional tomographic imaging can address the issue of tissue overlap in traditional two-dimensional imaging, effectively improving breast cancer detection rates and reducing false-positive recall rates. • A 49.5μm micro-pixel single-crystal silicon flat-panel detector can reduce radiation dose during examination.
4	uMammo 870i		• A multifunctional mammography platform integrating dual-angle 3D tomography, intelligent exposure control technology, and intelligent fusion 2D technology, delivering high quality and low dose to efficiently meet diverse clinical needs and enhance diagnostic performance.
5	uMammo 590u		• Economical 2D digital mammography system, rated 5 stars by the U.S. ECRI Patient Safety Organization • Equipped with a large-size dedicated flat-panel detector for mammography, it meets the imaging requirements for breast soft tissues and micro-lesions. • Featuring an intelligent compression system for the examined area, it enables one-click quick and intelligent positioning.
6	uMC Reveal		• The next-generation low-dose large flat-panel mobile C-arm, equipped with the industry-leading large-size flat-panel detector and the uRADIX full-process dose and image processing platform, achieves high-definition imaging with low dose during surgery. • Featuring an innovative lightweight design, it reduces the resistance of the cart during movement and the burden of relocation. At the same time, it provides greater freedom of intraoperative positioning, delivering a smooth daily operation experience and offering flexible, spacious surgical space for doctors in orthopedics, gastroenterology, urology, and other departments.

Serial Number	Product Model	Schematic diagram	Product introduction and highlights
7	uMC 560i		• Surgical flat-panel mobile C-arm, suitable for various surgical procedures • Equipped with a single-crystal silicon flat-panel detector, it significantly reduces radiation dose. • 2-million-pixel imaging chain system, greatly improving image resolution.
8	uDR Aurora		• Equipped with the uAID full-process intelligent imaging platform, it empowers clinical practice with industry-leading AI technology, achieving intelligent imaging that covers the entire workflow from 'positioning - shooting - processing - diagnosis - quality control'. • Supports innovative features such as intelligent voice guidance, uVision smart positioning, automatic FOV, and uAID intelligent quality control, comprehensively empowering clinical examination workflows, enhancing examination efficiency, ensuring image quality, and aiding precise diagnosis. • Provides specialized clinical solutions for multiple departments, including low-dose pediatric solutions and intelligent orthopedic solutions, supporting fully automatic standing/supine long bone stitching applications. It delivers high-quality orthopedic panoramic imaging for clinical use, enabling precise preoperative and postoperative assessments of the spine and lower limb joints.
9	uDR 780i Pro /780i		• Enables real-time monitoring of patient status and completion of examination procedures in isolation rooms, suitable for various clinical scenarios • Supports over 200 fully automated one-click positioning functions, enabling automatic centering and tracking, paired with dual wireless large panels to efficiently empower clinical workflows.

Serial Number	Product Model	Schematic diagram	Product introduction and highlights
			• Supports advanced applications for fully automated vertical and horizontal stitching, assisting in preoperative examinations and postoperative outcome evaluations of the spine and lower limb joints.
10	uDR 760i		• Equipped with dual large wireless panels, it can more flexibly and efficiently meet the examination needs of larger-sized patients, supports built-in charging, and is durable. • Fully automatic gantry motion can be achieved, featuring automated positioning to enhance clinical workflow efficiency.
11	uDR 380i Pro /380i		• Equipped with a remote control terminal, featuring remote visual exposure technology, enabling real-time monitoring, voice guidance, remote parameter adjustment, and remote exposure, thereby improving shooting success rates. • Equipped with motorized motion assistance function, 47cm compact body design for easy use in narrow spaces and bedside
12	uDR 330i		• Adaptable to extreme environments with high temperature, extreme cold, high altitude, high humidity, and high salinity, featuring waterproof, dustproof, and shockproof characteristics • The device is portable and easy to use, with convenient transportation.

Serial Number	Product Model	Schematic diagram	Product introduction and highlights
13	uDR 596i		• Fully automatic floor-mounted digital DR • Intelligent one-click positioning function improves clinical workflow efficiency • Equipped with dual wireless large panels, it can meet the examination needs of large-sized patients. • Features fully automatic standing position stitching function, assisting clinicians in achieving precise pre- and post-operative assessments of the spine and lower extremity joints.
14	uDR 566i		• Floor-mounted digital DR with automatic tracking function, improving clinical work efficiency. • Equipped with dual wireless large panels, it can meet the examination needs of large-sized patients.
15	uDR 266i		• U-arm DR with wireless high-definition large flat panel • Equipped with intelligent one-touch positioning function to improve clinical workflow efficiency • Equipped with a large wireless tablet, it can meet the examination needs of large-sized patients.

(4) Molecular imaging system

The molecular imaging system (Molecular Imaging, abbreviated as MI) can display specific molecules at the tissue, cellular, and subcellular levels, reflecting molecular-level changes in vivo, thereby enabling qualitative and quantitative studies of biological behavior through imaging. Molecular imaging technology can detect abnormalities at the cellular and molecular levels during disease progression, investigate the onset, development, and outcomes of diseases (such as cancer and Parkinson's syndrome), and evaluate the effects of pharmaceuticals and treatments.

The company is one of the few domestic enterprises that have obtained PET/CT product registration and achieved mass production of complete machines. It has mastered detector development technology, electronics technology, reconstruction and control technology, etc., enabling high spatial resolution, high time-of-flight

(TOF) resolution, high sensitivity, large axial FOV, and whole-body dynamic scanning, with its technical level leading the industry. Among these, high spatial resolution can provide superior clinical image quality, aiding in the detection of early lesions, disease staging, treatment planning, and therapeutic effect monitoring. High TOF resolution can significantly enhance image signal-to-noise ratio (SNR) and clarity. High sensitivity and large axial FOV can effectively improve image quality and scanning speed. Whole-body dynamic scanning provides robust support for personalized precision diagnosis and treatment, new drug development, and other clinical and research applications. The company's MI products can be equipped with advanced post-processing applications such as multi-modality image fusion, dynamic analysis, tumor tracking, brain analysis, and heart analysis, providing precise analysis for the clinical diagnosis and treatment of tumors, neurological, and cardiovascular diseases. The company has successively launched several industry-leading products, including the industry's first PET/CT product with 4D whole-body dynamic scanning capability, uEXPLORER (Total-body PET/CT); the PET/CT product with the industry's highest 180ps-level TOF resolution, uMI Panorama; uMI Panvivo, featuring a new generation of fully self-developed detector design; the first domestically produced integrated PET/MR product, uPMR 790; the first domestically produced digital TOF PET/CT product, uMI 780; and the first domestically produced PET/CT product, uMI 510.

The company's main MI products are as follows:

Serial number	Product Model	Schematic Diagram	Product Introduction and Highlights
1	uEXPLORER (Total-body PET/CT)		• The industry's first 4D panoramic dynamic PET/CT, suitable for cutting-edge research scenarios. • Paired with a 672-ring optical guide detector and an 80-slice CT, it only takes 30 seconds and 1/40 of the dose to complete high-definition full-body scan imaging. • It enables real-time dynamic full-body scanning and parameter analysis, supporting pharmacokinetic research and providing support for pathology and pharmaceutical studies. • One of the Top 10 Technological Breakthrough Products in the World selected by the *World Physics Journal* in 2018
2	uMI Panorama 28C/Stellar/35C/35S/GS		• Equipped with the industry's first self-developed high-end medical imaging dedicated chip, as the world's first commercial PET/CT to achieve an ultra-high temporal resolution of 180ps, it redefines the clinical PET/CT image quality standards. • Featuring an all-core digital PET detector and a large-bore CT with a maximum rotation speed of 0.25s, it leads in all performance metrics. • Empowering nuclear medicine clinical practice and research with full-chain intelligent workflows, advanced AI algorithms, and rich scientific applications

3	uMI Panvivo		• With 2.9 mm NEMA spatial resolution and an effective sensitivity of 181 cps/kBq, it ensures image clarity and lesion detection capability, delivering exceptional clinical diagnostic confidence. • AI empowerment across the entire workflow, covering quality control, acquisition, reconstruction, and quantitative analysis, enhances operational efficiency and reduces manual labor; equipped with the industry's first multi-nuclide AI iterative reconstruction algorithm, expanding its applicable nuclear medicine imaging range, enabling precise diagnosis for multiple diseases. • An extremely compact overall machine design significantly improves site accessibility; a freely expandable detector platform allows for in-place upgrades from short-axis to long-axis, achieving doubled diagnostic and therapeutic capabilities and a new development pathway.

4	uPMR 890		• 32cm longest PET axial field of view, 2.76mm finest crystal size, 1mm highest PET reconstruction resolution, and a new-generation 80mT/m industry-leading MR gradient system • AI full-stack empowerment, equipped with the industry-leading DPR deep progressive learning PET iterative reconstruction algorithm, DeepRecon MR intelligent deep reconstruction technology, and ACS intelligent light shuttle MR acceleration technology, achieving simultaneous improvements in scan time, signal-to-noise ratio, and resolution, breaking the limits of PET/MR whole-body scanning, and further strengthening and expanding new clinical and research applications • Equipped with the SuperFlex Coil ultra-flexible coil, it utilizes a new polymer conductor composite material that is ultra-light and ultra-flexible, providing better conformity to the patient's body and enhancing scanning comfort. It achieves superior image quality even in certain forced postures. The adoption of a new preamplifier decoupling technology allows for a coil density of up to 103 units/m², enabling faster imaging speeds and higher image signal-to-noise ratios. This significantly improves the visualization of fine structures and broadens clinical application scenarios.
5	uPMR 790		• The first domestically produced integrated high-performance PET/MR, suitable for clinical and research scenarios • Combining a 3.0T MR and a 112-ring PET system, equipped with AI scanning and reconstruction algorithms to achieve fast and high-definition scanning • Achieving data stream fusion of physiological signals, PET, and MR

6	uMI 780		• The first domestically produced digital TOF PET/CT, suitable for clinical and research scenarios • Equipped with a 112-ring digital light guide detector and an 80-slice CT, it features large field-of-view high resolution and fast high-definition scanning capabilities • Equipped with a wealth of advanced applications, fully supporting clinical and research needs
7	uMI Vista		• Digital PET/CT, suitable for clinical scenarios • Equipped with an 84-ring optical detector and 80-slice CT • Optimize cardiac scanning workflow to support clinical cardiac examinations
8	uMI 550		• Digital PET/CT, suitable for clinical scenarios • Equipped with an 84-ring digital light-guide PET detector and a 40-slice CT • Equipped with multiple intelligent applications to achieve more efficient workflows
9	In-vehicle PET/CT		• Digital mobile PET/CT, suitable for clinical scenarios, with high mobility and stability • Equipped with an 84-ring digital light-guide PET detector and a 40-slice CT • Paired with a dedicated mobile workstation, suitable for mobility inspections

2. Radiotherapy products

Radiation Therapy (RT) systems utilize α, β, and γ rays produced by radioactive isotopes, as well as X-rays, electron beams, proton beams, and other particle beams generated by various X-ray therapy machines or accelerators to treat tumors, making it a crucial method for cancer treatment today. The most mainstream radiotherapy equipment globally includes medical linear accelerators, cobalt-based gamma knives, and a small number of proton and heavy ion devices. Among these, medical linear accelerators can be widely applied to treat primary or metastatic tumors in multiple parts of the body.

The core components of RT products include the accelerating tube, multi-leaf collimator, power source, modulator, precision control module, and onboard imaging equipment. During the clinical treatment process, the medical linear accelerator system (Linac), in conjunction with the treatment planning system software (TPS), oncology information system software (OIS), and radiotherapy simulator (Simulator), collectively completes the radiotherapy procedure: First, the radiotherapy simulator locates the lesion, and based on the positioning images, the physician delineates the regions of interest such as tumors and organs. Then, the treatment

planning system software generates a treatment plan according to the therapeutic regimen. Finally, the medical linear accelerator system executes the treatment plan. The aforementioned treatment plan and relevant patient information are recorded and managed by the oncology information system.

With the rapid development of precision medicine, precision radiotherapy has become the trend in the advancement of tumor radiation therapy technology. Precision radiotherapy aims to destroy tumor lesions while ensuring the maximum protection of normal human tissues or organs. Therefore, the precise definition and delineation of tumor targets and surrounding normal organs are the foundation of accurate radiotherapy. The company pioneered the integrated diagnostic-grade CT-guided accelerator technology, which combines diagnostic-grade CT and accelerator with dual-center coaxial fusion, effectively addressing changes in tumor morphology, size, or position throughout the radiotherapy course. Equipped with intelligent software, it ensures precise radiotherapy while significantly improving the work efficiency of medical staff. The company has developed the industry's first integrated CT-guided linear accelerator uRT-linac 506c, the versatile flagship CT linear accelerator uLinac VisionaryTx with multi-photon and multi-electron capabilities, the industry's pioneering integrated ring-shaped CT linear accelerator uLinac HalosTx, the next-generation integrated 6MV single-photon large-aperture CT linear accelerator uLinac EternaTx, the first NMPA-approved AI-driven organ and tumor contouring software uIPW, the intelligent radiotherapy planning software uTPS, the radiotherapy record and verification software uRVS, the radiotherapy information management system uOIS, the radiotherapy quality control system uAssureTx, and the radiotherapy remote collaboration platform, among other hardware and software products, establishing a comprehensive and independently controllable end-to-end radiotherapy solution.

The company's main RT products are as follows:

Serial Number	Product Model	Schematic diagram	Product introduction and highlights
1	uLinac VisionaryTx		• The multi-photon multi-electron all-in-one flagship CT linear accelerator boasts comprehensive treatment technologies, equipped with the industry's first and only dual-layer equivalent 2.5mm multi-leaf collimator & full-field 40cm×40cm irradiation, delivering precise stereotactic radiotherapy with sharp 'blade' precision. • Pioneering a single-isocenter non-coplanar whole-body intelligent SRS/SBRT stereotactic radiotherapy solution, enabling precise radiotherapy through rapid one-click non-coplanar planning and fully automated implementation with high-precision irradiation. • Diagnostic-grade CT imaging enables precise adaptive radiotherapy, pioneering on-demand triggered adaptation to flexibly provide optimal solutions based on patient conditions. • Equipped with All In One one-stop radiotherapy, it reduces the waiting time for the first radiotherapy session from the traditional several days to just a few minutes. By integrating one-stop services with radiotherapy emergencies and SRS/SBRT, it optimizes the timeliness of radiotherapy and enhances treatment efficacy.

Serial Number	Product Model	Schematic diagram	Product introduction and highlights
2	uLinac HalosTx		• The industry's first integrated CT ring linear accelerator, equipped with a new-generation 87cm large-aperture diagnostic-grade CT image guidance system, provides clinical users with more confident and comprehensive clinical evidence. • With the support of diagnostic-grade CT Eagle Eye imaging, ultra-wide-range in vivo dose monitoring, and intelligent software, it simultaneously observes patient anatomical and dose information, maximizing the precision of personalized radiotherapy for patients. • Online adaptive radiotherapy and highly automated one-stop radiotherapy applications streamline the entire workflow, reducing time consumption, minimizing reliance on personnel experience, and achieving a breakthrough in clinical efficiency and treatment processes.
3	uLinac EternaTx		• Next-generation integrated 6MV single-photon large-aperture CT linear accelerator • Equipped with an 87cm integrated large-aperture diagnostic-grade CT, the industry's fastest 6.5cm/s MLC, and a 6D high-precision treatment couch • Paired with the new Dose-Guided Radiation Therapy (DGRT) application, it enables transition from image guidance to dose guidance before treatment, and supports stereotactic intelligent one-click non-coplanar therapy, online adaptive radiotherapy, and one-stop radiotherapy
4	uRT-linac 506c		• The industry's first integrated CT-guided linear accelerator • High-resolution CT image guidance, combined with adaptive radiotherapy planning systems, provides customized treatment plans • One-stop full radiotherapy workflow support, multi-functional machine, integrates rapid workflow design to improve work efficiency • Supports dynamic rotation intensity-modulated radiotherapy uARC technology and fast Monte Carlo algorithm, improving clinical treatment efficiency

Serial Number	Product Model	Schematic diagram	Product introduction and highlights
5	uRT-linac 306		• Conventional linear accelerator system, suitable for clinical users • Supports auto-contouring, auto-planning, auto-QA, and 540° ultra-long single-arc treatment mode to enhance treatment efficiency
6	Native radiotherapy cloud ecosystem		• Innovating based on cloud architecture (B/S architecture), we launched the United Imaging Intelligent Radiotherapy Software Solution, integrating five key components: the AI-driven contouring system uIPW, radiotherapy planning software uTPS, comprehensive radiotherapy quality control platform uAssureTx, radiotherapy information management system uOIS, and the radiotherapy remote collaboration platform. This creates a fully digital and intelligent radiotherapy solution across the entire workflow. • Collaborate with integrated CT linear accelerator systems to enhance quality and efficiency, rapidly providing personalized and precise treatment plans, empowering advanced treatment technologies such as adaptive radiotherapy and one-stop radiotherapy. • Support the intelligent transformation and upgrading of departments, empower innovation in multiple scenarios of medical, educational, and research, and help build an efficient, flexible, and interconnected native radiotherapy cloud ecosystem.

3. Life Science Instruments

Life science instruments include various types of products such as preclinical imaging equipment, optical observation devices, electron microscopes, and chemical analysis instruments. Among them, preclinical imaging equipment primarily achieves structural and functional imaging through radiological observation of animal models, thereby supporting fundamental research in life sciences. Currently, preclinical imaging equipment has been widely applied in research on the mechanisms, diagnosis, and treatment methods of major diseases such as brain science, oncology, and cardiovascular diseases.

The company entered the life science instruments field by starting with preclinical imaging equipment. To date, it has launched two products: the domestically

developed first preclinical ultra-high-field magnetic resonance imaging system uMR 9.4T and the domestically developed first preclinical large-animal whole-body PET/CT imaging system uBioEXPLORER, as detailed below:

Serial Number	Product Model	Schematic diagram	Product introduction and highlights
1	uMR 9.4T		• The first domestically produced 9.4T preclinical ultra-high-field MR, suitable for research institutes, universities, pharmaceutical companies, etc. • High-performance gradients, suitable for research on various animal models in brain science, oncology, cardiovascular diseases, and other major diseases, including mechanisms, diagnosis, and treatment methods. • Equipped with ultra-low temperature radiofrequency probes to enhance signal-to-noise ratio and achieve clear image quality; offers a wide range of sequence applications to support users in translational medical research
2	uBioEXPLORER		• China's first preclinical large-animal whole-body PET/CT imaging device, suitable for research institutes, universities, pharmaceutical companies, etc. • Features a 50cm axial field of view and 50cm aperture, supporting large animal imaging; boasts ultra-high sensitivity, enabling low-dose rapid scanning. • Equipped with digital light guide detectors, supports TOF high-definition reconstruction for precise imaging.
3	uMicroEXPLORER PET/CT		• Domestically developed preclinical ultra-high-performance small animal whole-body PET/CT imaging equipment, suitable for hospitals, universities, research institutes, pharmaceutical companies, etc. • Equipped with dense array cutting and assembly technology for fine crystals and built-in light guide technology, based on silicon photomultipliers (SiPM), it also features the industry's first detector architecture with dual-ended readout, delivering leading-edge ultra-high performance. • Features a 178 mm ultra-long axial field of view and ultra-high sensitivity, supporting single-bed whole-body dynamic imaging for rats, sub-second dynamic reconstruction, and high-throughput simultaneous imaging of 4 mice.

			• Exclusive dual-end readout technology, paired with digital light guide detectors, enables uniform full-field imaging and ensures consistent image quality for high-throughput multi-mouse imaging. • High-resolution CMOS flat-panel detector CT system, achieving a minimum pixel spatial resolution of 8 μm, comparable to standalone Micro CT
4	uCT microPCCT Max/Core		• China's first photon-counting spectral micro-CT imaging system (uCT microPCCT series) • The innovative solution employs photon-counting detectors and micro-focus tubes, offering superior energy discrimination for X-ray photons and near 'zero-noise' data readout, enabling ultra-high-resolution spectral imaging with high signal-to-noise ratio and better suppression of beam-hardening artifacts.

II Discussion and Analysis of Business Operations

In the first half of 2025, the global macroeconomy sought recovery amid fluctuations, with a new wave of technological innovation and industrial upgrades resonating in sync, driving the global healthcare industry chain to evolve deeply toward full-chain and high-value directions. Meanwhile, as the aging population accelerates and the demand for chronic disease prevention and treatment forms a historic intersection, coupled with disruptive technological breakthroughs such as artificial intelligence, precision medicine, and translational medicine, the value anchor of the healthcare industry has clearly shifted from single-parameter innovation in diagnostic and therapeutic equipment to the accelerated evolution of a digital and intelligent health management ecosystem covering the entire cycle of 'prevention-diagnosis-treatment-rehabilitation.'

Faced with this structural opportunity, technological innovation is no longer an optional choice for enterprises but the strategic cornerstone and core engine for companies to define the future of the industry, navigate economic cycles, and achieve sustainable growth.

In this process, the ongoing industry consolidation has accelerated the medical equipment sector's shift toward a more standardized, orderly, and market-oriented direction. While optimizing resource allocation, it has also helped leading high-quality innovative enterprises stand out, driving the industry to gradually break free from low-end repetition, homogeneous competition, and chaotic, cutthroat rivalry, evolving toward high-end, intensive, and strategic upgrades. The large-scale medical equipment renewal policy launched in 2024 has injected new growth momentum into the industry. Since 2025, the large-scale equipment renewal has gradually become normalized and specialized, significantly boosting the procurement enthusiasm of medical institutions at all levels. The demand for innovative diagnostic and therapeutic equipment such as imaging and radiotherapy has rapidly expanded. In terms of primary healthcare system development, with the accelerated construction

of county-level medical consortia, enhancing the diagnostic capabilities of primary medical institutions has become a core driver and strategic hub for equipment renewal. This year, county-level medical equipment renewal has emerged as one of the most active segments in the market. Public data shows that the renewal demand driven by the construction of county-level medical consortia has already captured a significant share of the overall market. Meanwhile, projects initiated by individual hospitals and regional entities are also advancing in parallel, presenting a multi-tiered and multi-channel release trend across the market.
Equipment upgrades are demonstrating more market-oriented operational characteristics, with the proportion of independent procurement continuously increasing, meeting the upgrade needs of medical institutions to keep pace with clinical trends in areas such as high-end medical imaging and radiotherapy. From a funding structure perspective, diversified channels such as special funds for county-level medical consortia, and self-raised funds by medical institutions are also being increasingly leveraged, ensuring the sustainability of equipment upgrades at all levels of medical institutions.

During the reporting period, United Imaging Healthcare adhered to its core strategy of ‘innovation-driven development and global collaboration for win-win outcomes,' transforming external environmental disruptions into endogenous momentum for high-quality development. Through breakthroughs in core technologies, collaborative innovation ecosystem, and enhancement of high-end product value, United Imaging Healthcare has achieved a leading global position in multiple fields of high-end medical diagnostic equipment. In the first half of 2025, the company demonstrated robust strategic resilience and continuous innovation capabilities, maintaining high-quality growth in overall operations. It achieved multiple breakthroughs and improvements in key areas such as product innovation, core business dimensions, and the expansion of globalization strategies.

(1) Financial Data and Operational Performance: Advancing Both Scale and Quality, with Profitability Entering a Structural Improvement Phase

In terms of business scale, in the first half of 2025, the company achieved steady growth, with total operating revenue reaching 6.02 billion yuan, a year-on-year increase of 12.79%. Domestically, with the accelerated implementation of industry policies, the company leveraged its product advantages and market competitiveness to achieve stable growth in domestic revenue. Overseas, the market performance was even more outstanding. Despite disruptions from geopolitical and tariff policy changes, the company expanded and deepened its global market presence through its technological product advantages and supply chain strengths, achieving a 22.48% year-on-year increase in overseas revenue to 1.14 billion-yuan, accounting for 18.99% of total revenue. Overseas business has become a key engine for the company's sustained growth.

By business segment, the service business continued to maintain strong growth momentum, with revenue increasing by 32.21% year-on-year to 816-million-yuan, accounting for 13.56% of total service revenue. The company's long-term cooperation model and deep-value services have continuously enhanced user stickiness and service value. With the continuous expansion of product installations and steady market share growth, coupled with the rising proportion of service revenue, the overall profitability will be further boosted, laying a solid foundation for future R&D investment, global expansion, and strategic resource allocation.

In terms of profitability, during the reporting period, United Imaging Healthcare achieved a net profit attributable to the parent company of 998 million yuan, a year-

on-year increase of 5.03%. Net profit attributable to the parent company after deducting non-recurring items was RMB 966 million, up 21.01% year-on-year, reflecting sustained improvement in profitability quality, primarily due to the company's achievements in cost control and profit structure optimization.

As of the end of the reporting period, the company's overall gross margin was 47.93%. The revenue share of mid-to-high-end equipment in core product lines such as MR, CT, and molecular imaging has steadily increased, with high-value-added products continuously driving growth and profitability. Service business revenue grew by over 30% year-on-year, with gross margins remaining above 60%. As global installed capacity continues to expand and the maintenance system matures, its potential contribution to profits is accelerating.

Meanwhile, the company is steadfastly advancing intelligent manufacturing and global supply chain collaboration. Through integrated production and research, process innovation, and systematic cost reduction, it continuously unleashes efficiency dividends. Additionally, it actively expands cold chain coverage and optimizes international logistics (e.g., shifting from air to sea freight), building a more robust and sustainable profit model. Looking ahead, these measures will further enhance the company's medium-to-long-term value creation capabilities and solidify its leading position in the global high-end medical equipment industry.

During the reporting period, United Imaging Healthcare maintained strategic investments in core areas while balancing efficiency, demonstrating strong cost control capabilities. Sales expenses increased slightly with revenue growth, totaling 938 million yuan, with a sales expense ratio of 15.60%, remaining within a stable range overall. R&D expenses continued to focus on breakthroughs in next-generation platform technologies and key products, with R&D expenses amounting to 766 million yuan during the reporting period, representing an R&D expense ratio of 12.74%. Administrative expenses were well controlled at 257 million yuan, with an administrative expense ratio of 4.28%, maintaining an overall stable and slightly declining trend, reflecting the continuous improvement in corporate governance and operational efficiency.

Looking ahead, United Imaging Healthcare will continue to strengthen its talent pipeline, enhance technical capabilities, optimize product portfolios, improve organizational and operational efficiency, consolidate market competitiveness, and maintain its leading position in the global high-end medical imaging and radiotherapy fields.

(2) Supply Chain Management and R&D Investment: Building Long-term Competitiveness

Faced with the rapid expansion and accelerated technological iteration of the global high-end medical equipment market, supply chain resilience, cost efficiency, and innovation capabilities have become core strategic issues for industry competition: how to achieve the optimal balance between cost and efficiency while driving R&D process optimization and production cost reduction to achieve high-quality mass production; how to enhance supply chain resilience and logistics efficiency through intelligent and digital means to meet the global market demand for rapid iteration of multiple products and versions; and how to balance global layout, compliance, and sustainable development to build a flexible supply network and achieve efficient delivery while maintaining a balance between cost and efficiency—all these are critical tests of a company's long-term competitiveness. In response to these challenges, United Imaging Healthcare continues to strengthen supply chain management

and R&D system construction, closely integrating efficient resource allocation with strategic forward-looking planning to support the company's long-term sustainable growth and enhance its core competitiveness.

During the reporting period, the company continued to advance refined management, focusing on improving cost efficiency and optimal resource allocation, deepening cost control, and optimizing the expense structure, thereby laying a solid foundation for sustained profitability enhancement and long-term competitiveness. On the expenditure front, the company strengthened budget management across all business units, implemented a dynamic budget adjustment mechanism, closely aligned expenses with business outputs, and enhanced the efficiency of fund utilization and resource allocation. Meanwhile, the company continuously reduces non-value-added expenditures and eliminates operational redundancies and duplicate investments by upgrading organizational processes and leveraging IT solutions, thereby optimizing the overall operational structure and providing strong support for strategic resource allocation and core business development.

On the procurement front, the company fully leverages its centralized procurement advantages to establish a coordinated mechanism, promoting efficient linkage between direct and indirect procurement. It also strengthens supplier tiered management and dynamic evaluation mechanisms to enhance the reliability and coordination of key components and materials supply. Additionally, the company accelerates the implementation of localization and modular standardization solutions to improve procurement flexibility and cost stability. Through close collaboration and technical support with suppliers, it fosters capability enhancement and sustainable development across the upstream and downstream of the industrial chain. During the reporting period, through multi-path initiatives such as business negotiations, procurement-research collaboration, and design optimization, the company achieved efficient end-to-end procurement operations, continuously optimized procurement efficiency and cost structure, further strengthened supply chain resilience, and provided support for overall value creation across the industrial chain.

In the manufacturing segment, the company focused on intelligent manufacturing and flexible production, continuously improving production line layout efficiency, yield rates, and unit manufacturing cost control capabilities. Key production lines have gradually taken over core manufacturing process modules, significantly enhancing integrated manufacturing capabilities. Meanwhile, the company is comprehensively advancing the deployment and upgrading of intelligent manufacturing systems such as MOM (Manufacturing Operations Management), ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and AEP (Automated Execution Planning). Through deep collaboration across R&D, manufacturing, planning, procurement, and quality control, the Company has comprehensively enhanced its capabilities in order processing, production planning, delivery coordination, and quality control. By leveraging efficient resource allocation, it has achieved effective conversion of orders into revenue, further strengthening its market competitiveness and strategic execution.

Meanwhile, the company focuses on optimizing product architecture and enhancing platform capabilities, strengthening standardized design and component reuse mechanisms to continuously reduce marginal costs in R&D and manufacturing processes. Through modular and centralized software platforms and AI application deployment, the company significantly improves system development and delivery efficiency, gradually establishing advantages in scale replication, extending product lifecycles, and amortizing investments across the entire product lifecycle.

In overseas markets, the company focuses on key regions and core customers, promoting localized resource allocation and channel optimization to further reduce acquisition and service costs while enhancing sales and operational efficiency. In the maintenance service segment, the company leverages digital platforms to strengthen remote operation and predictive maintenance capabilities, reducing failure rates and service response costs. This not only improves customer satisfaction but also optimizes the structure of after-sales investments.

At the overall supply chain strategy level, the company anchors on the four strategic directions of 'resilience, integration, innovation, and cost leadership,' driving the transformation from 'single-point cost reduction' to 'systematic efficiency improvement.' During the reporting period, the company continued to advance the construction and layout of global production bases, strengthening capacity and supply chain diversification to enhance risk response capabilities. In terms of integration, by establishing end-to-end processes from the client side to the supply side and implementing the MOM manufacturing operations management system and decision-making closed-loop mechanism, the company comprehensively improved information flow efficiency and resource scheduling capabilities. In terms of core material supply, the company has established a tiered management and backup mechanism for key components across product lines, introduced multiple suppliers, and promoted the Vendor Managed Inventory (VMI) model to build a highly resilient supply network.

Regarding logistics management, in response to the rapid growth of overseas operations, the company has systematically optimized its transportation structure, promoted the shift from air to sea freight, improved the cold chain coverage and standardized shipping models for MRI systems, and achieved a year-on-year reduction in unit transportation costs despite a doubling of total shipment volume, demonstrating the agility and resilience of its global logistics system.

In terms of inventory management, the company has gradually optimized its inventory structure amid rapid business growth. Within the year, the company will further strengthen dynamic inventory management from raw materials to finished products, ensuring robust cash flow and improved operational asset efficiency.

Looking ahead, the company will continue to advance the transformation of its supply chain towards 'visualization, intelligence, and collaboration,' building a comprehensive cost control system that spans the entire product lifecycle from R&D and manufacturing to sales and service. Through platform-based management, modular deployment, and refined execution, the company will further enhance resource utilization efficiency and profitability resilience, laying a solid foundation for sustained growth in the high-end medical equipment sector.

In terms of R&D investment, in the first half of 2025, United Imaging Healthcare firmly implemented an innovation-driven strategy, continuously strengthening the allocation of core resources in forward-looking R&D directions. The company invested 1.14 billion yuan in R&D, with the total number of R&D personnel increasing to 3,391, accounting for over 40%, forming a high-tech, high-quality, and high-potential talent echelon. The construction of the R&D team and systematic project management were advanced simultaneously, effectively ensuring the independent control and continuous innovation capability of product technologies. During the reporting period, the company's R&D expenses amounted to 766 million yuan, with an R&D expense ratio of 12.74%, consistently maintained at a high level within

the industry, fully demonstrating the company's long-term commitment and strategic resource allocation capability under its technology-driven strategy.
On the R&D path, the company is conducting parallel development across multiple product lines, covering a full-stack innovation layout from next-generation product development, breakthroughs in underlying hardware, intelligent applications to platform system architecture. This not only requires stable and sustainable R&D investment but also places higher demands on organizational collaboration, project management, and technological evolution. To this end, the company continuously optimizes and refines its standardized, modular, and platform-based R&D system, driving the evolution of the R&D model from 'single-point technological breakthroughs' to 'systematic capability building.' In terms of R&D organization, the company advances technology roadmaps incrementally, allocating resources scientifically to projects at different maturity stages. In resource management, it focuses on optimizing the R&D workforce structure and cross-team collaboration, promoting talent allocation to high-value areas, implementing efficient collaboration mechanisms, and fostering a high-incentive environment to ensure the full release of innovation potential.

The company adheres to clinical value as the core orientation of R&D, placing greater emphasis on the adaptability, conversion efficiency, and synergistic value of R&D outcomes. This ensures that product and technological innovations genuinely serve clinical needs and patient value. While maintaining the depth of technological exploration and the continuity of innovation, the company continuously accelerates the transformation and industrialization of core technological achievements. Taking the uIPD platform as an example, United Imaging Healthcare significantly enhances the development efficiency and quality consistency of multiple products and versions through unified architecture, standardized interfaces, and modular design, laying a solid foundation for future technological evolution and global adaptability.

Looking ahead, the company will continue to strengthen its R&D system centered on value creation, accelerate breakthroughs in key core technologies, deepen platform capabilities and ecosystem collaboration, comprehensively enhance the strategic contribution and return on investment of R&D, continuously advance in technological breakthroughs, accumulate system capabilities, and steadily improve global competitiveness, thereby building a long-term sustainable technological leadership advantage.

(3) Domestic and International Market Expansion: Focus on Global Synergistic Layout, Regional Deep Cultivation to Drive Sustained Growth

In the first half of 2025, with the accelerated release of global medical demand and the steady recovery of domestic procurement needs, the company achieved dual improvements in both quantity and quality in domestic and international markets. This not only further solidified the competitive advantage of its comprehensive product portfolio but also propelled its global expansion to greater depth, steadily enhancing its overall market position.

In the domestic market, China's medical equipment industry is exhibiting a trend of simultaneous recovery and upgrading. Procurement demands from medical and research institutions at all levels are gradually rebounding, with structural opportunities accelerating their release. United Imaging Healthcare closely follows industry trends and policy directions, continuously deepening its localization layout and independent innovation capability building in the ever-changing market environment. Leveraging the traction of technological iteration, the company accurately captures the full spectrum of needs from national-level research institutions to grassroots

medical systems, driving the formation of a more profound and resilient growth pattern in the Chinese market through its comprehensive coverage strategy of 'high-end leadership + diversified penetration'.

During the reporting period, United Imaging Healthcare's revenue in the Chinese market was 4.87 billion yuan, a year-on-year increase of 10.74%. According to third-party authoritative data, the company's comprehensive market share in medical imaging and radiotherapy equipment increased by 3.4 percentage points year-on-year, ranking second in the Chinese market, with a steady and continuously improving market position. Core imaging diagnostic product lines such as MR, MI, and XR continued to consolidate and expand their leading advantages, achieving comprehensive coverage from high-level hospitals to grassroots medical institutions, thereby enhancing both the accessibility of innovative technologies and market penetration. The CT product line accelerated product innovation while scaling up production—the world's first dual-wide-body dual-source CT system, uCT SiriuX, officially entered the NMPA's special review process for innovative medical devices. The domestically developed first photon-counting spectral CT, uCT Ultima, was officially deployed at Zhongshan Hospital affiliated with Fudan University and Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine for clinical testing and research during the reporting period, and recently received NMPA approval for market launch. Radiotherapy and interventional product lines represented by RT and DSA experienced rapid growth—their market shares in China increased by 17.70 percentage points and 2 percentage points year-on-year, respectively, during the reporting period, forming a comprehensive strategic framework of 'dual-drive, synergistic enhancement' in diagnosis and treatment. The integrated panoramic health ecosystem of diagnosis, intervention, and treatment not only continuously enhances the company's technological innovation capabilities and product portfolio competitiveness but also injects sustained momentum into optimizing industry structure, leading high-quality development, and elevating the level of China's self-controlled medical technology.

By product line, in the first half of 2025, the company's MR equipment generated revenue of 1.97 billion yuan, a year-on-year increase of 16.81%, with the market share of its magnetic resonance business steadily rising. With the continuous advancement of MR technology in recent years, the uMR Jupiter 5T has gradually become a focal point in clinical and research fields. Through innovative hardware architecture and sequence optimization, this system has overcome the engineering bottlenecks at ultra-high field strengths, demonstrating unique advantages in imaging resolution, full-body coverage, and research value. During the reporting period, the uMR Jupiter 5T maintained strong growth momentum, with its market share in China increasing by over 20 percentage points year-on-year. The cumulative installed base nationwide exceeded 40 units, widely deployed in top-tier medical institutions and research facilities. In terms of research achievements, the uMR Jupiter 5T has become a key platform for high-level academic research globally. Since its launch over two years ago, the device has facilitated the publication of 50 SCI papers with a cumulative impact factor exceeding 200. In the second quarter of 2025 alone, it yielded 11 research outputs across various fields, including neurological diseases, body imaging diagnostics, and cutting-edge technology exploration, consistently leading the new wave of innovation in MRI research. With the gradual establishment of relevant application guidelines, continuous improvement of clinical standardization pathways, and ongoing iteration and upgrading of core technologies, the uMR Jupiter 5T will undoubtedly drive more cutting-edge research toward clinical translation. It will further refine precision diagnostics, push scientific innovation to the forefront, and promote the internationalization of medical development, comprehensively accelerating medical imaging into a new era.

Secondly, the 3.0T MR product line performed particularly well, with its market share in China increasing by over 5 percentage points year-on-year during the reporting

period. As new products such as the uMR 880, uMR Max, and uMR NX were successfully deployed in medical institutions at all levels, their intelligent clinical solutions and high-performance platforms continued to gain strong market recognition. On July 17, 2025, the company's next-generation uMR Ultra 3.0T MRI system officially received FDA (510k) approval for market launch. This not only marks United Imaging Healthcare's successful entry into the world's most stringent and influential market system with its high-end MRI products but also highlights the company's strong capabilities in core technology innovation. In the future, the company will initiate the domestic registration process for uMR Ultra, accelerate the innovative application and clinical value transformation of advanced imaging technologies in China, and lead magnetic resonance imaging into the era of LIVE Imaging.

Facing the structural evolution of the 1.5T MR market, the company proactively assesses industry trends, systematically optimizes product portfolios and market response mechanisms, and solidifies its leading advantage in core technology platforms. During the reporting period, the company maintained its leading position in the Chinese market for ≤1.5T superconducting MR systems, while continuously launching innovative products to strengthen technological capabilities, enhance market competitiveness, consolidate comprehensive advantages, and build a more robust and flexible competitive system. Leveraging long-term independent R&D achievements, in February 2025, the company took the lead in launching the world's first silicon carbide MRI system, uMR 600. This system not only achieved breakthroughs in core components of a single product but also, through the integration of full-industry-chain technologies, realized four major core technological breakthroughs in key performance indicators across the entire MRI product chain: a direct 57% reduction in energy consumption, a 30% improvement in intelligent diagnostic efficiency, and the incorporation of a full-imaging-chain intelligent process optimization solution, an all-scenario ultra-clear rapid imaging solution, and a full-lifecycle carbon management solution. These innovations inject new momentum into the evolution of MRI systems toward green and low-carbon, intelligent and efficient, lightweight and integrated directions, marking the entry of MRI systems into the new energy era.

Looking ahead to the second half of the year, in the high-end 3.0T market, the company will take technological innovation as the core driving force, accelerate the launch of upgraded and flagship 3.0T strategic new products, closely align with customers' clinical needs, delve into clinical application scenarios, and build differentiated competitive advantages in precision, intelligence, and customization. At the same time, the company will continue to optimize product performance and pricing strategies, steadily expand the scale of high-quality orders, deepen the construction of brand influence, promote comprehensive coverage and in-depth expansion in the high-end market, and further consolidate its leading position and competitive advantages in the 3T MR segment.

In the 1.5T MR market, the company will leverage its multi-tiered and differentiated product gradient layout to precisely match diverse budgets and clinical needs, deepen coverage of grassroots and regional medical institutions, solidify a broad and stable market foundation, and drive sustained high-quality growth of the business system. Meanwhile, the company will fully utilize its technological expertise in the silicon carbide GPA platform and AI imaging chain to continuously advance the intelligent upgrades of the uMR 600/670 series, creating an innovative 1.5T MR product line that combines outstanding performance with exceptional ease of use. This will enhance product competitiveness and consolidate the company's leading position in the global MRI field.

As an industry benchmark in the ultra-high-field MR field, uMR Jupiter 5T leverages its leading hardware architecture, exceptional computational capabilities, and

intelligent AI empowerment to continuously push the boundaries of scientific research and clinical applications. It is expected to create more landmark milestones in global MR research and clinical practice. By integrating multi-center collaborative projects and authoritative expert consensus, it accelerates the transformation of technological leadership into market competitiveness. With the continuous advancement of new materials, new technologies, and AI applications, as well as the ongoing upgrades in algorithms and computing power, the next-generation uMR Jupiter 5T is expected to lead the innovative development of human metabolic functional imaging, opening a new chapter in high-end magnetic resonance imaging technology and further solidifying the company's strategic leadership in the global high-end magnetic resonance field.

Additionally, the company will strengthen brand building and ecosystem collaboration, deepening strategic partnerships with core customers through various industry activities to enhance user experience and market recognition. Leveraging intelligent solutions and innovative achievements, it aims to build an open and win-win cooperation ecosystem centered on clinical and scientific value, driving continuous improvement in the competitiveness of the company's magnetic resonance equipment. In the future, leveraging its leading technological advantages, precise market strategies, and comprehensive service system, the company's MR business is expected to achieve steady growth in the second half of the year, continuing to lead the development of the high-end imaging equipment industry.

In the first half of 2025, the company's CT business maintained steady development, with CT equipment revenue reaching 1.52 billion yuan. In the face of ongoing changes in the market environment, the company has optimized its product portfolio, accelerated the commercialization of innovative products, improved regional response speed, and deepened its focus on key markets. These efforts have not only strengthened the foundation of its core business and enhanced market resilience but also continuously solidified strategic positioning and unlocked future growth potential, injecting robust momentum to drive technological upgrades, lead industry development, and achieve strategic breakthroughs.

In the Chinese market, the company has maintained a leading share in the CT product line, leveraging its comprehensive product portfolio, reliable delivery capabilities, and full lifecycle service support. Among them, the grassroots market performed strongly, with core models achieving rapid volume expansion in multiple regions, driving simultaneous improvements in market coverage depth and service reach capabilities. The high-end market achieved phased breakthroughs driven by technological innovation: In July 2025, the company's independently developed, world-first dual-wide-body dual-source CT system—uCT SiriuX—successfully passed the review by the National Medical Products Administration and was included in the special review program for innovative medical devices. From static to dynamic, from a single time phase to a comprehensive view of cardiac motion, it broke through the imaging field-of-view limitations of dual-source spectral imaging, marking a new level of independent innovation by the company in the high-end imaging field. Meanwhile, the next-generation flagship products such as uCT ATLAS Pro/Elite are gradually entering the market, with commercialization progress accelerating continuously. This not only strengthens the core business but also completes the reserve of key technology platforms, opening up vast opportunities for the next phase of strategic upgrades.

Photon-counting spectral CT, as a significant technological innovation in the field of medical imaging, has opened up new dimensions for precision diagnosis and treatment, leading radiology into a new era of clearer imaging, more accurate diagnosis, and safer treatment. Leveraging long-term technical expertise and sustained

R&D investment, United Imaging Healthcare has achieved systematic breakthroughs in key areas such as semiconductor detectors, system architecture, algorithm innovation, and spectral applications, fully mastering the core technologies of photon-counting spectral CT. During the reporting period, the company's independently developed photon-counting spectral CT was officially deployed at Zhongshan Hospital affiliated with Fudan University and Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, initiating clinical testing and medical research.

On August 25, 2025, United Imaging Healthcare’s independently developed uCT Ultima, China’s first photon-counting spectral CT, obtained marketing authorization from the National Medical Products Administration (NMPA). This achievement represents a significant milestone in the advancement of China’s medical technology. With this approval, United Imaging Healthcare has become the first Chinese company worldwide to commercialize photon-counting spectral CT, marking a new stage in the Company’s journey of independent innovation and participation in global high-end medical equipment competition.

In terms of imaging performance, United Imaging's photon-counting spectral CT is the first domestically produced photon-counting CT to achieve ultra-high-resolution imaging and precise spectral imaging across multiple body regions. First, in ultra-high-resolution imaging (UHR), the company has overcome detector size limitations by reducing the detector pixel area to 1/9 of the traditional size, enabling clear visualization of micro-lesion structures and providing higher spatial resolution for more accurate diagnosis. Meanwhile, the company effectively compensates for signal attenuation caused by pixel reduction through its independently developed correction and reconstruction algorithms, significantly suppressing noise and ensuring stable image quality. In the field of precise spectral imaging, United Imaging Healthcare has achieved key technological breakthroughs, enhancing the quantitative accuracy of spectral imaging while significantly reducing metal artifacts and beam hardening artifacts. In high-definition spectral imaging applications for the heart, the uCT Ultima supports a collimation width of 4cm, providing a superior solution for stable imaging under high heart rates and complex clinical conditions.

Due to the continuous beating of the heart, imaging systems are required to have extremely high temporal and spatial resolution. Therefore, cardiac imaging quality has long been regarded as a key indicator for evaluating CT performance. United Imaging's photon-counting spectral CT not only achieves greater coverage in cardiac scanning but also completes multiple key technological innovations in the presentation of vascular and internal cardiac structures. It enables high-resolution cardiac spectral imaging, cardiac stent imaging, and cardiac plaque imaging. With clearer structural presentation, more comprehensive functional reflection, and more precise lesion identification, it systematically enhances cardiac imaging diagnostics, providing solid support for the early detection and accurate assessment of cardiovascular diseases.

Additionally, addressing the industry challenge of processing large data volumes in photon-counting CT, United Imaging has also implemented full-chain innovations, enabling deeper clinical exploration in extensive and complex scenarios such as cardiac imaging. In terms of safety, this system achieves superior image noise/contrast-to-noise ratio (CNR) under the same dose conditions, significantly enhancing image clarity and diagnostic reliability, thereby further ensuring the safety and accessibility of patient examinations. The approval and market launch of photon-counting spectral CT not only highlights United Imaging Healthcare's forward-looking layout in the next-generation CT technology field but also injects lasting momentum into the global development of precision diagnostics and self-reliant

medical imaging industry, driving the transformation of imaging diagnostics toward higher resolution, lower dose, and stronger value.

Looking ahead to the second half of the year, the company will continue to focus on the three strategic priorities: 'enhancing product strength, strengthening platform value, and optimizing market structure.' The ultra-high-end product line will undergo continuous iteration and upgrades, creating differentiated clinical value around the direction of multidisciplinary integration, further enhancing comprehensive competitiveness in key scenarios. For the mid-to-high-end market, the company will optimize product arrays and adjust strategies to improve the adaptability and response efficiency of overall solutions, steadily expanding more diverse market spaces. For the grassroots market, the company will rely on the new-generation intelligent CT quality control system and high-reliability platform components to continuously enhance the synergy of performance, service, and intelligence, improving overall system efficiency and user experience. Meanwhile, the company will accelerate research collaboration, conducting real-world studies with clinical institutions to thoroughly validate the clinical value of its products across multiple scenarios, thereby further expanding professional recognition and market awareness. The company is confident that in the new market cycle, with a more comprehensive product portfolio, more professional service capabilities, and a more forward-looking strategic approach, it will further achieve structural advancement in its CT business, continuing to lead technological breakthroughs and value enhancement of domestically produced high-end medical equipment on the global stage.

In the first half of 2025, the molecular imaging (MI) market continued to recover, with the market size maintaining rapid growth and industry attention significantly increasing. With the signing of a series of important domestic and international orders and the breakthrough application of high-end new products, the company further consolidated its leading position in the global molecular imaging field.

During the reporting period, the company's molecular imaging product revenue reached 841 million yuan, a year-on-year increase of 13.15%. The PET/CT product line maintained its position as the market leader in China for ten consecutive years. By the end of the reporting period, the company had installed over 600 molecular imaging devices globally, covering nearly 30 countries and regions including China, the U.S., Japan, Italy, Germany, and France. Among these, the cumulative installations of PET/CT in the U.S. market exceeded 150 units, ranking first globally in long-axis PET/CT installations.

With the accelerated global promotion of long-axis PET/CT systems such as uEXPLORER and uMI Panorama GS in top-tier medical institutions, the company is reshaping the diagnostic imaging workflow through ultra-fast imaging, precise decision-making, and safety assurance. By integrating whole-body insights, dynamic tracking, and quantitative empowerment, it advances the implementation of precision medicine. Simultaneously, leveraging high-throughput R&D, low-threshold applications, and clinical-research integration, the company accelerates the translation of scientific achievements, comprehensively meeting the nuclear medicine imaging needs of users at all levels.

Meanwhile, targeting primary healthcare institutions and emerging regional markets, the company extends coverage through short-axis PET/CT products, capitalizing on their cost-performance advantages to drive the adoption of innovative technologies and widespread application. This serves as a key pillar for expanding market reach and building scale advantages. Moreover, with the rapid development of the PET/MR market, China has long ranked first globally in PET/MR installations. By

2024, the scientific research output based on PET/MR has surged to a leading global level, fully demonstrating China's strategic leadership in PET/MR technology R&D, academic influence, and clinical promotion. As of the end of the reporting period, the company's PET/MR products ranked first in cumulative installations in the Chinese market, further solidifying its leadership and sustained growth potential in the field of molecular imaging.

For the second half of 2025, the company will anchor its three strategic pillars—'breakthrough in long-axis, popularization of PET/MR, and deepening of short-axis'—to continuously drive the molecular imaging business toward both quality and efficiency improvements, ushering in a new phase of high-quality development that leads the industry.

In the long-axis PET/CT market, the company will base its efforts on cutting-edge trends, closely align with clinical needs, and strengthen academic leadership. With the rapid development of new diagnostic and treatment models such as proton and heavy ion therapy, radionuclide therapy, AI-assisted diagnosis, integrated diagnosis and treatment, and precision medicine, the company will accelerate the deployment and scaling of long-axis PET/CT systems in key clinical scenarios such as high-level hospitals, proton/heavy ion centers, and specialized children's hospitals. This will drive deeper integration of research and clinical practice, further enhancing the industry influence of its technology and services. In addition, the company will establish a series of demonstration projects driven by research and closely aligned with clinical collaboration to promote the in-depth application of long-axis products in multicenter studies, specialized disease solutions, and the formulation of industry technical standards. This will further solidify the leading position of the company's MI product line in high-end clinical and academic ecosystems.

In terms of short-axis PET/CT, the company will continue to consolidate its key position as a stable business foundation. In the second half of the year, a new generation of short-axis products with superior performance and higher cost-effectiveness will be launched, focusing on prefecture-level hospitals, primary medical institutions, emerging regional markets, and private healthcare markets, driving coordinated efforts across all channels to achieve broader market coverage and more competitive pricing advantages.

The PET/MR business will accelerate its transformation from 'exclusive to research' to 'a clinical standard,' entering a critical development phase. The company will seize the strategic opportunities brought by medical insurance policy adjustments and innovative drug synergies, focusing on advancing clinical implementation in key areas such as neurodegenerative diseases (e.g., Aβ AD), pediatric medicine, and oncology treatment, to build a dual-driven development model of 'neurology + therapy.' Leveraging the multimodal data platform and automated diagnostic and treatment pathway optimization, we aim to enhance the clinical adaptability and market penetration of PET/MR products, achieving an organic integration of precision diagnosis and treatment with large-scale application.

Additionally, the company will focus on core disease areas to comprehensively advance the construction of an intelligent platform that integrates 'diagnosis, treatment, and research into one system.' Leveraging the next-generation molecular imaging technology platform represented by uMI Panvivo, we collaborate with top-tier medical and research institutions to focus on high-value diseases such as liver cancer, nasopharyngeal carcinoma, prostate cancer, and Alzheimer's disease. We conduct real-world studies and validate AI-assisted decision-making models to efficiently translate research outcomes into market drivers, thereby strengthening the company's

technological ecosystem barriers and clinical leadership in the field of molecular imaging. Finally, the company will take "Meta MI Multi-Dimensional Ecosystem" as the core to systematically build an academic and collaborative network for nuclear medicine specialties. Through multi-level, high-frequency academic activities such as case competitions, youth academic group tours, specialized disease reading training camps, and quality control alliance forums, we further build brand influence driven by academics. At the same time, the company will leverage the in-depth development of marketing intelligence to enhance project implementation efficiency and drive sustainable market growth in molecular imaging business.

Radiotherapy, as one of the core methods in cancer treatment, has a wide range of clinical applications and clear therapeutic efficacy. International studies indicate that approximately 60%-70% of malignant tumor patients should undergo radiotherapy during their treatment course. However, in reality, radiotherapy still faces three systemic challenges: 'scarce resources, complex processes, and low efficiency.' First, the distribution of high-quality radiotherapy resources is uneven, with some regions experiencing shortages of equipment and professionals, making it difficult to meet the growing demand for treatment. Second, the radiotherapy process is complex and involves numerous steps, requiring multidisciplinary collaboration from positioning and contouring to planning and execution, which makes it hard to ensure efficiency and consistency. Third, the lack of a real-time response mechanism to dynamic tumor changes during treatment can easily affect efficacy and delay the optimal treatment window, posing significant challenges to precision therapy.

Against this backdrop, the radiotherapy industry urgently needs to use the latest technological advancements as an engine to upgrade treatment models from 'accessibility' to 'high quality' and transform from 'traditional processes' to 'intelligent integration.' The deep integration of artificial intelligence, automation, and multimodal imaging provides a feasible path for full-process intelligent and personalized treatment, while also creating a window of opportunity for leading innovative enterprises in the industry to build differentiated competitive advantages. The accelerated convergence of precision medicine, smart technologies, and telemedicine is driving a profound transformation in radiotherapy, a critical modality in cancer treatment. Currently, radiotherapy equipment is evolving towards intelligence, adaptability, and multi-modal integration, driving treatment pathways to become increasingly personalized and precise, while also imposing higher demands on technological innovation, product layout, and clinical adaptability.

During the reporting period, United Imaging Healthcare focused on its core strategic axis of 'full-process intelligence, precision in solutions, and ecological integration,' systematically advancing the comprehensive development of its radiotherapy business. As the company's radiotherapy product portfolio continues to expand, technological advantages strengthen, and ecosystem layers further develop, the company continuously enhances the accessibility and coverage breadth of high-quality radiotherapy solutions, achieving synergistic breakthroughs across multiple market tiers. During the reporting period, the company's RT business revenue reached 242 million yuan, with a significant year-on-year increase of nearly 18 percentage points in market share in China, forming a second growth curve integrating diagnosis, intervention, and treatment alongside DSA.

In response to the increasingly complex clinical demands and the evolving technological landscape of the radiotherapy industry, United Imaging Healthcare will anchor its strategy on three pillars— “innovation-driven, market-deepening, and ecosystem empowerment”—to systematically advance the high-quality development

of its radiotherapy business. The Company will continue to build core competitive advantages characterized by forward-looking leadership and ecosystem integration, while further strengthening its keen insights into key projects, policy directions, and technology trends. By engaging early in solution validation and fostering deep collaboration, the Company ensures it can secure strategic positions in critical application scenarios and steadily expand its presence and influence at the higher end of the value chain.

At the market level, the Company will focus on precise alignment of its product portfolio and dynamic optimization of resource allocation, driving coordinated improvements in product adaptability, coverage breadth, and delivery efficiency. These efforts will accelerate the transformation of high-quality radiotherapy capabilities from “implementable” to “replicable,” shaping a market landscape characterized by deep coverage and multi-point growth.. In terms of technological innovation, the company will continue to focus on AI-driven initiatives as the core driver, deepening the application and transformation of cutting-edge technologies such as multimodal imaging, spatial segmentation radiotherapy, and biologically targeted adaptive therapy (ART), thereby advancing radiotherapy from 'process optimization' to 'paradigm shift.' Meanwhile, the company will strengthen the synergistic integration of PET/CT with radiotherapy, immunotherapy, and other technical pathways, creating integrated and differentiated diagnostic and treatment solutions for complex diseases, and solidifying the core technological barriers of the precision treatment ecosystem. In terms of informatization and intelligent construction, the company is accelerating the deployment of B/S architecture-based intelligent radiotherapy systems and cloud platforms, building a remote treatment management network for multi-campus and multi-scenario collaboration, continuously enhancing the digital resilience and response capabilities of hospitals, and laying a systematic foundation for 'cloud-based radiotherapy'. At the same time, the company will take the construction of a radiotherapy academic ecosystem as a strategic focus, continuously organizing high-frequency and diverse academic activities such as case competitions and remote consultations, strengthening the endogenous growth of expert collaboration networks and brand influence, and building a closed-loop radiotherapy ecosystem that integrates 'technology-service-trust' as a trinity.

In the future, the company's radiotherapy business will continue to advance China's radiotherapy equipment from 'local leadership' to 'global breakthrough' with stronger comprehensive capabilities, higher strategic positioning, and more stable global deployment, facilitating precision medicine toward a broader and more accessible future.

In the first half of 2025, with the gradual release of hospital equipment renewal demands and the ongoing promotion of regional centralized procurement policies, the domestic XR and DSA markets generally exhibited a steady recovery trend. The XR product line continues steady growth, while the DSA business quickly returned to normal after previous policy disruptions, with accelerated procurement pace and significant increase in transaction amounts. The overall industry sentiment is gradually recovering, showing a positive development trend.

During the reporting period, the company achieved breakthroughs in both XR and DSA businesses, fully unleashing their growth potential. In the XR field, the company adheres to the dual-wheel strategy of 'scenario-driven + intelligent leadership,' continuously deepening product layout and regional penetration, with market coverage steadily expanding. Key product lines such as suspension, column, mobile DR, and mammography work in synergy to build comprehensive solutions

spanning from urban hospitals to grassroots medical institutions, further solidifying the leading position in the digital conventional imaging market. In terms of intelligence, the uDR Aurora platform accelerates the adoption of suspended DR scenarios, leveraging AI image quality control and automated workflows to significantly enhance operational consistency and diagnostic efficiency, helping customers achieve the dual goals of improved workforce efficiency and standardized practices. In the mammography product line, the company has launched the first domestically produced 3D breast biopsy system, uStereo, while simultaneously iterating the new-generation digital mammography platform. This comprehensively builds a high-end integrated solution covering screening, diagnosis, and intervention, further solidifying the leading position of domestic brands in the women's health sector.

Meanwhile, the DSA business continues to make strides in product innovation, market expansion, and clinical validation, demonstrating robust growth momentum. In the first half of 2025, the company's overall DSA orders showed steady growth, with its market share in China increasing by over 5 percentage points year-on-year. Market penetration in several key regions has significantly accelerated, achieving installation breakthroughs in areas traditionally dominated by imported brands, marking the transition of domestically produced high-end interventional imaging equipment from being 'chosen' to becoming the 'preferred choice'.

Represented by the uAngio AVIVA ceiling-mounted DSA system, this product addresses grassroots and clinical pain points, optimizing functional integration, operational convenience, and spatial adaptability, delivering a solution that combines clinical practicality with deployment flexibility. Against the backdrop of an increasingly normalized centralized procurement market, the uAngio AVIVA series products have rapidly gained high recognition from channels and customers due to their solid performance and excellent cost-effectiveness. In lower-tier markets, they have formed a virtuous cycle where genuine experience drives word-of-mouth promotion and technical trust fuels installation growth, providing a powerful engine for the scalable replication of DSA business. More crucially, its industry-first disruptive 'zero-noise' imaging technology significantly enhances image quality and diagnostic efficiency. While ensuring radiation doses remain far below the industry average, it improves image resolution by 57%, increases the signal-to-noise ratio by 4.6 times, and further reduces radiation doses by 70%.

The uAngio AVIVA system has not only garnered widespread clinical acclaim domestically but also achieved FDA approval in the U.S. in May 2025 and CE certification in the EU in June, marking United Imaging Healthcare's DSA officially entering the global mainstream market. It became the first and only domestically produced DSA system to simultaneously obtain the triple authoritative certifications of NMPA, CE, and FDA, achieving a critical leap from domestic leadership to global recognition. During the reporting period, the authoritative organization ECRI rated it as a global four-star DSA with 'Excellent' performance, safety, workflow, and compatibility—the only Chinese DSA product to date to receive four 'Excellent' ratings.

In the second half of 2025, the company will continue to consolidate its leadership in key XR product lines such as DSA, suspension, columns, mobile DR, and mammography within targeted niche markets. By leveraging portfolio value and refined channel management, it will ensure steady business progress. In terms of brand building, the company will deepen collaboration with industry experts, strengthen customer experience resonance, and gradually enhance the global influence of its XR brand. Meanwhile, focusing on key markets and demonstration scenarios, we will drive the continuous accumulation of positive word-of-mouth to create a demonstration effect. With the deep empowerment of ten innovative technologies and integrated solutions, the XR product line will achieve a leap from value-based

sales to intelligent leadership, building a more modular, standardized, and impactful market response system.

Moreover, with DSA achieving the leap from domestic leadership to international certification, becoming the first and only domestically produced system to receive the triple authoritative certifications of NMPA, CE, and FDA, it has officially entered the global mainstream market system. In the future, the DSA product line will continue to focus on high-performance and high-safety technological innovations, leveraging innovative solutions such as zero-noise technology and intelligent imaging algorithms to further enhance image quality, surgical efficiency, and radiation safety, achieving comprehensive optimization of clinical value.

In the first half of 2025, amid a complex and volatile international environment, the company's overseas business demonstrated strong resilience and steady growth. Overseas revenue reached 1.142 billion yuan, a year-on-year increase of 22.48%, accounting for 18.99% of total revenue. The delivery of overseas projects and customer follow-up are accelerating, and it is expected that with the faster conversion of overseas projects in the second half of the year, overseas business will return to a faster revenue growth trajectory.

In terms of orders, the overseas market shows strong growth momentum and vast market potential. During the reporting period, overseas market orders maintained rapid growth, with strong demand from international clients, particularly in high-end and innovative product segments, leading to significant optimization in order quality and structure. Key markets such as North America, Europe, India, Latin America, and emerging markets successfully secured multiple high-value orders, laying a solid foundation for the steady revenue growth of overseas operations throughout the year. Meanwhile, the company has further strengthened its investments in empowering overseas agents, expanding channels, and project execution, which will significantly enhance order conversion efficiency and delivery speed, driving the international business to achieve a rapid closed-loop from orders to revenue realization.

From a regional performance perspective, in the first half of 2025, United Imaging Healthcare continued to achieve a series of impressive results in the international market.

As the core market of the global medical technology industry, since its full entry into the U.S. market in 2018, United Imaging Healthcare has consistently focused on deep collaborations with top academic institutions and industry key opinion leaders (KOLs), successfully establishing a high-end brand demonstration effect centered on innovative equipment and a comprehensive scientific research service system. By promoting the application of United Imaging Healthcare's full-chain innovative ecosystem solutions and comprehensive local clinical, research, and service systems, the company has gained widespread validation and recognition among high-end customer groups in the U.S., with continuously growing brand influence and technological awareness.

As of the end of the reporting period, United Imaging's high-end imaging equipment has covered over 70% of U.S. state-level administrative regions, with cumulative installations exceeding 400 units/sets, including over 150 PET/CT devices deployed. During the reporting period, several landmark projects were successfully implemented, with a series of innovative devices entering multiple top-tier research and clinical institutions, including Ivy League-affiliated hospitals, world-renowned

medical schools, and leading specialized research centers, fully demonstrating the company's comprehensive competitiveness in technological innovation, product performance, and localized services.
In the first half of 2025, the company achieved dual-driven growth in orders and revenue in the U.S. market, with overall business maintaining a strong upward trend. Particularly in core product lines such as MR, MI, and XR, the company successfully entered several top global clinical and research institutions, completing equipment installation and application deployment. This not only accelerated the release of new orders but also significantly enhanced the value contribution of services and aftermarket. Looking ahead to the second half of the year, the company will leverage its continuously evolving technological innovations, rapidly upgrading product matrix, and deepening strategic partnerships to further expand its in-depth layout in the high-end medical imaging equipment sector, continuously increase market share, and establish new heights in global brand influence.

During the reporting period, United Imaging also actively participated in top global academic conferences, such as SNMMI (Society of Nuclear Medicine and Molecular Imaging) 2025 and the International Society for Magnetic Resonance in Medicine (ISMRM), through which it established closer collaborative relationships with academic and research institutions worldwide. Particularly, collaborations with top-tier institutions such as the University of California, Davis, Yale University, and Massachusetts General Hospital of Harvard Medical School have not only deepened the company's interaction with academia but also provided strong support for technological innovation in the field of high-end imaging and diagnostic equipment.

At the 75th SNMMI Annual Meeting held in the U.S., United Imaging made a grand appearance with the strategic stance of a 'Global Leader in Molecular Imaging,' showcasing its next-generation nuclear medicine and molecular imaging product portfolio along with digital and intelligent innovations. During the conference, the company collaborated with top global medical institutions such as the University of California, Davis, Yale School of Medicine PET Center, Peking Union Medical College Hospital, Tongji Hospital of Huazhong University of Science and Technology, and Peking University Cancer Hospital to jointly publish 36 scientific research achievements. These covered multiple cutting-edge areas, including systemic disease diagnosis and treatment, new drug development, advanced molecular imaging technologies, proton therapy efficacy evaluation, precise neurological system quantification, and AI-based image enhancement. This not only highlights United Imaging Healthcare's technical influence and innovation leadership on the international academic stage but also signifies the company's accelerated efforts to establish a strategic stronghold in the global molecular imaging field.

Among them, the NeuroEXPLORER (NX) brain PET, jointly developed by the company with Yale University and the University of California, Davis, has achieved a major breakthrough in the field of neuroimaging. Its innovative technology provides a novel solution for the diagnosis and treatment of neurological disorders. At the conference, Dr. Johannes Czernin, Editor-in-Chief of the Journal of Nuclear Medicine (JNM), announced that the paper titled 'Performance Characteristics of the Next-Generation Human Brain PET/CT Imager NeuroEXPLORER,' co-authored by the NeuroEXPLORER team led by Dr. Hongdi Li, Chief Technology Officer of United Imaging Healthcare, was awarded the dual honors of 'Best Clinical Paper' and 'Paper of the Year' for 2024, selected by the editors.

The successful implementation of the 'High-Profile, Full-Coverage' top-level strategy in the U.S. has not only driven widespread recognition among local high-end

customer groups but also significantly enhanced the company's global brand influence and technological reputation. Through in-depth collaboration with top-tier local research and clinical institutions, the company has not only achieved breakthroughs in technological innovation but also accumulated valuable experience in clinical research, cutting-edge technology transformation, joint innovation, and academic research and clinical applications. This process has not only facilitated rapid expansion of local U.S. operations but also provided strong brand endorsement and replicable commercial pathways for other overseas regional markets, further consolidating the company's global market position.

Currently, the U.S. market has become a key component of the company's global strategy, with significant market opportunities yet to be fully realized in the future. With the implementation of more landmark projects and further improvement of the localized service system, the U.S. market is expected to maintain steady growth by the end of 2025.

In the first half of 2025, the company maintained strong growth momentum in the European market, with rapid expansion in business scale. With the sustained release of equipment replacement demand in mature Western European markets and the accelerated introduction of high-end medical imaging products in emerging Eastern European markets, United Imaging Healthcare successfully secured and implemented multiple projects in Europe during the reporting period, further solidifying the company's brand influence and premium positioning in the European market.

As a crucial part of the company's globalization strategy featuring 'high-profile initiatives and a core with multiple extensions,' the development achievements in the European market are a concrete manifestation of the company's long-term strategic proactive layout. As early as 2018, the company established a subsidiary in Poland, marking the beginning of its European market expansion. Upholding the long-term commitment of 'In Europe, Serve Europe,' United Imaging Healthcare continues to deepen its presence in the European market. Following the establishment of United Imaging Healthcare's European headquarters in the Netherlands in 2024, the successful deployment of the Total-body PET/CT uEXPLORER in top-tier Italian hospitals, and the breakthrough entry of digital PET/CT into Germany and France—two core markets—the company's momentum in Europe further accelerated in the first half of 2025. This period marked a comprehensive harvest in commercial growth, organizational development, and market breakthroughs, steadily advancing the overall strategy from market access to a high-quality, in-depth development phase.

In terms of business expansion and market penetration, the company accelerates the ripple effect from point to surface in the European market by 'entering mainstream public systems, deepening strategic cooperation networks, and establishing clinical research benchmarks,' continuously enhancing brand recognition and technological influence to consolidate its strategic leadership in the global high-end medical imaging equipment sector.

In France, the company actively engages with large private GPO systems, establishing partnerships with multiple regional healthcare conglomerates, resulting in the bulk deployment of high-end CT and MR equipment. Meanwhile, Europe's first uMI Panorama GS was successfully installed at UNICANCER CENTRE LEON BERARD, a Top 3 comprehensive cancer research center in France, further strengthening the company's influence in Europe's core clinical and scientific research

sectors. Additionally, Germany and Spain once again adopted digital PET/CT and high-end MRI systems, marking continued recognition of the company's brand influence and local service capabilities.

In terms of organizational development, the company continues to strengthen its localization in the European market, enhancing service delivery and customer relationship management capabilities. In the first half of 2025, the company accelerated the improvement of sales, service, and operational systems in multiple European countries, continuously expanding the size of local teams to enhance response efficiency and customer loyalty. Meanwhile, the company is steadily advancing the establishment of local teams in Southern and Northern Europe to ensure sustainable support for regional business development. Through product and technological innovation, organizational synergy, channel optimization, and the integration of global resources, the company has established a comprehensive localized development system in the European market that integrates R&D, service, and sales tailored to the characteristics of the European market.

In the future, with the continuous deployment of new equipment, the gradual improvement of regional headquarters' functions, and the deepening of local collaborations, the company is expected to achieve steady and sustained growth in the European market by 2025. Overall business performance is anticipated to reach new heights, serving as a crucial pivot for the globalization strategy and a key driver of sustained growth.

During the reporting period, the company maintained strong momentum in the Asia-Pacific region and emerging markets, continuously expanding its market presence. The company adheres to a globalization strategy of 'aiming high and striking hard, with one core and multiple wings.' Building on the validation of its brand and capabilities in mature markets, it has successfully replicated its advanced product portfolio, end-to-end service system, and localized operational experience in emerging markets, accelerating the formation of a synergistic multi-regional development landscape.

Among these, the Latin American and Southeast Asian markets have performed particularly well, with business achieving rapid leaps and significant growth in both orders and revenue, becoming key growth drivers for the company's global expansion. Meanwhile, the company has continuously achieved 'first-order breakthroughs' or 'landmark implementations' in developed regions of the Asia-Pacific, fully unleashing its high-end product capabilities and localized delivery capacity, gradually building a broad, high-quality, and sustainable growth system for emerging markets.

In the Asia-Pacific region, the company has signed a strategic cooperation agreement with IHH, a leading healthcare group in Singapore, and established partnerships with top medical institutions in Malaysia, Thailand, Vietnam, and other countries. Meanwhile, the company achieved a breakthrough in expanding its global key accounts (KA), successfully partnering with Singapore General Hospital, ranked first in Asia and ninth globally. This collaboration marks a significant milestone in the company's globalization journey, providing strong endorsement for deepening its presence in the high-end Asia-Pacific market.

In Australia, the uMR 680 successfully won the first tender project under the local public healthcare system, signifying the entry of the company's high-end MR products into the mainstream medical procurement systems of Australia and New Zealand. This has enhanced the brand's recognition and influence in the mainstream

public market. This milestone not only lays the foundation for subsequent products to enter more regional tenders but also accelerates the localization expansion process. During the reporting period, the company successfully completed the installation of the 8th PET/CT system in the Australia-New Zealand region in Melbourne. This project further solidifies the company's competitive edge in the high-end molecular imaging sector and will inject confidence and momentum into its sustained growth in the developed markets of the Asia-Pacific region.

In India, the company partnered for the first time with three hospitals under the Apollo Group, securing orders for multiple high-end imaging devices such as uMR Ultra, uMI Panvivo, and uCT 868. This not only opened the market of South Asia's most influential private healthcare group but also marked an accelerated breakthrough phase for the company's brand in India's high-end medical sector. It strongly supports the high-quality construction and upgrading of the local healthcare system, promotes the popularization and accessibility of innovative medical equipment, and tangibly enhances patients' diagnostic and treatment experiences as well as their health standards.

In the Middle East and African markets, the company has also made breakthrough progress in high-end product development. In Turkey, the company secured its first order for the 5T Jupiter MRI, officially introducing the ultra-high-end product line to the Middle Eastern market, demonstrating strong technological leadership. In Kuwait, the first uMI Panorama 35 was successfully contracted, marking substantial progress in the company's high-end product deployment in the Gulf region. In Morocco, the uMI Panvivo 30 and PET/MR equipment completed their first deliveries, advancing nuclear medicine solutions into the North African market and supporting regional healthcare capacity upgrades.

Currently, United Imaging Healthcare is continuously deepening its market presence across various regions, with its strategic global business layout of multi-point deployment and balanced development becoming increasingly clear. Looking ahead to the full year, with the rapid introduction of innovative products, accelerated delivery of key projects, continuous expansion of the customer base, and the ongoing improvement of localized organizational capabilities, the international market is expected to maintain strong growth momentum, injecting more vigorous and sustainable impetus into the company's high-quality global development.

(4) R&D and Supply Chain System: Innovation-driven, Win-win Cooperation, Building a Sustainable and Resilient Global Supply Chain System

In the face of continuous advancements in medical technology and profound adjustments in the global industrial landscape, the company remains committed to innovation as the core driver, establishing a sustainable R&D innovation and supply chain system that integrates R&D breakthroughs, clinical collaboration, and industrial transformation, advancing from 'product leadership' to 'ecosystem leadership'. During the reporting period, the company continuously increased R&D investment and optimized global resource allocation, enhancing its innovation capabilities from core technologies to system integration. Multiple blockbuster products were successfully commercialized, helping elevate global medical diagnosis and treatment standards to new heights.

By the end of the reporting period, the company had obtained approvals for over 140 products, including 53 certified by the U.S. FDA, 57 approved with the EU CE

mark, and 7 products passing China's special review channel for innovative medical devices. A series of flagship products with global influence have been successively launched: The world's first uMR Ultra MR system enhances soft tissue diagnostic clarity with dynamic high-definition imaging technology; the uCT SiriuX dual-source CT system breaks the traditional trade-off between spatial and temporal resolution through its unique dual-wide architecture, achieving full cardiac coverage and multi-modal fusion; and the uAngio AVIVA, the first and only domestically produced zero-noise DSA system certified in China, the U.S., and Europe, has set a new industry standard for signal-to-noise ratio in low-dose high-definition imaging. These breakthroughs not only expand the boundaries of precision diagnosis and treatment capabilities but also comprehensively enhance United Imaging Healthcare's technological influence in the global high-end medical equipment market.

In the field of cutting-edge technological innovation, United Imaging Healthcare has achieved generational breakthroughs across multiple core product lines, comprehensively building a future medical technology roadmap oriented towards 'platformization + intelligence'.

In April 2025, the company's self-developed radiotherapy intelligent contouring system, uIPW (Intelligent Physician Workspace), officially obtained Class III medical device certification from the National Medical Products Administration, becoming the first system in China with AI-based automatic contouring capabilities for multiple target areas and organs. This marks a new era of standardization and precision in China's intelligent radiotherapy. uIPW not only restructures the front-end workflow of radiotherapy but also lays a solid foundation for 'intelligent radiotherapy full-chain solutions' with its three core capabilities: precise multi-organ contouring, adaptive lesion adjustment, and an evolutionary model supported by over 8,000 expert-level datasets. In the future, uIPW will serve as a pivotal fulcrum in United Imaging's 'Equipment + AI' integrated diagnosis and treatment strategy, continuously evolving into a high-precision, full-process, and fully closed-loop intelligent treatment platform.

In July 2025, the world's first dual-wide-body dual-source CT system, uCT SiriuX, was officially included in the National Special Review Channel for Innovative Medical Devices. This system is the first to integrate a wide-body detector with a dual-source architecture, featuring three industry-first technologies: the world-leading 8ms cardiac temporal resolution, dual-wide 16cm full-organ coverage, and a 470mm ultra-large spectral field of view. It achieves a systematic leap in imaging speed, coverage, and spectral accuracy. uCT SiriuX breaks through the limitations of traditional static CT, pioneering multidimensional real-time observation of dynamic structures, blood flow processes, and functional metabolism, delivering unprecedented "four-dimensional dynamic imaging" capabilities. This opens new frontiers in clinical CT applications, accelerating precision medicine into a new era of quantifiable and predictable advancements.

In the field of photon-counting CT (PCCT), the company leverages its long-term technical expertise in CZT materials, detector architecture, and image algorithms to overcome numerous system-level integration and imaging processing challenges. The system has completed full-machine testing and entered the clinical phase. By breaking through traditional scanning limitations in ultra-high-resolution imaging mode, the company has achieved precise capture of complex structures such as the heart, providing more clinically valuable quantitative solutions for complex diseases like coronary artery lesions and tumor foci. Currently, the related technologies have accumulated 113 patent applications, with 58 already disclosed, and high-level research results have been published in internationally authoritative journals such as IEEE TMI. In the future, the company will continue to promote the engineering and industrialization of PCCT, creating a new paradigm for next-generation high-

end CT to serve the needs of early disease screening and precise diagnosis of multiple diseases, while simultaneously driving the integrated upgrade of upstream industries such as detection materials and signal chips.

In the field of ultrasound, the company adheres to the strategic direction of 'full coverage, high performance, and digital intelligence,' systematically building the capabilities of the next-generation intelligent ultrasound platform. By constructing ultra-high-channel hardware systems and an intelligent algorithm-driven imaging software platform, the company has formed a comprehensive product matrix ranging from ultra-high-end equipment to handheld wireless devices, covering diverse clinical scenarios such as cardiovascular, neurological, obstetrics and gynecology, and critical care. Meanwhile, United Imaging Healthcare continues to intensify its technological breakthroughs in image reconstruction, AI-assisted diagnosis, and sensor platforms, with several new devices already entering the clinical validation phase. In the future, the company will focus on achieving breakthroughs in specialized application areas. By collaborating with top-tier hospitals on clinical research partnerships and demonstration projects, it aims to build a top-down brand-driven system and accelerate the global expansion of its ultrasound products.

Additionally, the company will further promote the accelerated implementation of 'equipment + AI' in medical imaging diagnosis and treatment scenarios, building an intelligent healthcare ecosystem. Particularly in AI empowerment, the company has secured FDA approval for over 20 AI-enabled devices, solidifying its leading position in the industry. Around 2018, the company began systematically integrating AI technology into medical imaging and radiotherapy equipment, comprehensively empowering its entire product line from the initial stages of product definition and design. Today, United Imaging's entire range of imaging and diagnostic equipment, from hardware, software, applications, workflows, and more, has been empowered by AI platforms. These include the uAIFI MRI brain-like platform, the uSense CT active sensing platform for CT, the uExcel molecular imaging infinite technology platform, the uAid full-process XR smart imaging technology platform, and a series of other digital-intelligent super technology platforms. The continuous breakthroughs in these digital-intelligent super platforms not only keep the company at the forefront of the current wave of medical imaging AI but also provide strong support for the future launch of innovative products that lead the industry and fill technological gaps. Through the deep integration of platform-based innovation and AI technology, the company is driving medical imaging technology to new heights of intelligence and precision, injecting new momentum into the development of the global healthcare industry.

Looking ahead, the company will further promote the deep integration of AI with big data and intelligent sensing systems, evolving toward an 'intelligent decision support system' and building a full-process intelligent service platform covering pre-diagnosis prediction, in-diagnosis decision-making, and post-diagnosis management. AI will no longer be limited to image recognition and feature annotation, but will become the intelligent hub connecting data to decisions and hospitals to patients. United Imaging will also take 'platformization + intelligence' as its core strategic axis, continuously expanding its technological moat and leading the leap in medical technology from 'precision equipment' to 'smart systems'.

In terms of global collaboration among industry, academia, research, and medicine, as of the end of the reporting period, the company's cumulative patent applications exceeded 9,700, with invention patent applications accounting for over 80%. During the reporting period, over 260 new patent applications were filed, primarily focusing on key technology areas such as next-generation platform technologies.

Relying on the continuous output of the equipment platform and technological openness, the company achieved significant results in scientific research collaboration during the reporting period, with its technological innovation capabilities continuously translating into broad and profound academic influence. By the end of the first half of 2025, clinical and scientific research collaborations based on United Imaging Healthcare's equipment platform had covered multiple countries and regions worldwide, partnering with numerous leading domestic and international research institutions to form a stable and efficient scientific research collaboration network. The company's scientific research achievements continue to expand, with multiple research findings published in top international academic journals such as Nature and Radiology, showcasing its industry-leading technological prowess and innovation capabilities. During the reporting period, the company actively participated in international academic exchanges, consistently contributing high-quality papers at major top-tier academic conferences and authoritative journals, further solidifying its academic standing and influence in the global medical imaging field.

At this year's ISMRM 2025, the premier global academic conference in the field of magnetic resonance, the School of Biomedical Engineering at ShanghaiTech University collaborated closely with United Imaging Healthcare. Leveraging the company's innovative MR technology platform, they showcased 43 groundbreaking achievements. Among these, 10 were selected for oral presentations (Oral), 2 for Power Pitch sessions, and they secured 1 gold award, 3 silver awards, and the runner-up position in the engineering category. These achievements span cutting-edge fields such as cardiac imaging, infant brain imaging, and low-field portable devices, showcasing the international competitiveness of integrated innovation in 'industry-academia-research-medicine' and injecting strong momentum into United Imaging's ecosystem innovation. By continuously enhancing the academic and clinical application value of its products, the company has achieved remarkable results in building a high-end medical brand image, particularly in the field of rigorous medicine, gradually establishing itself as an industry benchmark.

Meanwhile, to comprehensively support the rapid global expansion and high-quality development of its business, United Imaging Healthcare is systematically building an integrated, efficient, and highly responsive global customer service system, continuously elevating the brand value and business extension capabilities of its after-sales services. As of the end of the reporting period, the company's global installed base has exceeded 36,000 units/sets. Leveraging a team of over 1,000 service engineers, three regional service centers, and a global network of more than 30 spare parts warehouses, the company has established a multi-tiered service organization. This enables an 8-hour coverage mechanism synchronized with time zones worldwide, building a service guarantee capability of "7×24-hour response + localized support + efficient fulfillment." The company is continuously strengthening its global service operation system centered on "customer focus, regional pivots, and platform core," significantly reducing customer response times and parts turnover cycles, achieving a leap from "service delivery" to "service experience."

In terms of service mode, the company is steadily optimizing its strategic layout to adapt to the continuous expansion of equipment installations and the growing demand for professional services from customers. By strengthening local team building, deploying an independent spare parts system, and enhancing training capabilities at the grassroots level, the company continues to improve its service control and quality stability in key markets, contributing to the realization of a value loop integrating 'product-service-customer' as a trinity. Currently, United Imaging Healthcare is continuously refining its overseas service marketing and revenue system, focusing on service value creation and comprehensive customer lifecycle management. Through differentiated pricing mechanisms, the digitization of service

sales processes, and collaboration with local teams, the company's service revenue has maintained rapid growth, forming another growth curve alongside the expansion into new overseas markets.

Looking ahead, the company will further transform its global service platform from a 'support function' to a 'growth engine,' accelerating the establishment of a unified global service management mechanism and digital service capabilities, thereby continuously strengthening the foundational support for overseas business development. Leveraging the synergy of 'equipment + services', United Imaging Healthcare is driving the dual breakthrough of brand power and value for its innovative solutions in the international market with higher-level global delivery and service capabilities.

(5) Sustainable Development: Anchoring High-Quality Sustainable Growth with a New Paradigm of High-Level Governance

Sustainable development and green low-carbon transformation have become the inevitable path for high-quality growth of global enterprises. United Imaging Healthcare has always deeply integrated environmental, social, and governance (ESG) responsibilities into its corporate strategy, committed to leading the industry toward a more sustainable future that is greener, fairer, and more resilient through systematic management and continuous innovation.

In terms of carbon management, the company has established a dedicated carbon management task force to systematically advance environmental governance and the construction of a carbon emission management system. It has explicitly set a medium-to-long-term goal of reducing Scope 1 and Scope 2 carbon emission intensity by 50% by 2035, using 2023 as the baseline. To further enhance the standardization and transparency of carbon information disclosure, the company participated in the CDP (Carbon Disclosure Project) questionnaire for the first time and achieved the highest management-level rating of B, demonstrating its strong governance and forward-looking approach in the field of environmental information management.

Thanks to its long-term commitment in corporate governance, social responsibility, and environmental and sustainable development, the company has achieved outstanding performance in authoritative ESG rating systems: its MSCI ESG rating was upgraded to 'A,' ranking among the top 15% in the global medical device industry in the S&P Global Corporate Sustainability Assessment (CSA). It was also successfully listed among the 164 leading companies in China in the 'Sustainability Yearbook (China Edition) 2025,' becoming an exemplary representative of Chinese high-end medical technology enterprises in practicing sustainable development.

In terms of green product transformation, the company's uCT 780 X-ray computed tomography system successfully passed the ISO 14067 product carbon footprint verification in July 2025, becoming the first CT product in China's large medical equipment sector to obtain this certification. This certification was jointly completed by United Imaging Healthcare and the internationally authoritative organization SGS, strictly adhering to the ISO 14067 standard. It systematically evaluates the carbon emissions throughout the entire process of the equipment, from raw material acquisition and component production to final assembly, achieving a 'cradle-to-gate' lifecycle carbon footprint assessment. This achievement not only quantifies the environmental impact of the product but also helps the company identify high-carbon emission factors in the development process, further optimizing the production workflow and enhancing environmental friendliness. This groundbreaking

certification marks the company's leap from concept to empirical validation in 'green intelligent manufacturing' and product lifecycle carbon management, setting a green benchmark for the industry.

Centered on the 'Ecodesign' concept, the company is continuously advancing the development of a low-carbon R&D system, systematically driving the green transformation across product design, manufacturing, and supply chain processes. In the future, United Imaging Healthcare will accelerate energy-saving upgrades and green process innovations, continuously promote the deep integration of environmental and business practices, fully support the national 'dual carbon' strategic goals, and actively build an efficient, environmentally friendly, and sustainable medical equipment industry chain ecosystem.

At the same time, United Imaging Healthcare will also prioritize advancing global healthcare equity and accessibility as the core direction of its corporate social responsibility. Against the backdrop of highly uneven global distribution of medical resources and widespread health inequalities, the company, with the vision of 'Making a Difference for Universal Health,' actively empowers the development of grassroots healthcare systems in developing countries by providing affordable, high-performance precision diagnosis and treatment solutions. It is committed to narrowing the healthcare service gaps between different regions and populations within developed nations. Regardless of patients' diverse geographical locations, body types, or cultural backgrounds, the company consistently focuses on inclusive technology and scalable platforms as its core, driving the concept of 'universal healthcare' from theory into reality.

At the critical juncture of mid-term development in 2025, United Imaging Healthcare will continue to drive innovation as its core, closely aligning with global trends and clinical needs in medical imaging and precision diagnostics. The company will accelerate the construction of a more resilient, responsive, and efficient global operational system and organizational capabilities, solidifying the strategic foundation for sustainable growth.

Looking ahead, United Imaging Healthcare will leverage more advanced intelligent solutions as technological vehicles, supported by a more flexible global delivery and service system, and driven by deeper original R&D and ecosystem innovation capabilities. The company will continue to promote the diversified implementation and accessibility of precision medicine, contributing to a more efficient, equitable, and sustainable global healthcare system, and fostering greater equality in innovative healthcare worldwide.

Analysis and Outlook on Changes in Non-Enterprise Accounting Standards Financial Indicators
□Applicable√ Not applicable

Significant changes in the company's operations during the reporting period, as well as matters that had a significant impact on the company's operations during the reporting period and are expected to have a significant impact in the future
□Applicable√Not applicable

III Analysis of Core Competitiveness During the Reporting Period

i Analysis of Core Competitiveness

The company is a leading domestic and globally rare medical technology enterprise that masters core technologies in high-end medical imaging diagnostic products, radiotherapy products, and life science instruments. It possesses full lifecycle management capabilities from R&D, production, sales, to after-sales maintenance.

1. Comprehensive product portfolio and leading product performance

(1) Comprehensive product coverage

The company has developed a diverse product line centered around high-end medical imaging equipment, covering diagnostic products such as MR, CT, XR, PET/CT, PET/MR, radiotherapy products including conventional RT and CT-guided RT, as well as life science instruments like animal MR and animal PET/CT, meeting needs from preclinical research to diagnosis and treatment. The company's equipment is equipped with independently developed medical imaging processing software and advanced applications, enabling the organic integration of research, diagnosis, treatment, and planning, providing a one-stop solution for precision diagnosis and treatment.

(2) Advanced product performance

The company has developed multiple products that are industry or domestic 'firsts,' including the industry's first PET/CT product with 4D whole-body dynamic scanning capabilities, uEXPLORER (Total-body PET/CT), which was named one of the 'Top 10 Breakthrough Technologies in the World' by Physics World magazine in 2018; the domestically first photon-counting spectral CT, uCT Ultima, which pioneered ultra-high-resolution whole-body multi-site imaging and precise spectral imaging for domestic photon-counting CT; the industry's first whole-body imaging MRI system, uMR Jupiter 5T, tackled core component and technology challenges in ultra-high-field MRI, achieving ultra-high-field whole-body clinical imaging; the industry's first 75cm bore 3.0T MRI product, uMR Omega, featuring multiple patented technologies such as zero helium evaporation, active/passive shimming, and quench protection; the world's first 'zero-noise' smart bionic aerial robotic angiography system, uAngio AVIVA, which, combined with advanced Burst Denoise technology, improves the signal-to-noise ratio by 4 times while reducing radiation dose by 40-86%; and the industry's first diagnostic-grade CT-guided integrated radiotherapy accelerator, uRT-linac integrated CT linear accelerator, among other products.

2. Strong comprehensive R&D capabilities

(1) Vertical R&D System

The company has established a vertical innovation system that integrates technology, products, and software, focusing on the core components of each product line to drive core technology R&D. This lays a solid foundation for achieving independent control of core technologies and building competitive barriers for products. The company's self-developed ratio ranks among the top in the industry, with all major core components of each product line being independently developed and produced.

(2) Platform-based R&D model

The company has established a general software and hardware R&D platform, adopting a cross-product-line platform-based R&D model to provide a foundation for technology sharing and exchange, as well as product integration and iteration. At the R&D level, the common underlying architecture facilitates innovation in developing multimodal products; at the project level, shared software and hardware designs enhance R&D efficiency and accelerate product iteration; at the product level, a unified system, combined with consistent industrial and interface design, ensures high consistency in brand image and user experience across the company's different product lines, contributing to strengthened brand influence and sustained product promotion.

(3) Cutting-edge Innovation Strategies

The company guides innovation direction through forward-looking research and market trends. On one hand, the company actively engages in forward-looking research to explore and seize new opportunities in industry transformation and development, providing technological reserves for its R&D innovation. On the other hand, each product division maintains close ties with the market, continuously driving technological innovation and iterative upgrades across the entire product line through rapid responses to market demands.

(4) Global R&D Talent Pool

Talents are the foundation of the company's continuous R&D innovation. Through internal cultivation and external recruitment, the company has established a globally-minded R&D echelon led by top scientists and individuals with extensive industry management and R&D experience. As of the end of the reporting period, the company had a total of 8,420 employees, including 3,391 R&D personnel, accounting for 40.27% of the total workforce.

3. Comprehensive intellectual property layout

The intellectual property system is the core support for technological innovation and a crucial safeguard for the sustainable development and globalization of enterprises. The company has established a comprehensive database and intellectual property management platform, achieving platform-based management of intangible assets throughout their entire lifecycle. The company's intellectual property system covers patents, trademarks, copyrights, and technical secrets. As of the end of the reporting period, the company had filed over 11,000 intellectual property applications, primarily patents, with invention patent applications accounting for more than 80% of the total. The company has been granted over 6,100 intellectual property rights, including more than 3,600 invention patents. At the same time, the company strictly protects its technical secrets in accordance with the Information Security Management Measures and the Trade Secret Management System, aiming to build a comprehensive intellectual property layout system to safeguard the company's technological innovations from various perspectives.

(1) Forward-looking layout strategy

Since its establishment, the company has consistently regarded patent layout strategy as a crucial means to enhance its competitiveness. By integrating its own technological path, cutting-edge industry technologies, and market expansion directions, it continuously builds patent barriers. The company's patent mining

mechanism spans the entire lifecycle of technology R&D, with patent applications extensively covering all product lines. Meanwhile, during the R&D process, the company proactively plans and secures patent protection for potentially implementable future technologies to gain a competitive edge, ensuring the acquisition of more foundational patents and higher layout efficiency.

In terms of trademarks, the company initiated trademark layout in line with product launch plans during its early stages, leveraging the advantages of the Madrid trademark system for global trademark deployment, laying the foundation for overseas market expansion.

The company has developed a comprehensive intellectual property strategy that balances offense and defense, integrating its technical roadmap, industry trends, and market expansion direction.

(2) Establishment of the system framework

In line with its development strategy, the company has established a comprehensive and systematic intellectual property management system, covering the acquisition, maintenance, and utilization control of intellectual property. At the risk control level, it can support intellectual property risk identification and legal dispute resolution; at the document and regulation level, the company has established control procedures covering intellectual property documents and legal regulations; at the information security level, the company implements strict confidentiality management for intellectual property information resources.

4. Multi-dimensional marketing network

The company integrates direct sales and distribution models, establishing a diversified and multi-dimensional marketing system that covers domestic and international markets, including top-tier research institutions, universities, tertiary hospitals, and grassroots organizations. The company actively implements the national hierarchical medical treatment strategy, penetrating grassroots medical markets with a rich product portfolio, and promotes the decentralization of medical resources through innovative devices and internet integration. In overseas markets, as of June 30, 2025, the company has established a sales network in multiple countries and regions worldwide, including the United States, Japan, Poland, Australia, New Zealand, South Korea, South Africa, Morocco, and Malaysia. The company's products have successfully entered nearly 90 countries and regions, including the United States, Japan, South Korea, New Zealand, Italy, and India.

5. Comprehensive after-sales service

The company is customer-experience-centric, building a comprehensive customer service system around routine after-sales needs, emergency response requirements, and feedback demands. The company has established an after-sales team that pays attention to detail and strives for excellence, providing customers with comprehensive services including training, installation, maintenance, upgrades, and upkeep. Additionally, the company places great emphasis on continuous communication with customers and obtaining feedback to facilitate product optimization and upgrades by the R&D team.

6. Integration and innovation of industry, academia, research, and medicine

The company is gradually transitioning from a single dimension of empowering clinical practice with products and technologies to building a deeply integrated innovation system of industry-academia-medicine collaboration with comprehensive technological support. The company has established a full chain from 'basic research-clinical application-translational medicine-industrial transformation,' driving product definition, performance optimization, application expansion, and clinical demonstration through clinical needs and major medical challenges. This forms a closed-loop management from innovation to commercial transformation, continuously expanding innovation leadership and commercial competitiveness.

ii Core Technologies and R&D Progress

1. Core technologies and their advancements, as well as changes during the reporting period

Through years of R&D accumulation, the company has mastered the following core technologies:

(1) Core technologies of Magnetic Resonance Imaging (MR) systems

Serial number	Category	Core Technology	Technical Advancement	Technology Source	Main Purpose	Application Product
1	Core hardware design and production technology	Design and production technology of superconducting magnets	1. The company is one of the few enterprises that have mastered the core technology of 5.0T and above high-field human superconducting magnets. 2. Magnet uniformity indicators at industry-leading levels 3. First to achieve a 75cm ultra-large patient bore 3.0T superconducting magnet	Independent R&D	Superconducting magnet design and manufacturing	MR, PET/MR
2		High-performance gradient coil design and production technology	1. Gradient strength covers 33mT/m to 300mT/m, and gradient switching speed covers 125T/m/s to 220T/m/s, leading the industry 2. Utilizing vacuum potting technology and advanced material formulations, it boasts high mechanical performance and operational reliability.	Independently developed	Gradient coil design and manufacturing	MR, PET/MR
3		All-digital megawatt-level gradient power amplifier (GPA) technology	1. The industry's first third-generation semiconductor SiC gradient power amplifier (GPA) technology and its industrialization 2. Gradient power amplifier power range covers 0.5 MW to 3.5 MW power levels, achieving industry-leading standards 3. All-digital control technology enhances the fidelity and stability	Independently developed	Gradient power amplifier design and manufacturing	MR, PET/MR

Serial number	Category	Core Technology	Technical Advancement	Technology Source	Main Purpose	Application Product
			of gradient magnetic fields			
4		All-digital radio frequency power amplifier (RFPA) technology	1. Adopt all-solid-state power amplification and high-density, highly integrated structural optimization technology to reduce volume and cost. 2. Utilize all-digital nonlinear compensation technology to improve signal fidelity and stability.	Independent research and development	RF power amplifier design and manufacturing	MR 、 PET/MR
5		High-field multi-channel RF transmission technology	Mastering multi-channel independent control technology can improve the uniformity of RF transmission magnetic fields, placing it at the industry's leading position	Independent R&D	RF transmit coil design and manufacturing	MR, PET/MR
6		Design and production technology of RF receiving coils	1. High-channel dedicated receiving coils can cover all parts of the body, leading the industry 2. Master low-noise preamplifier RF and advanced coil technology	Independent research and development	Design and manufacturing of RF receiving coils	MR, PET/MR
7		Distributed spectrometer and optical fiber digital transmission technology	High number of receiving channels and signal stability reach industry-leading levels	Independently developed	Design and manufacturing of magnetic resonance spectrometers	MR
8	Core software applications and algorithm technologies	Magnetic Resonance Fast Imaging Technology	1. Industry-first Light Spiral Imaging Technology Platform, achieving 0.5 seconds/frame rapid dynamic high-definition imaging 2. The Smart Light Shuttle Imaging Technology Platform integrates the advantages of artificial intelligence and light shuttle imaging technology, enabling whole-body imaging in just hundreds of seconds. 3. The industry's first dynamic imaging technology, the LIVE	independent R&D	MRI sequence and clinical application development	MR, PET/MR

Serial number	Category	Core Technology	Technical Advancement	Technology Source	Main Purpose	Application Product
			platform, marks a breakthrough in magnetic resonance imaging from 'photography' to 'videography'.			
9		Automated Magnetic Resonance Scanning Technology	1. Full-process intelligent empowerment enables smart scanning of various body parts such as the head, heart, spine, and abdomen. 2. Equipped with intelligent functions such as one-key Table In, multi-protocol convenient planning, automated post-processing, key component failure warning, and sleep/wake modes.	Independently developed	Implementation of intelligent magnetic resonance scanning workflow	MR, PET/MR
10		Advanced MR Applications and Post-processing Techniques	1. Possesses advanced application technologies that are industry-first in MR, including complex-domain diffusion reconstruction technology, multi-echo advanced susceptibility-weighted imaging technology, and 3D high-definition MATRIX technology. 2. Features multiple quantitative imaging technologies such as liver fat quantification FACT technology and dynamic scanning DCE technology. 3. Possesses multiple advanced post-processing applications, including fully automated cardiac chamber segmentation software based on deep learning and dynamic contrast-enhanced liver scan quantitative analysis software.	Independently developed	Advanced MR application and post-processing product development	MR, PET/MR

(2) Core technologies of X-ray computed tomography (CT) systems

Serial number	Category	Core Technology	Technological Advancement	Technical Source	Primary Use	Products Used
1	Key component design and manufacturing technology	detector	The "Space-Time Detector" significantly reduces electronic noise, lowers dosage while improving image resolution, achieving industry-leading performance.	Independently developed	CT detector manufacturing and processing	CT
2		X-ray tube	Features high power capability, high heat	Independently	CT Tube Design and	CT

Serial number	Category	Core Technology	Technological Advancement	Technical Source	Primary Use	Products Used
			content, and long lifespan, with improved image resolution through femtojoule technology	developed	Manufacturing	
3		high-voltage generator	1. By utilizing fully digital-controlled high-frequency inversion, high-voltage transformer step-up technology, and high-frequency rectification technology, the volume and weight of the high-voltage generator are reduced, and the switching speed of kV output pulses is improved. 2. Equipped with high-speed grid control technology and flying focal spot technology.	independently developed	CT high-voltage generator design and manufacturing	CT
4	full-chain low-dose technology	precision organ dose modulation technology	Precise dose modulation for different examination subjects and regions using artificial intelligence technology	Independently developed	Used to achieve low-dose scanning and reduce patient dose	CT
5		Deep learning noise reduction reconstruction technology	By reducing noise, the imaging capability of small lesions can be improved while lowering the radiation dose.	independently developed	Reduce dosage, enhance lesion detection capability, and assist doctors in diagnosis	CT
6		Iterative reconstruction noise reduction technology	Effectively reduces image noise and improves the signal-to-noise ratio, enabling lower radiation doses while enhancing image quality	Independently developed	Reduce the dose to improve lesion detection capability	CT
7	High-efficiency automated scanning technology	"Sky Eye" Platform Technology	Automatically identifies patient anatomy via cameras and intelligently matches it with scan protocols to optimize CT scan workflows.	independently developed	used to assist in completing CT scan preparation work, improving the efficiency of the scanning workflow	CT
8		Easylogic automated	Improves image reconstruction speed through	independently	improve the efficiency of	CT

Serial number	Category	Core Technology	Technological Advancement	Technical Source	Primary Use	Products Used
		prediction technology	algorithms, accelerating the scanning process	developed	the scanning workflow	
9		ePhase automated phase recommendation	By automatically selecting the optimal reconstruction phase from different cardiac cycles, it reduces the need for manual judgment and selection by operators, thereby improving coronary artery image quality and physician workflow efficiency.	independently developed	enhance image quality and work efficiency	CT
10		CardioCapture Coronary Artery Tracking Technology	Performs motion artifact correction on coronary arteries in cardiac CT images, reducing diagnostic challenges caused by pulsatile artifacts and significantly improving the success rate of cardiac scans.	independent R&D	enhance image quality and work efficiency	CT
11	Post-processing technology	Automated post-processing technology	A comprehensive CT image analysis application, including efficient and automated cardiovascular and cerebrovascular extraction, dynamic analysis, tissue segmentation, and report generation. Provides functional assessment results based on structural evaluation.	independently developed	precise post-processing to enhance accuracy and processing efficiency, aiding diagnosis	CT

(3) Core technologies of X-ray imaging systems (XR)

Serial number	Category	Core technology	Technological advancement	Technical source	Main purpose	Products Used
1	Image Reconstruction and Post-processing Techniques	Full Field of View Cone Beam Computed Tomography Reconstruction	Based on the innovative full-field-of-view scanning trajectory and reconstruction algorithm, the reconstruction field of view of cone	Independently developed	Increase the field of view size for cone beam CT reconstruction	DSA

Serial number	Category	Core technology	Technological advancement	Technical source	Main purpose	Products Used
		Technique	beam CT has been expanded to 431mm, achieving full abdominal coverage.			
2		Image reconstruction technology in breast tomosynthesis systems	Based on the imaging characteristics of tomographic X-ray photography systems, artifacts caused by data undersampling are suppressed, thereby improving resolution in different directions.	independently developed	Improve image resolution	Mammography machine
3		Multi-scale image enhancement and equalization techniques in static DR imaging	Based on human visual recognition MODE, the image undergoes non-linear multi-scale decomposition to achieve enhancement and noise reduction for specific features.	Independently developed	Highlight the lesion location	DR
4		Real-time multi-scale image processing technology in dynamic fluoroscopy	During real-time dynamic processes, based on human visual recognition patterns, multi-scale dynamic range equalization and multi-level detail enhancement are applied to ROI human body structures.	independently developed	Improve real-time performance and image clarity in dynamic imaging	Mobile C-arm
5	Low-dose imaging technology	Automatic exposure parameter adjustment technology in X-ray fluoroscopy equipment	Using target image brightness as a feedback parameter to ensure consistent image quality across different regions during real-time imaging while reducing radiation dose	independent R&D	reduce radiation dose	DSA, mobile C-arm
6		Wireless positioning technology based on	Integrating the motion behavior of mobile X-ray equipment with the	Independent R&D	Improve positioning accuracy and reduce	DSA, mobile C-arm

Serial number	Category	Core technology	Technological advancement	Technical source	Main purpose	Products Used
		optical encoding	image acquisition process to achieve wireless positioning, avoid additional trial exposures, and improve surgical efficiency, leading the industry		trial exposures	
7	Automated Electromechanical Control Technology	Multi-Degree-of-Freedom Electromechanical System Control Technology	Based on kinematic modeling and dexterous point-to-point planning technology, achieving precise motion and automatic path planning for high-degree-of-freedom devices	Independently developed	Rack motion control and obstacle avoidance	DSA
8		Medical equipment speed control and motor dynamic output adjustment technology	Based on angle sensors and automatic motion control technology, it achieves real-time adjustment of energy demand at different motor angles, enabling electric speed control according to the vehicle's tilt position, thereby enhancing the user experience for operators.	Independently developed	Improve the operational experience of electric motion	DR
9		Mobile X-ray Machine Auxiliary Positioning System and Technology	Adopting automatic spatial position detection technology to achieve automatic planning and memory functions for spatial positions	Independently developed	Auxiliary positioning during movement	Move the C-arm
10		X-ray machine motion trajectory planning technology	Motion trajectory planning for moving components using artificial potential field technology	Independently developed	Motion obstacle avoidance	DR

Serial number	Category	Core technology	Technological advancement	Technical source	Main purpose	Products Used
11		Remote monitoring and exposure control technology based on wireless communication technology	Based on wireless communication technology and video surveillance, remote monitoring and exposure control functions are achieved, reducing the radiation dose received by clinical medical staff.	Independently developed	Remote video monitoring and remote exposure control	DR
12	Core component technology	High-voltage generator technology	Utilizes parallel high-frequency power electronic switching technology to increase output power, employs high-frequency inverter technology to reduce component size and output ripple, enhances kV output pulse switching speed, and minimizes ineffective radiation dose	Independent research and development	Provides the high voltage, tube current, filament current, and rotating anode drive required for X-ray tube generation as an electronic control device	DSA, DR, mammography machines

(4) Core technologies of molecular imaging systems (MI)

Serial Number	Category	Core technology	Technological advancement	Technical source	Main purpose	Products Used
1	PET detector technology	Digital light guide PET detector design	A novel digital modular PET detector based on SiPM and LYSO crystals, featuring built-in light guide design, achieving industry-leading sensitivity and spatial resolution	Independently developed	PET Detector Design and Manufacturing	PET/CT PET/MR
2		Crystal Growth and Assembly Technology	Manufacturing methods and processes for large-size, high-luminosity scintillation crystals, providing support for high-performance detectors and representing industry-leading standards	Independent R&D	Manufacturing and processing of PET detector crystal materials	PET/CT PET/MR

Serial Number	Category	Core technology	Technological advancement	Technical source	Main purpose	Products Used
3		High-precision PET detector calibration technology	Efficiently extract detector status information, improve the accuracy of PET detector signal processing, thereby enhancing image quality to industry-leading standards.	Independently developed	Maintain PET system stability	PET/CT PET/MR
4		PET detector temperature control technology	Low-cost, high-efficiency cooling design enhances the temperature uniformity and stability of PET detector systems, achieving industry-leading performance.	Independently developed	Maintain PET system stability	PET/MR
5	Electronic technology	Discriminable coincidence event processing technology	Enhances coincidence efficiency and system count rate performance, achieving industry-leading standards	Independent research and development	High counting rate coincidence processing	PET/CT PET/MR
6		Cross-unit compliance technology	The long-axis PET system achieves ultra-high sensitivity, leading the industry.	Independently developed	Long-axis PET system compliance processing	PET/CT
7		Load balancing technology for parallel acquisition	Real-time balancing of multi-channel loads during parallel acquisition significantly enhances the data collection and processing capabilities of long-axis systems, achieving industry-leading performance.	Independently developed	High-speed PET data acquisition	PET/CT
8	Reconstruction and image processing techniques	Parallel image reconstruction method	The GPU-accelerated high-efficiency parallel reconstruction algorithm effectively improves computational speed, enhances quantitative accuracy through comprehensive physical corrections, and outputs high-quality images, achieving industry-leading standards.	Independent research and development	PET image reconstruction	PET/CTPET/MR

Serial Number	Category	Core technology	Technological advancement	Technical source	Main purpose	Products Used
9		Regularized iterative reconstruction algorithm	Incorporating noise control into iterative reconstruction to improve quantitative accuracy while suppressing image noise, enhancing lesion detection capability, achieving industry-leading performance	independently developed	improve the detection capability of lesions	PET/CTPET/MR
10		Artificial intelligence reconstruction algorithm	Reduces image noise, improves image quality, and shortens scanning time, achieving industry-leading performance	Independent research and development	Reduce image noise and achieve low-dose rapid scanning	PET/CT PET/MR
11		Artificial intelligence attenuation correction technology	Precise segmentation of whole-body tissues, for the first time including skeletal tissue information, significantly improving image quality and quantitative accuracy, setting the industry-leading standard.	Independently developed	Attenuation correction in the image reconstruction process	PET/MR
12		Motion artifact removal technology	Utilizing a data-driven approach to reduce PET image artifacts caused by respiratory and head motion, enhancing image quality to industry-leading standards.	Independently developed	Reduce motion artifacts and improve image quality	PET/CT
13		Tumor analysis	Fully supports PERCIST and RECIST standards, enables multi-timepoint comparative analysis with one-click completion, setting the industry benchmark.	Independently developed	Rapid and accurate diagnosis of tumor diseases	PET/CTPET/MR
14		Parametric imaging and analysis techniques	Provide quantitative analysis of drug metabolism based on multiple models, obtaining pharmacokinetic information at an industry-leading level.	Independently developed	Improve diagnostic accuracy	PET/CT

(5) Core technologies of radiation therapy systems (RT)

Serial number	Category	Core Technology	Technological Advancement	Technical source	Main purpose	Products Used
1	Electrovacuum technology	High-dose-rate isochronous dual-beam accelerating tube technology	Simultaneously delivers high-dose-rate treatment beams and ultra-low-energy imaging beams. The treatment beam in FFF mode can achieve a maximum output of over 1400 MU/min, significantly improving treatment execution efficiency. The low-energy imaging beam can deliver electron beams below 1.5 MV, greatly reducing the imaging dose required for image guidance.	Independently developed	Improve the efficiency and precision of radiotherapy	CT-guided linear accelerator, linear accelerator
2	Electronic Control Technology	Precision Dose Control System	Through fully digital real-time control systems, dynamic trajectory planning algorithms, and closed-loop dose algorithms, the minimum control dose tracking accuracy can reach below 0.1MU, with long-term stability below 1%; the dual-channel dose system's fully independent design avoids failure risks.	Independent R&D	Precise dosage control	CT-guided linear accelerator, linear accelerator
3	Precision Machinery and Control Technology	Dynamic Multi-Leaf Collimator System	Key intensity modulation technologies enable precise conformal treatment, with repositioning accuracy less than 0.5mm and minimum leaf width of 5mm; real-time dynamic control is achievable, supporting dynamic rotational intensity modulation technology to cover the entire radiation field.	Independently developed	Precision Conformal	CT-guided linear accelerator, linear accelerator
4	Image integration technology	Integrated CT Imaging Technology	Pre-treatment precise registration facilitates accurate detection of changes in target areas and surrounding tissues and organs; during treatment, imaging information is used to	Independently developed	Radiotherapy simulation and delineation, pre-treatment image-guided positioning correction,	CT-guided linear accelerator

Serial number	Category	Core Technology	Technological Advancement	Technical source	Main purpose	Products Used
			monitor and adjust the dose distribution of patient treatment, achieving personalized adaptive precision radiotherapy. Can achieve the entire radiotherapy workflow in a single equipment room, completing a fast one-stop treatment process		individualized adaptive radiotherapy, online treatment plan modification	
5	Precision Machinery and Control Technology	High-precision treatment couch and automatic deformation compensation technology	Through special dimensional design, graded motion, CT imaging combined with laser displacement sensors, and other technologies, it achieves the treatment couch with the longest motion range, highest stiffness, and smallest error in the industry.	Independent research and development	Tumor patient immobilization and positioning	CT-guided linear accelerator
6	Physical algorithm technology	Monte Carlo dose calculation algorithm	While ensuring computational accuracy, it achieves routine plan calculations in less than 1 minute, comparable to conventional clinical application algorithms.	Independently developed	Treatment plan design	CT-guided linear accelerator, linear accelerator
7	Physical algorithm technology	Treatment plan optimization calculation algorithm	Through advanced features such as direct optimization and rapid descent gradient, it supports multiple planning options, rapid plan creation, and also enables automatic planning and online adaptive radiotherapy.	Independent research and development	Treatment plan design	CT-guided linear accelerator, linear accelerator

(6) General software and hardware core technologies

Serial number	Category	Core Technology	Technical Advancement	Technology Source	Main Purpose	Application Product
1	Software	Medical image post-	1. Developed based on server multi-	Independently	Medical image post-	Full-line medical

Serial number	Category	Core Technology	Technical Advancement	Technology Source	Main Purpose	Application Product
	Technology	processing technology developed based on server multi-concurrency technology	concurrency technology, it offers flexible deployment and can provide IT cost solutions tailored to small to large-scale medical institutions. 2. It can be used as a post-processing tool within or across hospital departments, supporting application scenarios such as cross-campus remote usage. 3. Can be integrated with existing hospital information systems such as RIS	developed	processing	imaging equipment
2		Cross-modal software workflow technology	1. Prioritize clinical needs during the development process, aiming to enhance clinical efficiency through product development and iterative upgrades. 2. Achieve interaction consistency across different product lines within the company to improve user efficiency and reduce end-customer learning costs. 3. Facilitates the expansion from a single product to integrated products 4. Preprocess based on data characteristics, allowing users to see the preprocessing results when opening this data, thereby improving patient throughput	Independent R&D	User interaction workflow	Full range of medical imaging and radiotherapy equipment
3		3D medical image visualization engine technology	1. Deep integration of visualization with device data acquisition, reconstruction, and image preprocessing to achieve optimized display of vascular details near bones and precise visualization of ultra-high-resolution	Independently developed	Image visualization effect optimization	Full range of medical imaging equipment, radiotherapy equipment

Serial number	Category	Core Technology	Technical Advancement	Technology Source	Main Purpose	Application Product
			sub-pixel-level micro-lesions 2. Hyper Realistic Rendering (HRR) technology presents ultra-realistic details of tissue surfaces and internal structures, offering enhanced depth and spatial perception, thereby achieving results closer to real tissue textures, vascular pathways, and spatial relationships of lesions. 3. Full-body support for CT and MR imaging of the head, abdomen, shoulder, hip, breast, foot, and other regions with realistic rendering. It provides corresponding tissue color tables for different grayscale values, delivering optimal color representation and rendering effects for various tissues. 4. Zero-wait, second-level real-time rendering allows users to preview the rendering effects in real-time during interaction and complete detail iterations after the interaction stops.			
4		Medical image segmentation and registration technology	1. Accurate segmentation of complex structural tissues such as organs, blood vessels, bones, and lesion regions in multi-modality images 2. Supports motion correction and registration fusion for data of different modalities and phases	independent R&D	post-processing application image segmentation	Full range of medical imaging and radiotherapy equipment
5	Hardware Technology	Hardware Circuit Design Technology in	1. From conventional 1.5T to 9.4T high magnetic field strength environments, the	independently developed	Hardware design related to system	PET/CT, PET/MR, MR,

Serial number	Category	Core Technology	Technical Advancement	Technology Source	Main Purpose	Application Product
		Complex Electromagnetic Environments	electronic component design and hardware magnetic field compatibility design capabilities are at the top domestic level. 2. The first domestic manufacturer to achieve a 39*4Gbps high-speed data acquisition system at a rotation speed of 0.25s. 3. To address the strong radiation interference during radiotherapy, the RT system incorporates aerospace-grade single-event upset (SEU) mitigation technology, effectively reducing single-event upset effects and enhancing the reliability of the equipment control system as well as the product's service life.		control, data acquisition, and data reconstruction systems	CT, RT
6		ECG gating extraction technique under strong gradient fields	1. The first domestic ECG gating technology capable of supporting 5.0T MR applications 2. Capable of detecting ECG signals up to 300bpm, suitable not only for human scanning but also for supporting the research needs of animal ECG detection 3. The independently developed technical solution adopts high-performance hardware circuits and intelligent adaptive filtering algorithms, enabling the product to suppress gradient fields above 300mt/m/s, with a significant improvement in image quality.	independently developed	MR physiological signal gating device	MR, PET/MR
7		Multi-modality device registration and balancing technology	1. Achieve six-degree-of-freedom omnidirectional registration, with cumulative registration error less than the minimum	Independently developed	Multi-modality device registration and CT gantry	PET/CT, CT, RT

Serial number	Category	Core Technology	Technical Advancement	Technology Source	Main Purpose	Application Product
			resolution of each modality. 2. Support precise registration within 0.5mm for devices up to 3m in length and as many as 9 modalities, ensuring image fusion accuracy. 3. High-speed rotation balance technology achieves an unbalanced mass of less than 0.02% of the total weight for the CT rotating body, with a maximum vibration of less than 0.1mm in the CT scan field of view, supporting the highest rotation speed among mainstream high-end CT products in the industry.		dynamic balance	
8		High-precision motion control technology for heavy loads	1. Capable of meeting the needs of special patients, achieving a payload of 300kg and a motion speed of 55mm/s, with a motion repeatability accuracy of 0.1mm, leading the industry's mainstream product benchmarks. 2. The CT gantry can achieve a rotation speed of 0.25s/revolution, with an angular control accuracy of 0.1 degrees under a rotational inertia of 500kg·m².	Independent R&D	Precision motion control	Full product line
9		High-precision cooling temperature control technology	1. Utilizing precise thermal simulation technology and accurate temperature control technology to achieve temperature control accuracy for core components 2. Through high-precision cooling temperature control technology, the company has mastered temperature control analysis techniques at the system, core components,	Independently developed	System cooling temperature control	MR, PET/CT, PET/MR, CT-guided linear accelerator, linear accelerator

Serial number	Category	Core Technology	Technical Advancement	Technology Source	Main Purpose	Application Product
			circuit board, and chip levels, achieving overall system temperature control.			

2. R&D achievements obtained during the reporting period

As of the end of the reporting period, the company had filed a cumulative total of 11,656 intellectual property applications and obtained 6,102, including 9,721 patent applications and 4,912 patent grants. Among these, invention patent applications accounted for 8,043, representing over 80% of the total patent applications, with 3,699 invention patents granted. During the reporting period, the company filed 368 new intellectual property applications and obtained 337. In addition to the authorized invention patents mentioned above, the company also possesses multiple non-patented technologies, which form an important part of the company's technological competitiveness and play a significant role in its business operations.

List of intellectual property rights obtained during the reporting period.

	Newly added in this period		Cumulative quantity	
	Number of applications (units)	Number of approvals (units)	Number of applications (units)	Number of approvals (units)
invention patent	232	222	8,043	3,699
Utility model patent	30	35	1,298	941
Design patent	6	6	380	272
Software Copyright	28	10	322	303
Other	72	64	1,613	887
Total	368	337	11,656	6,102

Note 1: The 'cumulative quantity' exceeding the sum of the 'cumulative quantity' at the end of the previous year and the 'new additions in the current year' is due to patent transfers and the authorization of European patents from past years taking effect during the reporting period; the 'cumulative quantity' being less than the sum of the 'cumulative quantity' of the previous year and the 'new additions in the current year' is caused by the expiration of intellectual property rights from prior years.
Note 2: Others include 'copyrighted works' and 'trademarks'.

3. R&D Investment Status Table

Unit: Yuan

	Current period	Same period last year	Change range (%)
Expensed R&D investment	766,458,924.01	826,022,924.17	-7.21
Capitalized R&D investment	373,572,154.42	191,026,438.65	95.56
Total R&D investment	1,140,031,078.43	1,017,049,362.82	12.09
Total R&D investment as a percentage of operating revenue (%)	18.95	19.07	Decrease by 0.12 percentage points
Proportion of R&D expenditure capitalized (%)	32.77	18.78	an increase of 13.99 percentage points

Explanation for the significant changes in the proportion of capitalized R&D investment and its reasonableness

The company continues to increase R&D investment, with more R&D projects reaching the capitalization point during this reporting period.

4. Ongoing R&D Projects

Unit: 10,000 yuan

Serial Number	Project Name	Estimated total investment scale	Amount invested in the current period	Total investment amount	Progress or phased achievements	Proposed objectives	Technical level	Specific application prospects
1	MR R&D Project One	10,400.00	746.34	9,090.06	Registration certificate obtained	Obtained registration certificate	Industry-leading	Suitable for clinical scenarios
2	MR R&D Project II	11,000.00	1,861.10	7,492.81	Registration certificate obtained	Obtain registration certificate	Industry-leading	Suitable for clinical and research scenarios
3	MR R&D Project Three	15,000.00	5,357.81	13,840.69	Registration certificate obtained	Obtain registration certificate	Industry-leading	Suitable for clinical scenarios
4	MR R&D Project 4	25,000.00	4,841.43	20,784.65	Partially obtained registration certificate	Obtain registration certificate	Industry-leading	Suitable for clinical and research scenarios
5	MR R&D Project Five	13,500.00	1,539.61	11,620.60	Registration certificate obtained	Obtain registration certificate	Industry-leading	Suitable for clinical scenarios
6	MR R&D Project Six	13,700.00	773.72	7,656.51	Registration certificate obtained	Obtain registration certificate	Industry-leading	Suitable for clinical and research scenarios
7	MR R&D Project	7,000.00	760.36	5,407.42	In progress	Obtained registration	Industry-	Suitable for

	Seven					certificate	leading	clinical and research scenarios
8	MR R&D Project 8	6,400.00	1,188.96	4,963.82	Registration certificate obtained	Obtain the registration certificate	Industry-leading	Suitable for clinical and research scenarios
9	CT R&D Project One	4,600.00	428.23	4,160.19	Registration certificate obtained	Obtained registration certificate	Industry-leading	Suitable for clinical scenarios
10	CT R&D Project II	25,000.00	752.21	12,851.07	Partially obtained registration certificate	Obtain registration certificate	Industry-leading	Suitable for clinical and research scenarios
11	CT R&D Project Three	9,500.00	417.89	5,410.79	Registration certificate obtained	Obtained registration certificate	Industry-leading	Suitable for clinical and research scenarios
12	CT R&D Project 4	9,000.00	81.28	4,258.49	Registration certificate obtained	Obtain registration certificate	Industry-leading	Applicable to clinical scenarios
13	CT R&D Project Five	14,000.00	1,751.49	9,399.07	In progress	Obtain registration certificate	Industry-leading	Suitable for clinical and research scenarios
14	CT R&D Project Six	3,200.00	386.97	1,699.67	In progress	Obtain registration certificate	Industry-leading	Applicable to clinical scenarios
15	CT R&D Project Seven	15,000.00	1,127.49	11,063.48	Partially obtained registration	Obtained registration certificate	Industry-leading	Suitable for clinical and

					certificate			research scenarios
16	CT R&D Project 8	18,000.00	3,421.00	12,106.31	In progress	Obtain registration certificate	Industry-leading	Suitable for clinical and research scenarios
17	CT R&D Project Nine	8,000.00	1,425.27	4,842.30	Registration certificate obtained	Obtained registration certificate	Industry-leading	Suitable for clinical scenarios
18	CT R&D Project 10	6,800.00	1,057.75	3,001.61	In progress	Obtain registration certificate	Industry-leading	Suitable for clinical and research scenarios
19	CT R&D Project Eleven	3,000.00	507.31	1,663.40	In progress	Obtain registration certificate	Industry-leading	Suitable for clinical and research scenarios
20	RT R&D Project 1	6,000.00	702.37	5,568.75	In progress	Obtain registration certificate	Industry-leading	Applicable to clinical scenarios
21	RT R&D Project II	36,500.00	5,415.96	31,977.51	Registration certificate obtained	Obtained registration certificate	Industry-leading	Suitable for clinical scenarios
22	RT R&D Project 3	18,800.00	1,300.76	11,930.00	Partially obtained registration certificate	Obtain registration certificate	Industry-leading	Applicable to clinical scenarios
23	RT R&D Project IV	7,300.00	2,354.23	7,208.05	Partially obtained registration certificate	Obtained registration certificate	Industry-leading	Suitable for clinical scenarios
24	Software R&D	38,000.00	5,253.89	31,289.56	Partially obtained	Obtain registration	Industry-	Applicable to

	Project 1				registration certificate	certificate	leading	clinical scenarios
25	Software Development Project II	23,000.00	1,190.94	14,072.63	In progress	Registration certificate obtained	Industry-leading	Suitable for clinical scenarios
26	Software R&D Project 3	13,600.00	1,395.62	9,151.38	In progress	Support mass production and new product development for imaging products	Industry-leading	Applicable to clinical scenarios
27	XR R&D Project One	15,000.00	1,912.81	12,310.83	Registration certificate obtained	Obtained registration certificate	Industry-leading	Suitable for clinical scenarios
28	XR R&D Project II	28,300.00	4,791.83	26,704.43	Partially obtained registration certificate	Obtain registration certificate	Industry-leading	Applicable to clinical scenarios
29	XR R&D Project Three	6,100.00	1,039.55	4,517.22	Registration certificate has been obtained	Obtained registration certificate	Industry-leading	Suitable for clinical scenarios
30	MI R&D Project 1	5,000.00	271.50	2,564.76	Registration certificate obtained	Obtain registration certificate	Industry-leading	Suitable for clinical and research scenarios
31	MI R&D Project II	8,350.00	909.43	7,349.94	Registration certificate obtained	Obtained registration certificate	Industry-leading	Suitable for clinical and research scenarios
32	MI R&D Project 3	13,500.00	564.54	7,444.89	Registration certificate obtained	Obtain registration certificate	Industry-leading	Applicable to clinical scenarios
33	MI R&D Project	16,800.00	1,890.36	12,681.40	Partially obtained	Obtained registration	Industry-	Suitable for

	Four				registration certificate	certificate	leading	clinical scenarios
34	MI R&D Project Five	3,000.00	0.55	1,453.10	Partially obtained registration certificate	Obtain registration certificate	Industry-leading	Suitable for clinical and research scenarios
35	MI R&D Project Six	3,000.00	1,070.34	1,361.22	Partially obtained registration certificate	Obtained registration certificate	Industry-leading	Suitable for clinical and research scenarios
36	MI R&D Project Seven	7,500.00	1,896.00	4,961.43	In progress	Obtain registration certificate	Industry-leading	Applicable to clinical scenarios
37	Component R&D Project One	8,800.00	1,597.94	7,528.02	Partially obtained registration certificate	Obtained registration certificate	Industry-leading	Applied to equipment components
38	Component R&D Project II	1,900.00	393.73	1,454.84	Registration certificate obtained	Obtain registration certificate	Industry-leading	Applied to device components
39	Component R&D Project Three	3,000.00	488.93	2,065.20	In progress	Obtain registration certificate	Industry-leading	Applied to equipment components
40	Component R&D Project IV	11,000.00	747.82	7,092.51	In progress	Obtain registration certificate	Industry-leading	Applied to device components
41	Ultrasound R&D Project One	25,300.00	2,470.96	23,399.47	In progress	Obtain registration certificate	Industry-leading	Suitable for clinical scenarios
42	Ultrasound R&D Project Three	7,500.00	1,395.55	2,975.33	In progress	Obtain registration certificate	Industry leading	Suitable for clinical

								scenarios
43	Life Science Instrument Project 1	3,600.00	341.98	2,755.69	Registration certificate obtained	Research promotion and mass production launch	Internationally leading	Suitable for research scenarios
44	Life Science Instruments Project II	3,000.00	417.48	2,444.17	In progress	Obtain registration certificate	Industry-leading	Suitable for research scenarios
45	Life Science Instruments Project 3	8,600.00	1,291.55	7,730.60	In progress	Obtained registration certificate	Industry-leading	Suitable for research scenarios
46	Next-generation product pre-research project	10,000.00	3,247.99	9,625.50	In progress	Acquire next-generation product and technology planning	Industry-leading	Applicable to clinical scenarios
Total	/	550,550.00	72,780.83	410,931.37	/	/	/	/

5. R&D Personnel Information

Unit: 10,000 yuan Currency: RMB

Basic Information		
	Current Period	Same period of previous year
Number of R&D personnel (persons)	3,391	3,102
Proportion of R&D personnel to total company headcount (%)	40.27	39.47
Total R&D personnel compensation	85,341.17	72,618.68
Average salary of R&D personnel	25.17	23.41

Education level		
Educational Attainment	Number (persons)	Percentage (%)
Doctoral student	368	10.85
Master's student	2,329	68.68
Undergraduate	635	18.73
vocational high school	59	1.74
Total	3,391	100
Age structure		
Age range	Quantity (people)	Proportion (%)
Under 30 years old (excluding 30 years old)	1,322	38.99
30-40 years old (including 30, excluding 40)	1681	49.57
40-50 years old (including 40 but not 50)	350	10.32
50-60 years old (including 50, excluding 60)	32	0.94
60 years and above	6	0.18
Total	3,391	100

IV Major operational performance during the reporting period

Please refer to 'Section 3 Management Discussion and Analysis' in this report.

i. Analysis of Principal Business

1. Analysis of Changes in Financial Statement Related Items

Unit: Yuan Currency: RMB

Subject	Current Period Amount	Same period of previous year	Change ratio (%)
Operating revenue	6,015,901,402.16	5,333,486,253.17	12.79
Operating costs	3,132,664,301.76	2,708,826,710.47	15.65
Selling expenses	938,304,878.27	829,404,472.35	13.13
Administrative expenses	257,182,484.27	238,744,275.50	7.72
Financial expenses	-49,616,563.05	-65,345,878.19	Not applicable
R&D expenses	766,458,924.01	826,022,924.17	-7.21
Net cash flow from operating activities	48,759,799.77	-624,592,418.17	Not applicable
Net cash flow from investing activities	483,100,691.14	27,298,642.19	1,669.69
Net cash flow from financing activities	-521,753,297.02	-114,081,670.56	Not applicable
Gains from changes in fair value	-45,441,421.76	7,410,470.99	-713.21
Impairment loss on assets	-197,713.08	39,520,280.84	-100.50
Gains on disposal of assets	-640,729.77	622,909.34	-202.86
Non-operating income	2,148,497.13	1,551,981.76	38.44
Non-operating expenses	6,106,665.13	2,013,184.16	203.33

Note: The operating costs and selling expenses in the same period of the previous year have been restated by the company in accordance with changes in accounting policies. For details, please refer to Section 8 of the financial statements.

Explanation for changes in operating revenue: Mainly due to the company's stable operations and steady revenue growth during the reporting period.
Explanation for changes in financial expenses: Financial expenses remained flat compared to the previous year, with a slight decrease in investment income.
Explanation for the change in net cash flow from operating activities: Mainly due to the company's stable operations and significant improvement in sales collections during the reporting period.
Explanation for the change in net cash flow from investing activities: Mainly due to the company's purchase and redemption of matured wealth management products during the reporting period.
Explanation for the change in net cash flow from financing activities: Mainly due to the company's repayment of debts during the reporting period.
Explanation for the change in fair value gains and losses: Primarily due to fluctuations in the stock prices of financial assets invested by the company.
Explanation for the change in asset impairment losses: Mainly due to the improvement in the company's market conditions in the previous reporting period, leading to an increase in the net realizable value of inventory.
Explanation for the change in gains from disposal of assets: Mainly due to the disposal of fixed assets during the reporting period.
Explanation for changes in non-operating income: Mainly due to the receipt of default compensation and other factors during the reporting period.
Explanation for changes in non-operating expenses: Mainly due to the increase in donation expenditures during

the reporting period.

ii. Analysis of assets and liabilities

1. Assets and liabilities

Unit: Yuan

Project Name	Ending balance for the current period	Percentage of ending balance for the current period to total assets (%)	Prior year-end balance	Prior year-end balance as a percentage of total assets (%)	Percentage change in the ending balance compared to the previous year's ending balance (%)	Explanation
Derivative financial assets	0.00	Not applicable	489,944.97	0.00	-100.00	Mainly due to the maturity of last year's foreign exchange products
Notes receivable	26,496,454.24	0.09	1,056,048.00	0.00	2,409.02	mainly due to the increase in letter of credit settlements
Prepayments	335,576,410.88	1.17	195,777,640.89	0.70	71.41	Mainly due to the increase in prepayments for stockpiling agreements and technology R&D expenses
Contract assets	69,456,937.34	0.24	50,253,819.13	0.18	38.21	This was mainly due to an increase in warranty deposits within the sales proceeds during the reporting period.

Non-current assets due within one year	385,099,880.04	1.34	290,564,565.05	1.04	32.54	Mainly due to the increase in long-term receivables due within one year
Long-term receivables	41,001,381.52	0.14	114,605,452.67	0.41	-64.22	Mainly due to the increase in non-current assets classified as due within one year based on liquidity
Other non-current financial assets	138,370,307.25	0.48	82,366,375.73	0.29	67.99	Primarily due to the company's additional equity investment in Shanghai Intelligence
Development expenditure	564,909,459.25	1.97	329,169,118.87	1.17	71.62	Mainly due to the increase in R&D expenditures that met the capitalization criteria during the reporting period
Short-term loans	76,287,236.84	0.27	557,489,368.89	1.99	-86.32	This was mainly due to the maturity of loans from the previous year, and the company's limited new borrowing this year based on its own arrangements.
Notes payable	353,273,520.59	1.23	520,013,867.50	1.85	-32.06	Mainly due to the settlement of matured bills at the

						end of the reporting period.
Non-current liabilities due within one year	36,950,384.05	0.13	54,499,168.71	0.19	-32.20	Mainly due to the gradual expiration of leases, resulting in a decrease in the balance
Long-term employee benefits payable	3,171,240.43	0.01	5,642,483.55	0.02	-43.80	Mainly due to the increase in non-current liabilities reclassified as current liabilities due within one year.

Other remarks: None

2. Overseas assets status

Asset size

Of which: overseas assets 3,544,982,249.31 (unit: yuan, currency: RMB), accounting for 12.36% of total assets.

3. Major assets restricted as at the end of the reporting period

Unit: RMB yuan

Project	Ending book value	Restriction Reason
Cash and Cash Equivalents	135,782,404.77	Deposit
Total	135,782,404.77	/

Section II Corporate governance, environment, and society

I. Changes in the company's directors, senior management, and key technical personnel

Name	Position held	Change status
Ding Jun	Director	Departure
Bao Chen	Director	Election
TAO CAI	Director	Departure
TAO CAI	Employee Director	Election

Explanation of changes in the company's directors, senior management, and key technical personnel
Due to work reasons, Mr. Ding Jun submitted his resignation to the company, effective April 26, 2025. On April 25, 2025, the company held the 20th meeting of the second board of directors to review and approve the *Proposal on the Appointment of a Director*, agreeing to appoint Mr. Bao Chen as a director of the company. This proposal was approved at the company's 2024 annual shareholders' meeting. For details, please refer to the *Announcement of United Imaging Healthcare on the Resignation and Appointment of Directors* (Announcement No.: 2025-015) and the *Announcement of United Imaging Healthcare's 2024 Annual Shareholders' Meeting Resolution* (Announcement No.: 2025-026) published on the Shanghai Stock Exchange website (www.sse.com.cn). Due to corporate governance requirements, Mr. TAO CAI resigned from his position as director and was elected as the employee director by the company's employee representative congress. For details, please refer to the *United Imaging Healthcare Announcement on the Resignation of a Director and the Election of the Employee Director to the Second Board of Directors* (Announcement No.: 2025-028) published on the Shanghai Stock Exchange website(www.sse.com.cn).

Explanation of the Identification of Key Technical Personnel in the Company
The company identified 10 key technical personnel based on factors such as specific job responsibilities, educational and professional backgrounds, roles and contributions in past and current core technology development, and overall performance of the R&D staff.

No.	Name	Position
1	Zhang Qiang	Chairman, Co-CEO
2	HONGDI LI	Senior Vice President, Chief Technology Officer
3	QUN CHEN	Key technical personnel
4	Huang Xiangyu	Key technical personnel
5	YANFENG DU	President of the Computed Tomography Division
6	Li Guobin	President of Magnetic Resonance Division
7	Xiang Jun	President of X-ray Business Division
8	Wang Chao	President of Molecular Imaging Division
9	An Shaohui	Vice President of Molecular Imaging Division
10	Hu Wei	Vice President of Transformation Office

V Profit Distribution or Capital Reserve Conversion Plan

Semi-annual proposed profit distribution plan and capital reserve conversion plan

Whether to distribute or convert	Yes
Number of bonus shares per 10 shares (shares)	0
Dividend per 10 shares (RMB) (tax inclusive)	1.3
Number of additional shares per 10 shares (shares)	0
Explanation of the profit distribution or capital reserve conversion proposal	
The company plans to distribute a cash dividend of RMB 1.3 per 10 shares (tax inclusive), based on the total share capital registered on the equity distribution record date minus the total number of shares in the special securities account for repurchase. This profit distribution does not include bonus shares or capital reserve conversion into share capital. As of July 31, 2025, the company's total share capital is	

824,157,988 shares, minus 4,134,116 shares in the special securities account for repurchase. Based on this calculation, the total cash dividend to be distributed is RMB 106,603,103.36 (tax inclusive), accounting for 10.68% of the net profit attributable to shareholders of the listed company in the semi-annual consolidated financial statements for 2025. If the total share capital of the company or the total number of shares participating in the profit distribution changes before the equity registration date for the implementation of the equity distribution, the company intends to maintain the distribution ratio per share unchanged and adjust the total distribution amount accordingly.

The above profit distribution plan (proposal) has been authorized by the company's 2024 annual shareholders' meeting and approved at the 23rd meeting of the second board of directors.

VI The Status and Impact of the Company's Equity Incentive Plans, Employee Stock Ownership Plans, or Other Employee Incentive Measures

i. Relevant equity incentive matters have been disclosed in interim announcements with no subsequent progress or changes in implementation

Summary of Matters	Query Index
On June 13, 2025, the company convened the 21st meeting of the second board of directors, where resolutions such as the *Proposal on the Company's '2025 Restricted Stock Incentive Plan (Draft)' and Summary* were reviewed and approved.	For details, please refer to the announcement published on the Shanghai Stock Exchange website (www.sse.com.cn) on June 14, 2025.
On June 30, 2025, the company held the 2024 annual shareholders' meeting, where resolutions such as the *Proposal on the Company's '2025 Restricted Stock Incentive Plan (Draft)' and Summary* and the *Proposal on the Company's '2025 Restricted Stock Incentive Plan Implementation Assessment and Management Measures'* were reviewed and approved.	For details, please refer to the announcement published on the Shanghai Stock Exchange website (www.sse.com.cn) on July 1, 2025.

VII Carbon Emission Management

As a globally leading medical technology company, United Imaging Healthcare will elevate sustainability to a new strategic core level in 2025, further deepening the role of carbon management within the company's overall strategy. The company believes that during the rapid growth phase of global business, setting forward-looking emission reduction targets is not only a reflection of corporate social responsibility but also an intrinsic driver for enhancing operational efficiency, ensuring supply chain stability, and building core competitiveness.

During the reporting period, United Imaging Healthcare further improved the sustainable development governance framework. While establishing the Strategy and Sustainable Development Committee under the Board of Directors for top-level strategic oversight, the company also strengthened and refined specialized coordination and execution mechanisms for carbon emission management, with senior management personnel clearly designated to lead the specific implementation of carbon emission management, aiming to enhance decision-making efficiency and execution effectiveness in daily operations. As of the end of the reporting period, United Imaging Healthcare has systematically established a carbon governance system, covering the board of directors, the Strategy and Social Responsibility Committee, and the ESG Working Committee composed of key departments. The strategic goals of carbon reduction and carbon neutrality have been broken down into specific action plans, efficiently coordinating the work of cross-departmental carbon management teams. From strategic decision-making to operational execution, a governance system with clear responsibilities and efficient collaboration has been established.

To ensure the systematic and effective implementation of emission reduction actions, the company continues to refine institutional norms and establish clear emission reduction pathways. As of the end of the reporting period, United Imaging Healthcare has formulated the *Carbon Neutrality Planning White Paper*, released the *Organizational Greenhouse Gas Management Procedure*, and is actively drafting regulatory documents such as the *Energy Management Assessment Measures*, *Energy Consumption*

Management System, and *Energy Consumption Allocation Rules Table*. These documents clarify supervision and monitoring standards, platform functions and roles, as well as monitoring processes, promoting real-time monitoring of energy usage and feedback for corrective actions, thereby establishing a closed-loop management mechanism to enhance operational efficiency. Meanwhile, the company has further refined the responsibilities and performance indicators for each department, providing a solid institutional foundation and clear action guidelines for all employees to participate in energy conservation and carbon reduction. Focusing on four key pathways—optimizing energy structure, enhancing energy efficiency, driving green product innovation, and advancing supply chain decarbonization—the company is steadily progressing toward the goal of "net-zero emissions in operations and supply chain".

Following the first participation in the CDP (Carbon Disclosure Project) disclosure in 2024, where the company achieved an outstanding Management Level (B grade) in both the Climate Change and Water Security questionnaires, United Imaging Healthcare is now further deepening sustainability practices in 2025 with higher standards and more pragmatic actions. United Imaging Healthcare firmly believes that through relentless efforts on the path of green and low-carbon development, the company will not only contribute exceptional innovative strength to global healthcare but also become a steadfast practitioner in driving the industry's green transformation and building a sustainable future.

(1) Carbon Emission Reduction Targets
United Imaging Healthcare has formulated practical greenhouse gas emission reduction targets based on operational realities and business development: using 2023 as the baseline year, United Imaging Healthcare aims to achieve a 50% reduction in Scope 1 and Scope 2 carbon emission intensity per unit revenue by 2035. To achieve this goal, the company has set clear step-by-step emission reduction targets and is simultaneously advancing multiple carbon reduction initiatives across operations and value chain (see "(2) Carbon Reduction Actions" for details): on the operational front, the company continues to strengthen energy-saving and consumption-reduction measures and promote the use of clean energy; on the value chain front, the company collaborates with employees and suppliers to establish green and low-carbon practices as a long-term development direction.

(2) Carbon Reduction Actions
In active response to the national "carbon peak and carbon neutrality" strategy, United Imaging Healthcare continues to reduce the emissions intensity of core operations. By systematically implementing multiple emission reduction measures—including the use of cleaner sources of energy, energy management and operational efficiency enhancements—the company is advancing green and low-carbon transformation to support the orderly achievement of carbon reduction targets.

The company has integrated clean energy usage into the energy management system, strengthening institutional requirements for clean energy adoption. Through proactive promotion of photovoltaic project development and large-scale procurement of renewable electricity, the company continues to expand the use of clean energy. The company has established a comprehensive path and diversified measures for energy conservation and emission reduction of core operations, committed to energy consumption management and operational efficiency enhancements, and promoting the overall optimization of carbon management. At the same time, the company continues to strengthen low-carbon training and awareness campaigns for employees, enhancing the energy conservation and emission reduction consciousness across the entire workforce.

During the carbon emissions management phase across the entire value chain, the company actively explores collaborative emission reduction pathways with upstream and downstream partners. The company plans to categorize suppliers for management, promote their green transformation, and optimize downstream logistics and transportation solutions to reduce the carbon footprint of product transportation. By integrating low-power technologies at the product design stage, the company is committed to reducing the environmental impact of products from a full lifecycle perspective, fulfilling the company's promise of green technology.

1. Promote the use of clean energy
Construction of self-owned clean energy projects: During the reporting period, the company has been steadily advancing the layout of clean energy projects at various production bases. The total installed

capacity of the photovoltaic construction project at the Shanghai production base is expected to reach 5,175.14 kW. The procurement process has been completed, and it is projected to commence operation in 2026. The project is expected to generate over 5 million kWh of electricity annually, reducing carbon dioxide emissions by approximately 2,850 tons each year. It will serve as a crucial cornerstone for the company's energy structure optimization in the future. Meanwhile, the solar water heating system in operation at the Wuhan base since 2020 has cumulatively saved 90,000 kWh of electricity and reduced carbon dioxide emissions by 47 tons. In the first half of 2025, it achieved electricity savings of 10,000 kWh and reduced carbon dioxide emissions by 5 tons.

Green Power Procurement: On the basis of advancing self-owned clean energy projects, the company systematically increases the proportion of clean energy usage by leveraging market-based green power procurement pathways, further optimizing the energy structure to provide strong support for achieving carbon reduction goals. As a key practice vehicle for the company's green and low-carbon transformation, the Shanghai production base has steadily expanded its green power procurement pathways since entering the direct electricity trading market in 2024. In the first half of 2025, the base has cumulatively procured and utilized 6.81 million kWh of green electricity, with an estimated reduction of over 3,880 tons of carbon dioxide emissions. Building on this, the company has set a more forward-looking annual green electricity usage target, planning to procure 11.75 million kWh of green electricity for the year, which is expected to cover one-third of the park's electricity demand, further optimizing the energy structure and promoting the use of cleaner sources of energy. Meanwhile, the company is gradually transforming green electricity procurement experience into standardized practices, driving the transition from pilot exploration to systematic implementation. While continuously optimizing the energy procurement structure, the company is also advancing institutional development and process standardization, covering key aspects such as market research, solution comparison, economic feasibility analysis, and risk assessment to ensure the steady progress and replicability of green electricity applications.

During the reporting period, the Wuhan base has initiated the selection process for green electricity procurement plans, marking the steady expansion of green energy practices from individual points to broader areas. Subsequently, the company will promote the use of clean energy in more bases by considering the actual energy consumption characteristics of each park and local policy environments, which will gradually establish a green energy system covering multiple regions and pathways, laying a solid foundation for achieving the company's long-term carbon emission intensity reduction goals.

2. Implement energy-saving and emission-reduction measures

1) Internal operations management

United Imaging Healthcare has established a comprehensive energy management and carbon emission management system, deeply practicing energy conservation and emission reduction, and continuously enhancing operational efficiency.

At the level of management systems and institutional development, United Imaging Healthcare has built an energy management system covering policies, processes, standards, and tools, continuously strengthening the institutionalization and closed-loop management capabilities of energy consumption control. The company has progressively completed the formulation of foundational documents such as the *Energy Consumption Management System*, *Main Flowchart of Energy Consumption Management*, *Energy Management Assessment Measures*, and *Energy Consumption Allocation Rules Table*, which have entered the review process, establishing a management loop that covers responsibility delineation, process coordination, goal setting, and execution oversight. The company has fully launched digital infrastructure construction to provide data support for refined management. The smart energy online monitoring platform at the Shanghai base has commenced construction, and the energy consumption management system at the Wuhan base was upgraded in the first half of the year, aiming to achieve precise monitoring and scientific analysis of energy consumption. In April 2025, the company successfully passed the annual recertification of the ISO 50001 Energy Management System.

The company consistently prioritizes energy efficiency optimization as a key pathway to promote green operations, systematically advancing energy-saving upgrades in critical areas such as production processes, equipment systems, and intelligent lighting, which effectively reduces energy consumption per unit of output and enhances overall operational efficiency. During the reporting period, United Imaging

Healthcare gradually deepened the energy-saving transformation of processes and equipment at production bases, with a series of energy-saving technical renovation projects successfully implemented across major bases in the first half of 2025.

In terms of energy management and operational efficiency enhancements, United Imaging Healthcare continues to advance energy conservation and carbon reduction with a focus on intelligence and refinement. The Shanghai production base has completed the replacement of high-efficiency motors and variable frequency upgrades for the process cooling water system in the first half of 2025, with an estimated annual electricity savings of 16,000 kWh and a reduction of approximately 9.3 tons of carbon dioxide emissions. The Changzhou base has completed the renovation of the magnetic resonance process cooling water system, introducing high-efficiency magnetic levitation chillers in summer and utilizing a natural air cooling system in winter for coordinated operation, with an estimated annual electricity savings of 540,000 kWh and a reduction of approximately 300 tons of carbon dioxide emissions. The Wuhan base is accelerating the construction of a multi-scenario smart energy utilization system. In the first half of the year, the energy consumption management system upgrade plan has been completed, with plans to add electricity and water meters for precise monitoring. The LED smart lighting retrofit in the assembly workshop is expected to save 17,000 kWh of electricity annually, reducing carbon dioxide emissions by 9.5 tons. The gym's air conditioning and lighting systems have introduced time-control strategies, projected to save 50,000 kWh of electricity annually and reduce carbon dioxide emissions by 28.5 tons. In the second half of 2025, the Wuhan base will further implement intelligent centralized control for the circulating water and compressed air systems, expected to save 100,000 kWh of electricity annually and reduce carbon dioxide emissions by 57 tons. By continuously optimizing the energy structure and usage efficiency, the company is steadily advancing toward green and low-carbon operational goals through systematic actions and quantifiable results.

In terms of energy management and monitoring capacity building, United Imaging Healthcare systematically enhances the digitization and refinement of energy management by prioritizing institutional frameworks and leveraging platform empowerment. The Shanghai production base takes the lead in completing the top-level design of the energy management system, streamlining administrative business processes and establishing a standardized management framework covering energy measurement, monitoring, allocation, assessment, and anomaly handling. By formulating and implementing core policy documents such as the *Energy Consumption Management System*, *Main Flowchart of Energy Management*, *Energy Management Assessment Measures*, and *Energy Allocation Rules Table*, the company has laid the foundation for unified energy consumption management. Meanwhile, the smart park's online energy consumption monitoring platform is accelerating in construction and is scheduled for operation by 2026. By then, the company will utilize advanced transducers and the IOC energy operations dashboard to achieve 24/7 real-time monitoring, historical trend analysis, anomaly alerts, optimization suggestions, and remote management, forming a data-driven closed-loop management system that significantly enhances the visibility, response speed, and decision-making efficiency of energy operations. In the first half of 2025, the Wuhan base has completed the upgrade of its energy consumption management system and deployed an additional 150 electricity and water meters, achieving zonal monitoring of key areas and critical processes to provide precise data support for subsequent energy efficiency optimization. Other bases have also implemented phased smart upgrades tailored to their operational characteristics, working collaboratively to drive continuous improvement in the group's overall energy efficiency.

In terms of energy consumption data management, United Imaging Healthcare continues to refine energy consumption data collection and accounting mechanisms, establishing a multi-dimensional statistical framework that covers “energy types (electricity, water, gas, heat, etc.), energy consumption areas (production workshops, office areas, dormitories, etc.), energy consumption segments (production equipment, air conditioners, lighting, etc.), and time cycles (hourly, daily, monthly, quarterly, annual).” By adding energy metering sensors, the company achieves precise allocation of energy consumption to various departments, solidifying management responsibilities for energy-consuming entities. The company simultaneously builds a visual dashboard for energy consumption, ensuring real-time, transparent, and traceable energy usage. The Shanghai base adheres to the *Energy Management Assessment Measures*, clearly defining the entire process specification from data acquisition (automatic sensor collection and manual meter reading), data validation (outlier identification rules), data aggregation (standardized ledger format) to data accounting (unified formulas and parameters), ensuring the

comprehensiveness, accuracy, and comparability of data.

To ensure the compliance and authority of the management system, the company conducts annual internal audits and certifications of the energy management system in accordance with GB/T 23331-2020/ISO 50001:2018 and RB/T 119-2015 mechanical manufacturing industry certification requirements. Additionally, every five years, the company commissions a professional third party to conduct energy audits, with the audit results submitted to relevant government regulatory authorities for review.

In the future, the company will take data as the core, systems as the safeguard, and audits as the oversight, continuously integrating energy efficiency concepts deeply into the entire production and operation process, comprehensively improving energy utilization efficiency, and supporting high-quality development and the achievement of the “carbon peak and carbon neutrality” goals.

2) Value chain management

United Imaging Healthcare continues to advance carbon management across the value chain. Through multi-dimensional measures such as supply chain collaboration, logistics route optimization, and low-carbon product design, the company systematically enhances carbon reduction efficiency along the value chain, gradually building a green management system that covers the entire product lifecycle.

In the upstream supply chain management, United Imaging Healthcare adheres to the principle of “Green Access, Full-Process Control, and Collaborative Enhancement”. For new suppliers, the company conducts comprehensive evaluations and audits covering environmental protection, labor protection, and other requirements before granting access. Those who fail to meet the standards are excluded from the qualified supplier list. During collaboration, the company specifies green and environmental clauses in quality agreements and contract orders, requiring suppliers to use materials compliant with regulations and environmental standards. Leveraging the self-built GPM (Green Product Management) platform, the company achieves full-process, information-based control over the environmental requirements of purchased materials. To ensure suppliers continue to meet standards, the company conducts annual supplier evaluations and audits, covering dimensions such as technical capability, delivery performance, quality levels, and social and environmental responsibilities. The 2025 evaluation results show that all suppliers meet the company's requirements.

Meanwhile, the company promotes the establishment of a four-quadrant classification management system based on the dual dimensions of “company influence on suppliers” and “suppliers' emission reduction capabilities” exploring differentiated cultivation and collaboration pathways. Additionally, higher carbon management requirements are set for key suppliers, including implementing energy-saving retrofits, increasing the proportion of green electricity usage, and disclosing greenhouse gas emissions data, to enhance the overall supply chain's carbon transparency and resilience.

In the downstream transportation segment, the company is guided by low-carbon and high-efficiency principles. By optimizing production and shipping plans and reducing reliance on high-carbon emission methods (such as air transport), the company continuously increases the proportion of low-carbon transportation methods like sea and land freight. The company will prioritize logistics service providers with green transportation capabilities and specify green logistics requirements in cooperation agreements, including the preferential selection of low-emission transportation methods and the promotion of green fuel applications, which drives systematic carbon reduction across the entire transportation chain and accelerates the construction of a green, low-carbon, and sustainable supply chain ecosystem.

In terms of product and technological innovation, United Imaging Healthcare has consistently regarded green technology as a key pillar of the core R&D strategy, continuously driving the deep integration of cutting-edge technologies with sustainable development. During the reporting period, the company independently developed and launched the world's first silicon carbide magnetic resonance system, equipped with the industry's pioneering silicon carbide gradient amplifier, maximizing GPA performance, and integrating a new magnetic resonance sustainable development solution, which can save customers up to 57% in energy consumption. Compared to the previous generation system, this technological upgrade is expected to save approximately 39,000 kilowatt-hours of electricity per device annually and reduce carbon dioxide emissions by 22.1 tons, effectively enabling global medical institutions to significantly

lower energy consumption and environmental impact while maintaining clinical performance.

In the field of green manufacturing, the company continues to deepen the identification of greenhouse gas emission sources and lifecycle management, strengthen environmental control of auxiliary materials, and consistently introduce high-efficiency, low-energy-consumption production equipment to systematically reduce the carbon footprint of products. As of the end of the reporting period, the company's independently developed uCT 780 X-ray computed tomography equipment successfully passed the ISO 14067 product carbon footprint verification, becoming the first CT product in China's large medical equipment industry to receive this internationally authoritative certification. This achievement not only marks a critical leap in the company's carbon management throughout the product lifecycle but also sets a new benchmark for green and low-carbon transformation in the industry.

This certification was conducted by the internationally authoritative organization SGS in strict accordance with the ISO 14067:2018 standard, covering the entire chain from raw material acquisition and component production to equipment assembly. It employs the “Cradle to Gate” systematic assessment method to accurately quantify the total greenhouse gas emissions throughout the product's production cycle. The measurement results provide a scientific basis for the company to identify high-carbon emission processes, optimize design solutions, and improve production techniques, accelerating the comprehensive upgrade of green design, green manufacturing, and green application across the entire chain, which demonstrates United Imaging Healthcare's strategic commitment and practical achievements in leading the industry's green development through technological innovation.

Through systematic advancements in supply chain management, logistics optimization, and green product design, United Imaging Healthcare is gradually establishing a low-carbon collaboration mechanism that spans the entire upstream and downstream. Looking ahead, the company will continue to deepen capabilities in identifying and managing carbon emissions across the value chain, strengthen collaborative carbon reduction mechanisms with partners, accelerate the integration of green technologies into products and services, and drive continuous optimization of the entire carbon footprint, contributing greater momentum to the sustainable transformation of the medical technology industry.

II. Human Capital Development

United Imaging Healthcare firmly believes that outstanding corporate competitiveness stems from the creativity and cohesion of talent. Guided by the mission of “To Bring Equal Healthcare for All”, the company regards employees as the core driving force for achieving high-quality and sustainable development. The company consistently upholds respect for and protection of employees' rights, striving to create an equal, inclusive, and diverse work environment. Adhering to the core values of “Customer-Centric, Innovation-Driven, and Striver-Oriented”, the company systematically builds career-long growth paths and capability development systems for all employees. The company continuously expands career development channels, providing training systems and growth platforms that cover various stages, supporting employees in expanding their boundaries and achieving professional goals and personal value on the United Imaging platform.

To enhance organizational cohesion and employees' sense of belonging, United Imaging Healthcare has established and continuously optimized multi-level, regular communication mechanisms, actively listening to and promptly responding to employees' voices and opinions, encouraging their participation in the entire process of corporate development. Meanwhile, the company continuously improves the compensation and benefits system, implements health and safety management requirements for employees, and fosters a positive, caring, and warm workplace culture, which supports employees in achieving personal growth while aligning with the company's development, jointly building a sustainable and resilient organizational ecosystem.

i Talent Development Strategy

1. Global Layout: Deepening Diverse Talent Reserves to Support Innovation and International Expansion

United Imaging Healthcare closely aligns with corporate strategic objectives and annual business plans,

driving the synergistic enhancement of human capital and organizational efficiency through a closed-loop mechanism of “strategic decoding - talent planning - dynamic allocation.” Each year, based on the overall strategic direction, annual business plans, current organizational capabilities, and key talent profiles, the company formulates the annual human resources budget and the overall plan for the following year. The content covers annual workforce demand across functional and hierarchical dimensions, employment types (full-time employees, interns, part-time employees, outsourced personnel, and rehired retirees), key position investments, and labor cost inputs, ensuring the systematic, forward-looking, and flexible deployment of human resources in strategic execution. The planning proposal is implemented after approval by the company's Executive Management Committee and dynamically adjusted through monthly HR data analysis (covering core metrics such as total workforce, staffing alignment, progress in experience hires/campus recruitment, and talent retention rates). It spans all areas, including R&D, operations, marketing, and functions, providing scientifically sound support for the precise allocation of human capital.

In terms of talent acquisition, United Imaging Healthcare continues to refine the ”strategy-oriented, diversified coverage” talent reserve system. The company builds an international and professional talent pool for key areas of corporate development, expanding sources of high-potential talent through innovative recruitment strategies and channels (such as university-enterprise collaborations and global talent searches), providing solid support for diversified business expansion and global development.

As of the end of the reporting period, the company has established a diversified talent pool, with specific directions and strategic positioning as follows:

(1) Core R&D Talent Pool

Serve as the core support for the company's “Technology Leadership Strategy”. Focus on the core technology R&D needs of medical imaging equipment (such as MR, CT, PET-CT, RT, XR, etc.) to attract versatile technical experts with product market insight, systems engineering capabilities, project management, product management, and interdisciplinary backgrounds, to accelerate technological iteration and product innovation, thereby consolidating our leading position in the medical technology field.

(2) International Talent Pool

Focus on recruiting marketing and business development talents with a global perspective, cross-cultural communication skills, and local operation experience to support the company's global business layout and localization in overseas markets, facilitating international market expansion.

(3) Management reserve talent pool

Focus on cultivating key reserve talents with leadership potential and management capabilities, and build an organizational leadership pipeline through systematic training to ensure management resilience during rapid expansion and business transformation.

(4) Professional Functional Talent Pool

In addition to core strategic functions such as R&D, internationalization, and management, United Imaging Healthcare has simultaneously established a professional functional talent pool, focusing on the foundational support for efficient corporate operations, which covers key functional areas including production and manufacturing, supply chain management, quality control, digital tool applications, human resources, and financial support. This talent pool aims for “professionalism, precision, and efficiency”. Through stable talent reserves and capability enhancement, it ensures the smooth conversion of R&D achievements, the implementation in international markets, and the seamless operation of organizational management, providing solid operational support for the execution of corporate strategies.

This multi-dimensional talent layout not only provides United Imaging Healthcare with future-oriented organizational support but also injects continuous talent momentum into key pathways such as technological innovation, international expansion, and organizational upgrading, solidifying the core foundation for high-quality sustainable development. In the future, the company will continue to be guided by strategy, leveraging systematic safeguards and mechanism innovation to build a globally competitive

talent advantage, supporting the steady realization of sustainable development goals.

2. Compliance Empowerment: Safeguarding Employee Rights to Activate Sustainable Talent Growth

United Imaging Healthcare consistently regards "employee rights protection" as the baseline for sustainable corporate development and the starting point for "talent value activation". Through a comprehensive employment management system, clear operational guidelines, and a multi-tiered training and development mechanism (i.e., the closed-loop management of "policy – practice - feedback"), we build a talent development ecosystem that is "compliant, inclusive, and empowering", continuously injecting vitality and stable momentum into corporate innovation and high-quality development.

Compliance Management

The company strictly adheres to laws and regulations such as the *Labor Law of the People's Republic of China*, the *Labor Contract Law of the People's Republic of China*, the *Employment Promotion Law of the People's Republic of China*, and the *Law of the People's Republic of China on Safeguarding the Rights and Interests of Women*. The company has established core policies including the *Recruitment Management System*, the *Overseas Assignment Policy*, and the *Employee Leave Management Regulations*, covering the entire process, including recruitment, assignment, compensation, leave, and promotion, ensuring the human resources management system is legally compliant, transparent in process, and dynamically optimized. For example:

- **Recruitment process:** Establish a professional interview evaluation form based on "fair competition", explicitly prohibiting discrimination based on factors such as age, gender, nationality, race, ethnicity, or religion.
- **Promotion process:** Implement a dual-dimensional evaluation of "performance + potential", ensuring that truly outstanding talents can develop through more scientific measurement standards.
- **Overseas Assignment Process:** Develop a *Cross-Cultural Management Guide*, covering support measures such as visa processing, overseas medical insurance, and cultural orientation on national customs, to comprehensively enhance the willingness and satisfaction of expatriate employees.

Rights and Development

- **Occupational Health and Safety:** Building a "Two-Tier Protection System". Basic Tier: Annual health checkups for all employees (covering 100% of staff) + supplementary commercial insurance (reimbursement rate over 90%); Prevention Tier: Setting up radiation-proof workstations, providing protective equipment and special occupational health checkups (radiation exposure below national standards)**.**
- **Training and Development:** In 2025, the employee training participation rate is expected to reach 100%, covering three groups including new hires, current employees, and managers, with a focus on enhancing professional skills, leadership, and cross-cultural communication abilities.

Through the coordinated advancement of institutional norms, talent development, diversity and inclusion, and employee engagement, United Imaging Healthcare not only safeguards employee rights but also establishes a positive cycle of "employee growth - enterprise efficiency enhancement" providing solid human capital support for the company's high-quality development and sustainable strategic goals.

3. Global Layout: Deepening Diverse Talent Reserves to Support Innovation and International Expansion

United Imaging Healthcare continues to optimize and innovate recruitment models, building a global and diversified talent reserve system. During the reporting period, the company deepened university-enterprise collaborations with renowned domestic and international institutions, continued to advance internship programs, and attracted various high-potential talents through campus recruitment and experience hires, providing a solid talent foundation for technological innovation and business expansion.

In terms of digitization and the development of open recruitment channels, the company has further expanded the talent pool, ensuring transparency, fairness, and inclusivity in the recruitment process. Through multiple channels such as online and offline recruitment platforms, social media, and employee

referrals, the company effectively reaches high-quality candidates. At the same time, United Imaging Healthcare partners with renowned recruitment platforms domestically and internationally to attract global talent, and collaborates with third-party human resources outsourcing agencies to support the introduction of specialized professionals in specific R&D fields, ensuring a continuous supply of high-quality candidates for key positions.

The company adheres to a diverse and equal employment philosophy, providing fair job opportunities for candidates from different backgrounds, promoting the integration of diversity in gender, region, discipline, and cultural background, and optimizing the strategic alignment of the talent structure. Meanwhile, through systematic recruitment mechanisms and multi-channel talent acquisition strategies, the company has progressively enhanced the quality of talent development, established a sustainable foundation for talent growth, and provided solid support for boosting innovation capabilities, facilitating the implementation of global strategies, and driving long-term sustainable corporate development.

Guided by the global strategy, United Imaging Healthcare adopts a dual-driven approach of "university-enterprise collaboration + global talent search" to deepen diversified talent reserves, optimize the adaptability of talent structures, and support product innovation and overseas market expansion.

Core Achievements

Talent Scale and Structure: As of the end of the reporting period, the total number of employees reached 8,420, distributed across over 30 subsidiaries and offices worldwide, and has maintained steady workforce growth for consecutive years. Among them, more than 3,300 are R&D personnel (accounting for 40.27%), reflecting strategic investment in core technologies.

Recruitment and Channel Development: Leveraging multiple channels including online and offline platforms, social media, and employee referrals (employee referrals account for 28%, with a retention rate of 98%) to attract global talent; collaborating with renowned domestic and international recruitment platforms and third-party HR outsourcing agencies (supporting scarce fields such as AI and semiconductors) to ensure high-quality supply for key positions (967 new hires in 2025).

Diversity and Inclusion: Upholding the principle of fair employment, promoting the integration of diversity in gender, region, discipline, and cultural background (female employees account for 26.77%, with 26.41% in R&D roles); the retention rate of core and key talent in the first half of 2025 was 98.27%, with continuous improvement in talent development quality, providing a solid foundation for the implementation of the globalization strategy.

4. Ecosystem Co-creation: Building an Inclusive Talent Environment to Strengthen Organizational Resilience and Global Competitiveness

United Imaging Healthcare has made diversity, equity, and inclusion a key pillar of the company's talent strategy. Through a three-pronged approach of "cultural shaping + facility support + institutional safeguards", the company fosters an open, inclusive, and collaborative workplace ecosystem, enhancing the organization's ability to respond to market changes.

Specific practices

- **Cultural inclusion:** Firmly oppose unequal treatment based on 12 factors such as race, ethnicity, region, and gender (0 related complaints during the reporting period), and advocate a team culture of "respecting differences and encouraging voices".
- **Facility Support:** Advance the construction of supporting facilities such as multilingual office signage, accessible pathways for individuals with mobility challenges, dedicated dining areas for pregnant employees, and nursing rooms (planned upgrades include refrigerators and curtain partitions to enhance privacy), ensuring employees can realize their potential in a safe and friendly environment.
- **Policy Assurance:** Maintain a 100% employee labor contract signing rate, with 44 disabled employees meeting job requirements (accounting for 0.5%). Employment management adheres to compliance and transparency principles, providing institutional safeguards for a fair, stable, and efficient talent system.

Through the above practices, United Imaging Healthcare has synergized multi-dimensional talent-centric

strategic initiatives (strategic leadership, compliance empowerment, global layout, and ecosystem co-creation) to build an “inclusive, equitable, efficient and collaborative” talent development ecosystem, which effectively drives technological innovation breakthroughs and enhances global competitiveness, providing solid support for the realization of the company’s mission - “To Bring Equal Healthcare for All”.

ii Empowering Employee Growth, Building a High-Potential Talent Pipeline, and Fostering a Collaborative Organizational Ecosystem

United Imaging Healthcare consistently adheres to the development philosophy of “People-oriented”, committed to empowering employees' career growth and comprehensive development. Through a systematic talent cultivation system, diversified training resources, clear career development paths, and a comprehensive compensation and performance incentive mechanism, the company fosters a proactive organizational atmosphere, which achieves deep integration of employees' personal values with corporate strategic goals, builds a panoramic talent development plan, effectively enhances managerial leadership, and continuously expands employees' international perspectives and professional skills.

During the reporting period, the total training hours for all employees reached 149,872.74 hours, with an average of 17.80 hours per person and a training coverage rate of 100%, which encompassed key positions such as R&D, marketing, management, and administrative functions, fostering steady growth in high-potential talent pipelines, thereby providing solid support for enhancing the company's innovation capabilities and implementing a globalization strategy.

1. Clarifying Career Development Paths to Enable Talent Pipeline Advancement

United Imaging Healthcare regards talent development as the core driver of corporate innovation and sustainable growth. Based on a comprehensive job level system and qualification management mechanism, the company supports employees in creating personalized development plans aligned with their capabilities and career aspirations, fostering a virtuous cycle of skill enhancement and value creation. Meanwhile, the company actively promotes multi-directional talent mobility within the internal platform, implements internal transfer policies, and encourages employees to explore “Z-shaped” career paths, building an inclusive, flexible, and diverse career development support system to provide institutional guarantees for the deep alignment of employee growth with organizational strategic goals.

To systematically drive employee growth and organizational development, United Imaging Healthcare has further optimized a clear and scientific employee career development system. This system covers multiple stages, including career path planning, assessment of employee strengths/areas for development, development plan formulation and implementation, consensus on development goals, development plan execution, and review and evaluation, fostering continuous improvement in employee capabilities and value realization.

Through the continuous advancement of systematic career development programs, United Imaging Healthcare not only enhances employees' professional capabilities and leadership but also provides a solid foundation for building a stable talent pipeline, which helps the company maintain core competitiveness in a rapidly changing industry environment and achieve sustainable development.

Looking ahead, United Imaging Healthcare will continue to deepen the construction of the career development system, integrating ESG principles to promote employee diversity and inclusive growth, strengthening the sustainability and social responsibility of talent cultivation, effectively supporting the company's “People-oriented” development philosophy, fostering synergistic growth between the enterprise and employees, and jointly creating a brighter future for the healthcare industry.

2. Focusing on Training and Development to Unlock Talent Potential

The company places high importance on the strategic construction and sustainable development of the talent pool. A comprehensive development system has been established, covering core modules such as leadership development, professional competency enhancement, international talent cultivation, and newcomer training. The system systematically hones the strategic leadership and global adaptability of managers and potential successors, drives a leap in professional competence and vision across all

employee levels, strengthens overall organizational synergy, and continuously enhances innovation-driven capabilities and business execution.

1) Job-specific Development Training

United Imaging Healthcare closely aligns with the professional knowledge and skill requirements of specific business positions. By integrating internal and external training support resources, the company conducts diversified specialized training programs to enhance the adaptability and job capabilities of professional staff, fulfilling a firm commitment to supporting the career development of specific employees. Meanwhile, the company actively maintains interactive feedback with trainees to ensure that training initiatives continuously and effectively foster the professional and skill development of employees, while also helping to achieve business outcomes.

During the reporting period, by advancing talent cultivation and empowerment across multiple dimensions such as marketing, R&D, operations, functions, and internationalization, United Imaging Healthcare is comprehensively building a talent team with a global perspective, professional expertise, and exceptional execution capabilities, continuously strengthening the company's core competitiveness and sustainable development foundation.

Focusing on marketing business, in 2025, United Imaging Healthcare continues to advance the "Marketing Professional Training" program. Utilizing diverse training methods such as online courses, regional rotations, and external exchanges, the company aims to create a systematic and specialized development plan for domestic marketing talents. The course content covers key themes including strategy and tactics, practical experience, and team management, delivered by senior executives and external experts, cumulatively attracting over 1,500 marketing professionals to participate. Simultaneously, the company has implemented the "Regional Commander Training" program, targeting nearly 100 core marketing management personnel, including regional business directors and general managers. The training content encompasses role awareness, management skills, and strategic planning, comprehensively enhancing their practical management capabilities. United Imaging Healthcare fully recognizes the importance of customer service and reputation. In the first half of 2025, the after-sales service training center organized a total of 31 internal and external training sessions, totaling 1,888 hours, covering over 444 participants from more than 30 countries across Asia, Europe, Latin America, Africa, and the Middle East, continuously enhancing the technical proficiency and equipment maintenance capabilities of global engineers. At the same time, high-quality customer training courses are provided to deepen customers' understanding and application of the products, further improving customer satisfaction and brand loyalty.

Focusing on R&D business, United Imaging Healthcare collaborates with institutions such as Huixiang Tiandi to organize professional training programs, including the *Project Management Practical Training Camp*. Renowned experts deliver lectures to help R&D personnel systematically build their knowledge frameworks and enhance project management and innovation capabilities. The company also tailors differentiated course content based on the technical characteristics of each R&D business line to strengthen professional depth. In addition, the company actively encourages R&D personnel to participate in international academic conferences and industry summits, providing support for travel and other related expenses. Since 2023, 241 employees have participated in over 50 significant domestic and international academic and training conferences, including the International Society for Magnetic Resonance in Medicine (ISMRM), the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the American Society for Radiation Oncology (ASTRO), the annual IEEE Nuclear Science Symposium and Medical Imaging Conference (NSS MIC RTSD), and the European Congress of Radiology (ECR), further broadening cutting-edge perspectives and enhancing research and industrial innovation capabilities.

Focusing on operational business, United Imaging Healthcare has continuously deepened the “Six Sigma philosophy” within the organization. Experts from TÜV SÜD were invited to deliver training sessions covering key areas such as project management, risk assessment, and system tool analysis. A total of 45 relevant personnel participated, effectively enhancing operational efficiency and risk management capabilities. Simultaneously, the company conducted project management training on Enterprise Information Technology and Security Management Department (EIM) for project managers of the operational team. The training adopted an interactive learning approach combined with practical exercises,

focusing on improving project managers' capabilities in risk management and quality assurance. A total of 23 project managers participated, significantly strengthening the professionalism and standardization of project execution.

Focusing on functional business, United Imaging Healthcare collaborates with external experts to design and implement diversified capability enhancement projects based on practical scenarios, covering key directions such as design thinking, information security, and intellectual property. Since 2025, the company has organized 13 targeted quality regulation training sessions for headquarters functional departments, with a total of 2,651 participants and an average training duration of 1 hour per person. Such training has significantly enhanced employees' understanding of industry standards and compliance requirements, helping the company achieve steady improvements in operational efficiency and compliance, with the external audit pass rate for the quality management system maintaining a high level of 100%.

Focusing on international business, United Imaging Healthcare continues to advance overseas talent training programs across all levels, inviting top industry consulting experts to deliver systematic courses on product features, marketing strategies, and commercial regulations, thereby enhancing the professional capabilities of overseas business teams. In 2025, the company launched the “Overseas New GM Special Empowerment Program”, targeting newly appointed business leaders from 18 countries. The training covers cultural understanding, brand building, production & operations management, and leadership enhancement, facilitating their rapid transition from specialist roles to comprehensive management positions. Simultaneously, the company continues to provide STROBE model and leadership development training for incumbent overseas GMs, strengthening their role awareness, driving iterative upgrades in management capabilities, and comprehensively enhancing local business leadership and organizational performance. For frontline marketing employees in key regions such as Latin America, Central and Southern Africa, and Southeast Asia, the company has implemented the "Triangular" specialized training program. The curriculum covers strategy and tactics, market analysis, and practical case studies to accelerate the capability enhancement and market expansion of overseas teams. Since 2025, the company has provided online onboarding courses for over 150 new overseas employees and organized specialized supplementary training in financial knowledge, business compliance, international business overview, and operational mechanisms to help them quickly adapt to their roles. Over 120 training sessions were conducted in the North American and European markets alone, with an average training duration of 35.8 hours per person, further strengthening the overseas team's systemic capabilities and international operational foundation.

2) Graduate Training/Internship Program

United Imaging Healthcare regards the cultivation and development of graduates and interns as a crucial part of the talent strategy. The “Newcomer Program” has been launched, offering tailored training courses and career paths for fresh graduates and interns to nurture highly responsible and professionally competent talents.

In terms of intern training, United Imaging Healthcare implements a university-enterprise collaboration program, providing students with opportunities for in-depth workplace experience and professional development. The company annually selects interns from partner universities to intern at United Imaging Healthcare for a one-year period, offering employment opportunities upon graduation, with an intern retention rate consistently exceeding 50%. Additionally, United Imaging Healthcare collaborates with the Department of Engineering Physics at Tsinghua University and the Biomedical Engineering program at Huazhong University of Science and Technology to conduct internship programs, providing students with opportunities for social practice and helping them apply theoretical knowledge in practice.

In terms of training for fresh graduates, United Imaging Healthcare continues to implement comprehensive, forward-looking, and systematic graduate training programs to help new graduates accelerate their career growth and cultural integration. At the same time, the company has customized a specialized marketing traineeship program for the marketing sector to cultivate comprehensive marketing talents with the United Imaging Healthcare DNA. The fresh graduate training program covers new graduates in key functional areas such as R&D, marketing, administration, and operations. The training content includes onboarding training, corporate culture, workplace code of conduct, professional skills training, and mentorship from professional coaches. Additionally, to better support graduates in integrating into the company, the

company has introduced the “Month of Rapid Growth at Workplace” initiative based on previous survey results. This program offers 8 online courses centered around 4 major workplace competency themes, including presentation skills, communication and reporting, efficient delivery, and workplace professionalism. By providing fresh graduates with higher-quality courses and diverse learning and communication opportunities, these measures are designed to help them smoothly transition from students to professionals, laying a solid foundation for their career development. In addition, various departments also provide offline professional training for fresh graduates to help them acquire the necessary professional knowledge and skills, enhance their professional competence, and quickly adapt to the workplace.

Meanwhile, United Imaging Healthcare holds an annual training camp every August for newly hired graduates of that year. In 2025, the company plans to conduct 22 offline intensive training sessions covering cultural awareness, business orientation, workplace skills, and other relevant topics, targeting over 250 participants and covering 100% of the graduating cohort. Additionally, the company will focus on the marketing trainee group. Building on the aforementioned training, the company will implement job rotation and regional rotations to help trainees master product knowledge, enhance marketing skills, develop a holistic perspective through cross-functional practice, and lay a solid foundation for future marketing leadership. As of the end of the reporting period, United Imaging Healthcare's marketing traineeship program has been implemented for over 10 consecutive years, cultivating more than 193 marketing management trainees in total.

3) New employee onboarding training

As a key component of the "Newcomer Program," United Imaging Healthcare has developed a systematic and comprehensive onboarding training plan for new employees. The plan includes diverse formats such as standardized onboarding training, cultural boot camps, online learning, departmental professional training, and mentorship programs, aiming to help new hires quickly integrate into the organization, enhance job skills, and establish a foundation for career development. For new employees recruited through social recruitment, United Imaging Healthcare organizes cultural workshops. Through team interactions and open discussions, employees gain an in-depth understanding of the company's development history, strategic direction, and cultural essence in a relaxed and friendly atmosphere, thereby strengthening their sense of belonging and identification. In 2025, the company will continue to provide comprehensive and systematic training for all types of new employees, achieving a 100% training coverage rate for new hires, ensuring that training outcomes are highly aligned with organizational development needs.

3. Leadership Development and Succession Planning for Incumbent Managers: Building a Tiered and Systematic Management Competency Development System

United Imaging Healthcare adheres to the core philosophy of “Talent-Driven Innovation” and has established the “U-Change Leadership Development System”. This system accurately identifies managerial capabilities by introducing internationally authoritative assessment tools such as Hogan, establishing a three-tier strategic transmission framework covering the Strategic Leadership Level (L1), Strategic Promotion Level (L2), and Strategic Execution Level (L3). Additionally, the “Climber Plan” is leveraged to cultivate high-potential talent, creating a dynamic iteration mechanism of “a group in service, a group under cultivation, and a group taking up positions”, which provides comprehensive talent support for medical industry technology R&D, clinical transformation, and quality safety. The system has formed a virtuous cycle of “strategic decoding - talent empowerment - effectiveness improvement”, leveraging tiered capability building and dynamic talent pipelines to provide a solid foundation for breakthroughs in the global competitiveness of high-end medical equipment.

1） Leadership development for incumbent managers

United Imaging Healthcare has designed diversified competency development training programs for managers at all levels. Based on the company's U-Change leadership model, which covers three levels—L1 - Leaders (senior managers), L2 - Drivers (middle-level managers), and L3 - Practitioners (frontline managers)—the program combines courses, workshops, case studies, and other training methods to help managers enhance role awareness and management skills, enabling rapid professional growth.

a) **L1 – Leaders Program:** Focuses on the strategic vision and transformational leadership of senior managers, driving the senior management team to achieve deep consensus in business strategy, resource allocation, and cultural alignment through annual strategic calibration workshops and global healthcare innovation seminars. Through ongoing Top team and cultural workshops, a three-axis linkage mechanism of “strategy – organization - culture” is co-created, with strategic decision-making efficiency ranked among the top in the global healthcare industry according to BCG's organizational advantage survey.

b) **L2 – Drivers Program:** Focuses on strategic promotion and organizational efficiency enhancement. By implementing the "7-2-1" hybrid training model (70% practical business scenarios + 20% benchmark learning + 10% course input), the emphasis is on strengthening the transformation of practical scenario demands and cross-system collaboration capabilities of middle-level managers. By 2025, the program will cover 63 managers, with an average of 14 hours of training per person, effectively driving an 11% improvement in cross-departmental collaboration process efficiency.

c) **L3 – Practitioners Program:** Focuses on strategy implementation and team management. Through the mechanism of "standardized management tools + scenario-based assessment," the role transition of newly promoted managers is accelerated. By 2025, 122 frontline managers will complete specialized team management training (12 hours per person on average), reducing the competency cycle to 90 days.

2） High-Potential Talent Reserve (“Climber Program”)

Focusing on the forward-looking layout of talent in strategic areas, United Imaging Healthcare has established a high-potential talent identification and development system tailored to the characteristics of the healthcare industry. During the reporting period, the company completed dual-dimensional assessments (Hogan assessment and innovation potential assessment) for 133 high-potential talents, and systematically cultivated core talents in emerging fields such as high-end medical equipment manufacturing and medical AI through a combination of strategic project experience and executive mentorship. The reserve rate for key positions has reached 86.50%, providing solid talent support for the company's continuous innovation and strategic implementation in cutting-edge technology fields.

To comprehensively enhance the leadership skills of managers and cultivate a team with forward-thinking and exceptional leadership capabilities. The company has also meticulously designed the “Talent Club” online live course series, presented in a “night school” format, to help everyone continuously improve their capabilities in five key areas: strategy, globalization, innovation, operations, and organization and talent. This program, held from August 2023 to July 2025, offered a total of 33 sessions, achieving 100% training coverage for all managers.

3） Succession Pipeline Management and Development System

In terms of succession pipeline management, United Imaging Healthcare has established a systematic talent evaluation system for the succession pipeline. Through mechanisms such as nomination, collective discussion, and decision calibration, high-potential talents are reviewed across departments and organizations. The company also implements tiered and graded development of the succession pipeline, continuously enriching and expanding the talent reserve to ensure sufficient supply and optimized structure for management positions.

The company adheres to a strategy of dynamic management and prioritizing internal promotions, regularly assessing talent development status based on business growth needs to maintain the vitality and competitiveness of the talent pool. In 2025, the company identified over 816 management reserve talents spanning L1 to L3 levels. Through the implementation of succession plans, a total of 204+ reserve talents were promoted that year, accounting for 31.7% of the total reserve talent pool. The internal supply rate of managers significantly increased from 87.2% in 2024 to 96.0% in 2025.

In terms of succession pipeline development, the company formulates customized training and development plans for successors, including leadership training, Individual Development Plan (IDP), as well as challenging projects and practical opportunities, to help them clarify career goals and development paths, accelerate the achievement of person-job fit, and gradually enhance the depth and quality of the talent pipeline. In 2025, the company implemented the High-Potential Reserve Enhancement Program, providing over 24 hours of specialized training for 156 high-potential management reserve talents at the

L2-L3 levels. The courses covered core topics such as *High-Quality Decision Making*, *Lateral Collaboration*, and *Building A High-Performance Team*. Meanwhile, the company develops an IDP for each reserve talent, providing targeted practical and learning opportunities, such as participation in strategic transformation projects, to help them clarify career paths and accumulate core competencies while tackling new challenges.

United Imaging Healthcare will continue to deepen leadership and management development strategies, optimize the implementation mechanisms of succession plans, and ensure the construction of a solid managerial echelon during the process of global business expansion. The company will further expand the coverage of training and improve its quality, helping managers achieve outstanding performance in their roles and driving continuous innovation and high-quality development of the organization.

4. Professional Qualifications and Degree Support

United Imaging Healthcare adheres to the talent development philosophy of “People-oriented, Empowering Growth”, implementing flexible and diverse policies to support employees in obtaining certifications. The company encourages all staff, including full-time employees, interns, part-time employees, outsourced employees, and rehired retirees, to actively participate in course learning and certification applications based on personal interests, career development paths, and individualized learning needs, thereby comprehensively enhancing professional capabilities and career competitiveness.

To motivate employees to proactively improve their skills, the company has formulated and implemented the *Skill Certificate Subsidy Pilot Program*, providing monthly subsidies to certified employees, which further enhances employees' learning enthusiasm and establishes a virtuous mechanism of “promoting learning through certification and enhancing skills through learning”. The company strongly encourages employees to obtain 20 types of special operation certificates, including “Special Equipment Operator Certificate - Crane Safety Management” and “Special Operation Certificate - Welding and Thermal Cutting Operations”. Since 2015, 698 employees have successfully obtained the relevant qualifications. At the same time, the company supports employees in obtaining professional certifications such as PMP, Six Sigma, and Good Clinical Practice (GCP), effectively promoting the professional and systematic development of employees' career paths. As of the end of the reporting period, more than 50 employees have participated in obtaining various certificates, effectively promoting their career development and job competency enhancement.

In terms of high-level talent cultivation, United Imaging Healthcare actively builds continuing education platforms, encouraging and supporting employees to pursue advanced degrees. The company has jointly launched a part-time doctoral program with Shanghai Jiao Tong University and ShanghaiTech University to support employees in pursuing advanced studies while working, continuously breaking through professional bottlenecks, and empowering long-term career development. As of the end of the reporting period, the program has been conducted for five consecutive sessions since its establishment in 2020, with over 20 part-time doctoral students participating, including 2 high-potential talents selected from the Engineering Master's and Doctoral Training Reform Pilot Project.

Through a comprehensive skill certification incentive system and a high-end talent cultivation mechanism, United Imaging Healthcare continuously builds multi-level and multi-path career development pathways, injecting a steady stream of professional momentum into the company's technological innovation and high-quality development, further solidifying the strategic talent stronghold in the global competitive landscape.

5. Collaborative Talent Development Mechanism with External Institution

United Imaging Healthcare has extensively expanded collaborations with external professional educational institutions, steadily establishing a cooperative training mechanism. The company actively promotes professional academic research and exchanges, providing staff with a broader platform for advanced studies, and strives to build a high-quality talent pool to ensure the leading edge and applicability of professional knowledge and skills.

During the reporting period, United Imaging Healthcare further strategically enhanced the joint training

mechanisms with top-tier universities such as Shanghai Jiao Tong University, ShanghaiTech University, and Yale University, focusing on the systematic cultivation and innovation-driven development of high-level talent. By regularly organizing high-level academic lectures and multi-dimensional research exchanges, we deepen the interaction between staff and distinguished university mentors, expand cutting-edge academic perspectives, strengthen scientific research and innovation capabilities, and ensure that staff' professional knowledge and skills consistently maintain industry-leading status and high applicability. This initiative strongly supports the implementation of the company's technological innovation strategy, solidifying United Imaging Healthcare's competitive advantage and sustainable development foundation in the global medical technology field.

Regarding domestic universities, United Imaging Healthcare collaborates with Shanghai Jiao Tong University through the "Engineering Master's and Doctoral Training Reform Pilot Project," focusing on high-level talent development. Based on practical projects, corporate mentors and academic mentors maintain continuous interaction and communication. In the collaboration between United Imaging Healthcare and ShanghaiTech University, both parties empower each other through joint training of master's students and conducting diverse research and learning activities.

Regarding overseas universities, United Imaging Healthcare has established a reciprocal exchange mechanism with Yale University and the University of Utah, using research projects as the anchor to drive joint innovation. Among these, the Neuro Explorer project, a collaboration between Yale University's PET Center and United Imaging Healthcare, facilitates an exchange mechanism for scientists. Professors from Yale University visit United Imaging Healthcare an average of 2-3 times annually to deliver lectures, sharing cutting-edge advancements in PET technology, which provides invaluable opportunities for staff to update their professional knowledge and enhance their skills, fostering the generation of new ideas and solutions during the R&D process.

In the future, United Imaging Healthcare will continue to focus on collaborative projects, increasing the frequency of scientist visits, refining mechanisms and processes, and promoting deeper knowledge exchange and technical cooperation, further enhancing employees' capabilities in technological innovation and R&D.

iii Listening to Employees' Voices and Strengthening the Grievance Mechanism

1. Employee Feedback and Grievance Channels

United Imaging Healthcare places high importance on employee voices, providing diverse and open communication channels, and establishing smooth and secure mechanisms for employee grievance reporting. The company has issued the *Whistleblower Protection Policy*[1] and the *Internal Investigation Policy*, clearly defining channels for employee feedback and grievance procedures to safeguard their legitimate rights and interests. For different types of employee grievances, United Imaging Healthcare categorizes the channels into two major types:

1) **Work-related grievance** (e.g., performance compensation, compliance management, etc.) can be submitted through channels such as the Compliance Hotline Email and the Employee Voice Feedback Email.
2) **Personal rights grievance** (e.g., career development, life benefits, etc.) can be submitted through channels such as uTalk UIH Circle and the Online Consultation Helpdesk.

The company encourages employees to promptly file grievance reporting or escalation regarding human resources-related incidents such as child labor, forced labor, human trafficking, harassment, and discrimination. Regardless of location or time, employees can submit grievance reporting or escalation anonymously or under their real names through any channel. The company commits to responding within 24 hours, ensuring 100% closed-loop handling, strictly protecting employee privacy, and guaranteeing their rights are effectively safeguarded.

[1] *Whistleblower Protection Policy*: https://global.united-imaging.com/-/media/uih/pdf/investor/20240823/whistleblower-protection-policy_en.pdf

The main channels are as follows:
- Compliance hotline email: UIH_Compliance@united-imaging.com
- Employee Voice Feedback Email: Ourvoice@united-imaging.com
- uTalk UIH Circle: Feishu left menu bar >> More >> uTalk UIH Circle
- Online Consultation Helpdesk: Feishu Helpdesk >> HR Helpdesk

During the grievance handling process, the company strictly protects the information of the complainant or whistleblower, maintains confidentiality in the investigation and handling procedures, prohibits any retaliatory actions against the complainant, whistleblower, or investigation participants, and ensures that each complaint is handled fairly and justly.

Work-related grievance handling process (6 steps):
1) Grievance Submission: Employees submit grievances through designated channels.
2) Preliminary Review: Relevant departments quickly assess the validity and urgency of the appeal, prioritizing critical matters.
3) In-depth Investigation: A designated team conducts a confidential investigation, including interviews and document reviews.
4) Decision-making: The investigation team formulates recommendations and submits them to management for decision. For complex or significant issues, senior management collectively discusses and votes.
5) Result Feedback: The outcome is communicated to the complainant through direct interaction. If the appellant is dissatisfied, they may initiate a secondary review process.
6) Result Archiving: All grievances and processing records are archived to ensure future traceability of management.

Personal rights grievance handling process (4 steps):
1) Timely Response: Human Resources Department, Legal Compliance Department and other relevant departments will contact the employee within 24 hours.
2) Information Verification: Understand the grievance content and its validity, and supplement relevant verification information.
3) Investigation: Relevant departments collaborate with HRBP (Human Resources Business Partner) to directly conduct the investigation.
4) Result Feedback: Provide employees with feedback on the processing results and archive the outcomes.

Additionally, the company's employee union is democratically elected by the staff. Union representatives engage in equal, regular, and binding negotiations with management on matters concerning employees' vital interests, such as remuneration, working hours, rest and leave, insurance benefits, occupational safety and health, and vocational training, establishing a practical, traceable, and reviewable collective bargaining mechanism.

During the reporting period, the company received a total of 14 grievances and suggestions through various public channels, which were actively addressed with a 100% resolution rate in accordance with the aforementioned process. By continuously optimizing and promoting the employee feedback and grievance mechanism, United Imaging Healthcare effectively safeguards employees' democratic rights and drives the company's continuous improvement and healthy development.

Going forward, the company will continue to refine relevant mechanisms and expand more anonymous feedback channels to ensure that more genuine voices and constructive suggestions are heard and adopted, creating a safe and transparent communication environment for employees.

2. Performance Management System and Value Creation

United Imaging Healthcare upholds the performance management philosophy of “driving value creation, empowering continuous organizational capability enhancement, and stimulating employee motivation”. Relying on the company's *Performance Management Measures*, a performance management system has been established for all employees, covering key aspects such as performance goal setting, performance

feedback and coaching, performance evaluation, and result application. The company continuously improves the closed-loop performance management mechanism, fostering a virtuous cycle of value creation, value assessment, and value distribution, while strengthening the core role of performance in goal alignment, employee empowerment, and individual capability enhancement, achieving a win-win for personal development and organizational objectives.

1) Performance Goal Setting – Unleashing Individual Potential
Employee performance goals are managed in a closed-loop process through the company's internal talent management platform to ensure standardized procedures and traceable management. At the beginning of each year, when setting performance goals, the company accurately cascades core organizational objectives to all levels. Meanwhile, managers tailor individual goals for each employee based on their career development stage and job responsibilities, ensuring the goals not only unlock personal growth potential but also meet career development needs while aligning with the organization's strategic direction. Goal setting follows the SMART principles and Balanced Scorecard requirements, ensuring goals are specific, measurable, achievable, relevant, and time-bound, enabling differentiated and refined management for employees at all levels. The company encourages employees to actively participate in goal setting, enhancing motivation and accountability through open communication platforms, and implements dynamic management by tracking and reviewing goal completion quarterly, providing necessary corrective guidance. During the strategic review period, if there are changes in the external environment or key tasks, the company will adjust employee objectives accordingly to align with environmental and individual development needs.

2) Performance Feedback and Coaching—Achieving Mutual Commitment
The company supports the growth of all employees, addresses the challenges they encounter in achieving goals, and provides timely coaching and support, integrating performance coaching into their daily work and career development. In addition to the annual formal performance feedback interviews (typically conducted by supervisors, supplemented by system and email notifications), the company has established an open and timely feedback mechanism. Managers regularly provide performance feedback to employees through work review meetings and daily communication, ensuring every employee stays informed about their performance and areas for improvement. Meanwhile, the company encourages employees to share their insights and suggestions during daily coaching sessions to continuously drive personal growth and organizational progress.

To ensure managers effectively master employee performance feedback techniques, the company requires every newly promoted manager to complete mandatory training on performance feedback interview skills. Additionally, the HR department issues the *Performance Feedback Interview Manual* for easy reference and quick access to learning. Meanwhile, the HRBP will conduct performance goal setting and feedback coaching for managers annually, with a training coverage rate of 100%, ensuring that managers can proficiently master performance goal setting and feedback. This type of training combines course learning with role-playing, transitioning from professional knowledge to practical scenarios, helping managers master performance feedback and coaching skills more quickly.

3) Performance Evaluation—Value-Oriented, Fair and Objective
The company adheres to the principles of value orientation and comprehensive objectivity in conducting performance evaluations, considering factors such as performance scores, business strategies, environmental changes, corporate values, and contributions, to conduct horizontal calibration assessments for employees at the same level or in the same category from both the dimensions of work results and behaviors. The performance evaluation period is set from December to January of the following year, covering all employees. The evaluation process includes employee self-assessment, manager evaluation, TOC (Talent Organization Committee) resolution, performance result announcement and application, and performance appeals, ensuring that performance results align with employees' value contributions to achieve fairness, openness, and transparency. After the performance results are acknowledged, managers need to conduct formal feedback sessions with employees to analyze work performance and evaluation results, objectively assess strengths and areas for improvement, provide suggestions for enhancement, and jointly set goals for the next performance cycle and personal development plans, fully stimulating individual potential and enhance career development aspirations and capabilities.

4) Performance Application – Shared Benefits
Performance results are widely applied in scenarios such as salary adjustments, year-end bonuses, promotions, and non-monetary incentives, using performance evaluation outcomes as the primary basis for value distribution, motivating employees to fully create value and achieve shared benefits with the company. For employees whose performance needs improvement, the company will develop detailed and customized PIPs (Performance Improvement Plans). Managers are required to create tailored improvement plans for each employee's areas for enhancement and provide support and empowerment through performance coaching—covering knowledge, skills, and other aspects—to help employees improve their performance and achieve continuous growth.

3. Employee Satisfaction Survey and Continuous Optimization

United Imaging Healthcare places high importance on employee work experience, considering it a crucial component of organizational capability building and sustainable development strategy. The company conducts comprehensive, multi-dimensional employee surveys annually to continuously optimize the employee experience and enhance overall satisfaction, thereby driving organizational efficiency and employee value realization.

Since 2022, the company has engaged an external third-party organization BCG to conduct systematic, all-encompassing organizational surveys across 6 key areas—strategy, organization, talent, innovation, and others—spanning 12 critical dimensions. Through three consecutive years of strategic implementation, the company's overall score increased from 3.8 in 2022 to 4.0 in 2023 and further improved to 4.1 in 2024. The survey scores in the four dimensions of “job responsibilities, decision-making, performance management, and corporate transformation” have already placed the company in the top 25% of the global healthcare enterprise database.

In closed-loop survey management, the company systematically identifies organizational management issues through the structured process of “survey—feedback—action—evaluation”, guides responsible departments in developing specialized improvement plans, and incorporates the results of these improvements into performance evaluations to ensure the implementation of each optimization measure, achieving continuous enhancement of organizational capabilities. In 2024, employee feedback indicates that the company has shown the most significant improvements in the three dimensions of “organizational structure, process systems, and leadership”, achieving an average score improvement of over 10%. The specific manifestations are:

- **Organizational structure:** Implement more flexible, transparent, and rational organizational adjustments, enabling employees to experience clear and efficient workflows, thereby strengthening strategic execution capabilities;
- **Process system:** Introduce advanced digital tools to enhance work efficiency while encouraging employees to master the latest technologies and concepts, fostering personal growth and innovation capabilities;
- **Leadership:** Implement targeted talent development programs, providing innovative and developmental opportunities, enabling employees to experience both growth and value contribution within the organization.

The company conducts annual satisfaction surveys covering all employees, using data-driven insights to identify potential issues and formulate actionable plans, ensuring continuous optimization. The company-wide anonymous survey in August 2024 covered multiple dimensions, including corporate integration, job content, team collaboration, compensation and benefits, and personal development. The response rate was approximately 70%, with an overall employee satisfaction rate of 90.4%. The survey results indicate that benefit upgrades and management communication efficiency are key areas of employee focus. The company promptly organized thematic discussion meetings in the fourth quarter and implemented specific improvement measures, such as enhancing parking facilities for employees by adding additional parking zones, and establishing a dedicated meeting mechanism to improve communication efficiency. All measures were publicly announced to ensure transparent execution and supervision.

Since 2025, the company has conducted quarterly specialized satisfaction surveys on employee experience matters, including the cafeteria, workplace environment, shuttle buses, and dormitories, using a lottery

mechanism to boost participation rates. Upon completion of the survey, the company conducted an in-depth review and analysis, pinpointing key employee feedback and improvement measures, and disclosed them to all staff via internal communication tools to ensure transparency and collective oversight of the rectification process.

Looking ahead, the company will conduct the annual comprehensive employee satisfaction survey as scheduled in August 2025. The results will continue to serve as a key driver for optimizing organizational management and strategically enhancing employee experience, further strengthening organizational execution and employee value realization, and fostering mutual growth and strategic development for both the company and employees.

iii Compensation and Incentive System Construction

United Imaging Healthcare consistently adheres to a talent-centric strategic philosophy, closely integrating compensation incentives with organizational development and business strategy. By establishing a systematic and scientific compensation and equity incentive system, the company not only safeguards employees' legitimate rights and the market competitiveness of their compensation but also deeply aligns individual growth with the company's long-term value creation, achieving synergistic development between the organization and talent.

The company strictly adheres to the laws and regulations of the countries and regions where it operates, including the *Labor Law*, the *Employment Rights Act*, and the *Pay Transparency Directive*, ensuring the legality and compliance of compensation management. The company continuously optimizes the performance and compensation management system, designing rational incentive mechanisms tailored to the characteristics of each position, thereby supporting talent retention and the achievement of organizational strategic goals.

The company has established a compensation structure for all eligible employees, including fixed income, variable income, and long-term incentives. Comparative analyses are conducted based on market compensation levels, and the salary framework for each job grade is promptly updated to ensure the market competitiveness of employee compensation. The company has introduced diversified employee equity incentive programs at different stages of development, including Employee Stock Ownership Plans (ESOP), Type II Restricted Stock Incentive Plans, and Employee Strategic Allocation Stock Plan. As of the end of the reporting period, United Imaging Healthcare's employee equity incentive plans have cumulatively granted 78.526 million shares, covering over 4,000 participants. The employee equity incentive plan covers employees across different countries and levels, ensuring that every eligible employee can share in the growth and success of United Imaging Healthcare.

1) Employee Stock Ownership Plan (ESOP)

Convert pre-IPO virtual shares into actual shares, granting a total of 62.0559 million shares, covering over 800 high-performing employees. Strengthen employees' sense of responsibility and belonging as company shareholders through transparent vesting rules and flexible divestment mechanisms.

2) Type II Restricted Stock Plan

To further expand the scope of incentives, the company has specially launched a Type II Restricted Stock Incentive Plan for globally outstanding core employees, with a total of 2,475 employees participating and 6,621,900 shares granted. In 2025, it is proposed to grant an additional 4,471,300 shares to 1,368 individuals. The above plans are all linked to the operational performance of United Imaging Healthcare, with equity vesting tied to the company's market performance, incentivizing employees to contribute to enhancing United Imaging Healthcare's market value.

3) Employee Strategic Allocation Stock Plan

To reward employees for their achievements, the company launched an Employee Strategic Placement Share Plan prior to the IPO, with 754 participants subscribing to a total of 9,848,191 shares, amounting to RMB 1.133 billion in subscription funds, demonstrating the confidence of senior management and core employees in the development of United Imaging Healthcare.

Through systematic compensation and equity incentive arrangements, United Imaging Healthcare not only motivates employees to continuously create value but also enhances the stability and loyalty of the talent team. Looking ahead, the company will continue to optimize and improve compensation and incentive mechanisms, strengthen employees' sense of value recognition and responsibility, ensure that talent resonates with organizational strategy, and jointly promote the long-term sustainable development of United Imaging Healthcare.

iv Non-pay Benefits: Entered on employees as the key driving force, focusing on health care, career support, recognition and communication, energizing employees, aligning talent value with corporate strategy, building a comprehensive non-pay benefits ecosystem

United Imaging Healthcare adheres to an employee-centric strategic philosophy, viewing non-pay benefits as one of the key drivers for sustainable organizational development and talent value creation. Through a systematic and comprehensive U-Care non-pay benefits system, the company closely integrates employee care with organizational strategy, ensuring employees receive all-round support in health, career development, recognition, and communication. As a result, employees' sense of belonging, loyalty, and work motivation are enhanced, driving synchronized growth for both the organization and employees.

United Imaging Healthcare consistently focuses on “how to help employees better understand benefit policies” and “how to provide more benefit programs for employees”. The company has established the U-Care non-pay benefits system, covering four major areas - “Health Care”, “Career Support”, “Recognition” and “Communication” - and extends to all employees (including full-time staff, interns, part-time employees, etc.). We also tailor and update benefit strategies annually for employees and their families, fully considering the personalized needs of employees in different regions and positions as well as industry best practices, striving to ensure the competitiveness and advancement of non-pay benefits. At the same time, we strictly comply with the *Law of the People's Republic of China on Safeguarding the Rights and Interests of Women*, and do not differentiate treatment of female employees in career development based on age, pregnancy, childbirth, or other reasons, eliminating any form of workplace gender discrimination.

1) Health Care

- Healthcare Protection: Supplementary medical insurance is provided for all employees. In the first half of 2025, the commercial insurance expenditure totaled RMB 5,843,100, covering personal accidents, outpatient and inpatient medical treatment, critical illnesses, among other areas, and benefiting 100% of employees. For employees on overseas business trips, the company provides comprehensive overseas travel insurance to ensure that every employee can enjoy full medical coverage both domestically and internationally, creating a worry-free work environment. Meanwhile, various health check-ups are planned for the second half of the year, with an estimated cost of RMB 1,728,600. This initiative not only demonstrates the company's genuine care for employees' health but also reflects the practice of corporate social responsibility. Through a comprehensive health protection system, the company motivates employees' work enthusiasm, enhances team cohesion, and lays a solid foundation for the company's long-term development.
- Health Initiatives: Provide employees with free gym access, encourage the development of various clubs such as badminton, basketball, and football, and organize activities like basketball and badminton matches to enrich employees' leisure life, help them expand their social circles, and promote physical and mental health. Conduct activities such as traditional Chinese medicine consultations, oral examinations, and eye disease prevention irregularly to enhance employees' health awareness, strengthen team cohesion, and foster a positive corporate culture atmosphere. For example: the “My Jia Xinglin” Traditional Chinese Medicine Mini Bazaar event, eye disease prevention, oral examinations, and the company's collaboration with hospitals to carry out traditional Chinese medicine experience services, implementing health care initiatives.
- Dietary Care: Actively provide meal subsidies for all employees to ensure the quality of their meals, and specially set up dedicated dining tables for pregnant female employees to meet the dietary needs of different employee groups. For example: the cafeteria periodically organizes various food festival activities and the employee union's summer “Cooling Relief” campaign.
- Family Care: Provided discounted commercial insurance covering outpatient, emergency, and critical illness services for nearly 700 employees' family members, with an additional complimentary travel

accident insurance. Employees' family members can also enjoy discounted health checkup packages, summer camps for employees' children, and school enrollment assistance, enhancing employees' sense of belonging and happiness.

- Female Employee Care: Implement mandatory protections such as maternity check-up leave, maternity leave, breastfeeding leave, and childcare leave. Establish breastfeeding rooms, priority seating for pregnant women, and customized gifts for International Women's Day, providing comprehensive support for all female employees.

2) Career Support

- Onboarding Care: Provide comprehensive onboarding support at the organizational, departmental, and individual levels for new employees to help them quickly integrate into the company culture and understand business operations and workflows.
- Anniversary Recognition: Offer benefits such as anniversary leave and paid sick leave to employees who have completed a year of service, and enhance their sense of belonging and loyalty through anniversary events.
- Birthday Greetings: Provide birthday bonus benefits, with an investment of approximately RMB 800,000 in the first half of 2025, allowing employees to feel the company's care.
- Wedding Greetings: Provide wedding bonuses to bless employees' marital life and enhance their happiness.
- Childbirth Greetings: Provide maternity gifts and special leave to safeguard the rights of female employees, allowing them to feel the company's support for family life.
- Festival Greetings: Offer traditional holiday benefits, such as exclusive gifts for Women's Day, Dragon Boat Festival, and Mid-Autumn Festival, to enhance a sense of belonging and cohesion.

3) Recognition and Commendation

- Company Awards: Established non-material incentive awards such as Star of the Quarter, High-end Product Breakthrough, and Marketing Triumph to make employees feel recognized.
- Honorary Titles: Select Outstanding Employees, United Imaging Craftsmen, and other honorary titles. In 2024, there were over 20 company-level outstanding teams, more than 90 outstanding employees, over 40 department-level outstanding teams, and more than 300 outstanding individuals, with a total annual recognition investment of RMB 3.12 million.

4) Communication and Interconnection

- Satisfaction Survey: Conduct an annual company-wide satisfaction survey to gather employee feedback on the work environment, benefits, and career development, identify issues, and implement improvement measures. The 2024 survey received 5,891 responses, with 90.4% of employees expressing satisfaction with working at United Imaging Healthcare. The company continuously tracks issues, such as optimizing the authority-responsibility matrix, departmental responsibilities, and the U-Care non-material incentive system.
- Executive Communication: Organize one-on-one meetings between executives and employees, allowing employees to directly provide feedback to management, enhancing their sense of involvement and helping management formulate policies that better meet employee needs.
- United Imaging Healthcare Anniversary Celebration: Organize company-wide participation during important milestones like the company anniversary to strengthen a sense of identity and belonging. Reflecting on the company's development journey inspires employees' pride and sense of ownership.

Through the systematic and comprehensive U-Care non-pay benefits system, United Imaging Healthcare not only enhances employees' happiness and sense of belonging but also strengthens the organization's attractiveness and competitiveness. Looking ahead, the company will continue to optimize benefits strategies and practices, incorporating employee feedback and industry best practices to ensure the innovation, advancement, and sustainability of non-pay benefits. These efforts further energize employees, align talent value with corporate strategy, and achieve long-term mutual development for both the organization and employees.

VIII Product Safety and Quality Management

United Imaging Healthcare consistently regards product safety and quality management as the core

strategy for sustainable corporate development, continuously building a quality and safety management system that covers the entire product lifecycle. The company continuously improves the international and domestic certification program for product safety and quality, expands testing capabilities and scope, and strengthens the development of professional training capabilities for both employees and partners.

Meanwhile, the company actively promotes the coordinated development of supplier certification and training, integrating responsible marketing management, compliance audits, and regular inspections into the end-to-end management process to ensure that all upstream and downstream supply chains adhere to stringent quality and compliance standards. Through these initiatives, United Imaging Healthcare continues to provide high-quality, safe, and reliable medical devices and cutting-edge solutions for the healthcare sector, driving technological advancements in the industry and improving societal medical standards, thereby fulfilling the company's responsibilities and mission within the global healthcare ecosystem.

i. Product Safety and Quality Management Certification

In the increasingly stringent regulatory and compliance environment of the global medical device industry, ensuring the quality, safety, and environmental friendliness of products and services has become a core element for companies to achieve long-term sustainable development. United Imaging Healthcare consistently upholds internationally leading quality management and Environmental, Health, and Safety (EHS) management concepts, integrating them into the company's overall development strategy to form a comprehensive management system covering the entire lifecycle from design, production, supply chain, to after-sales service. The company continues to advance diversified domestic and international system certifications and rigorous internal and third-party audits, continuously strengthening operational compliance and risk management capabilities, ensuring outstanding product quality and reliability in the global market, thereby consolidating and enhancing international competitiveness.

5. Quality System Certification and Audits

All production facilities of United Imaging Healthcare have established a quality management system for the entire lifecycle of medical devices in accordance with applicable regulations and standards, fully ensuring the safety and effectiveness of marketed products. Applicable regulations and standards include, but are not limited to: China's medical device regulations (including the *Regulations on the Supervision and Administration of Medical Devices*, the *Measures for the Supervision and Administration of Medical Device Production*, the *Good Manufacturing Practices for Medical Devices*, etc.), domestic standard GB/T 42061-2022, international standards ISO 9001:2015 & ISO 13485:2016, U.S. medical device regulations (e.g., 21 CFR 820), Japanese medical device regulations (e.g., MHLW Ministerial Ordinance No. 169), Brazilian medical device regulations (e.g., RDC ANVISA n. 665/2022), South Korean medical device regulations, EU Directive 93/42/EEC (MDD), EU Regulation 2017/745 (MDR), Canadian medical device regulations SOR 98/282, Australian medical device regulations, etc.

As of the end of the reporting period, the scope of United Imaging Healthcare's quality management system certification has achieved 100% coverage across all factories. Meanwhile, United Imaging Healthcare has obtained ISO 9001:2015, ISO 13485:2016, and MDSAP (covering five countries: the United States, Canada, Japan, Brazil, and Australia) quality management system certifications for the full range of marketed products, including MR, PET/MR, CT, PET/CT, RT, DR, DSA, and medical image post-processing software.

As a crucial means of evaluating the effectiveness of management processes, audits play a significant role in the quality and safety management of United Imaging Healthcare's products. As of the end of the reporting period, the company's headquarters and subsidiaries—Wuhan United Imaging, Changzhou United Imaging, and the U.S. production base—underwent a total of 17 audits conducted by domestic regulatory authorities and third-party certification bodies. The audit types included Good Manufacturing Practice (GMP) system registration inspections for medical devices, ISO 13485:2016, ISO 9001:2015, MDSAP, EU Directive 93/42/EEC (MDD) and unannounced inspections, EU Regulation 2017/745 (MDR), INMETRO factory inspections, NRTL factory inspections, and CTF inspections.

6. Product Registration and Certification Management

In the highly competitive global medical device market, United Imaging Healthcare firmly believes that comprehensive product registration and certification coverage is a crucial foundation for expanding into international markets. The company's product innovation capabilities have also gained widespread recognition from global regulatory authorities. As of the end of the reporting period, the company's products have cumulatively received approval for over 140 models, including 52 products certified by the U.S. FDA 510(k), 53 granted EU CE licenses, and 7 products approved through China's special review channel for innovative medical devices. Particularly in AI empowerment, the company has secured FDA approval for over 20 AI-enabled devices, firmly maintaining a leading position in the industry. Looking ahead, the company will further promote the accelerated implementation of “equipment + AI” in medical imaging diagnosis and treatment scenarios, building an intelligent healthcare ecosystem.

Additionally, as of the end of the reporting period, the company has obtained certification for 42 product models from the Nationally Recognized Testing Laboratory (NRTL), 55 product models from the IEC Certification Bodies' Scheme (CB) for safety certification of electrical products, and 47 product models from the IEC CB scheme for electromagnetic compatibility certification.

To comply with standards and regulatory requirements, the company actively commissions third-party testing agencies to conduct product inspections. During the reporting period, the company conducted commissioned inspections on 74 product models and 82 configurations, obtaining 135 test reports. This series of certifications and test results ensures the compliance and competitiveness of the company's products in both domestic and international markets.

7. Environmental and Occupational Health and Safety Management

Building on the foundation of the quality management system, the company places high importance on environmental and occupational health and safety management. In accordance with the requirements of the ISO 14001:2015 and ISO 45001:2018 international management system standards, the company has established and implemented environmental and occupational health and safety management systems to ensure that business activities minimize environmental impact and prevent injuries and illnesses.

As of the end of the reporting period, the company headquarters has obtained ISO 14001:2015 and ISO 45001:2018 system certification certificates for the R&D and production sites of all products. At the same time, the company has taken the construction of a safety production system as a key focus, continuously promoting the standardized operation of safety production.

To further ensure the effectiveness of the EHS management system, the company actively accepts supervision and inspections from regulatory authorities at all levels. As of the end of the reporting period, the company headquarters and Wuhan United Imaging had undergone 19 rounds of supervision and inspections from provincial, municipal, and district-level authorities. The inspections primarily focused on safety checks for explosive precursor chemicals, fire safety inspections, canteen safety inspections, hazardous chemical safety inspections, radiation safety supervision checks, post-license supervision checks for pollutant discharge permits, environmental monitoring of pollutant emissions, hazardous waste environmental audits, and gas safety inspections. Under the comprehensive EHS system, the company achieved a 100% pass rate for supervision and inspections during the reporting period.

ii. Product Testing Scope and Capabilities

United Imaging Healthcare regards product quality and safety as the cornerstone of safeguarding patient health and supporting the sustainable development of the enterprise, fully implementing the main responsibility for the entire product lifecycle. The company strictly adheres to applicable laws and regulations globally and in all operational locations, establishing a proactive and precautionary quality management system that covers product initiation, R&D, production, market launch, and usage stages, deeply integrated with risk management. Key elements such as cybersecurity, AI applications, human-machine collaboration usability, product reliability, environmental impact, and resource sustainability are systematically incorporated into the management system to ensure safe, effective, compliant, and high-

quality product delivery worldwide, continuously enhancing healthcare accessibility and industry trust.

1. Testing Management and Quality Management System

The company deeply integrates quality control into all stages of R&D, ensuring product quality and safety through a stable and effective management system. As of the end of the reporting period, the company has established over a hundred product design and testing guidelines in accordance with relevant international standards, including the *Product Development Process*, the *Product Risk Management*, the *Product Cybersecurity Management Process*, the *AI System Lifecycle Process*, the *Product Usability Engineering Management*, the *Reliability Testing Standards*, the *Packaging Reliability Testing Standards*, the *Signal Integrity Testing Standards*, the *HALT Testing Standards*, the *Environmental Climate Testing Standards*, the *EMC Testing Standards*, the *ESS Testing Standards*, the *Environmental Mechanical Testing Standards*, the *Component Accelerated Life Testing Standards*, and the *Cable Procurement Design Verification Guidelines*.

At the same time, the company has equipped testing facilities and a dedicated testing team that meet the requirements of product testing, strictly controlling the testing process to ensure the results are authentic, accurate, complete, and traceable. As of the end of the reporting period, the company's various product lines possess professional and comprehensive testing capabilities to ensure product quality and safety. From the selection of raw materials to the study of product structure and performance, and further to the evaluation of product safety, efficacy, and quality, comprehensive testing is conducted, covering multiple aspects such as functional testing, material performance testing, mechanical performance testing, biocompatibility testing, electrical safety testing, cybersecurity testing, artificial intelligence algorithm testing, and usability testing. Through comprehensive, in-depth, and effective unit-level and system-level testing to ensure all needs from preclinical research to diagnosis and treatment are met.

2. Product Testing and Product Safety Management

By deeply integrating automated testing tools with methodologies, the company has achieved a dual leap in both testing efficiency and scope.

(1) In accordance with the *Risk Management Procedure*, and by referencing adverse events, recalls, warning letters, and other relevant regulatory communications concerning similar products issued by domestic and international medical device authorities, potential product hazards and dangerous situations are identified in advance throughout the product's entire lifecycle. Through the implementation and validation of risk control measures such as design, protection, provision of safety information, and user training, the overall residual risk of the product is minimized to an acceptable level, preventing potential quality and safety issues.

(2) Prioritizing cybersecurity and data compliance as core strategies, the company has established a cybersecurity protection system aligned with 12 international standards, including ISO 27001 and NIST CSF 2.0. This system meets regulatory requirements such as China's Classified Protection Level 3, the EU's GDPR, and the U.S. HIPAA. Corresponding security measures are embedded across all stages—demand analysis, architecture design, product development, testing and validation, production, and service operations. A defense-in-depth strategy is adopted, deploying seven layers of protection, including data encryption and situational awareness, making the company one of the first medical device enterprises globally to achieve ISO 27701 privacy certification.

(3) In 2025, the company will further strengthen risk identification, control, and acceptance activities related to usability, based on upgrades to usability engineering standards and regulations such as IEC 62366 and the FDA's *Human Factors Engineering Guidelines*, continuously enhancing risk management during user operations.

(4) By conducting a comprehensive analysis of the product's usage environment and key characteristics, diverse testing scenarios are designed to cover both common and extreme usage conditions. At the same time, United Imaging Healthcare emphasizes in-depth testing of critical aspects, employing methods such as repeated testing and temperature cycling to thoroughly identify and resolve potential issues and defects

in product design. Any issues or defects identified during testing are effectively addressed and resolved. Each product undergoes rigorous quality control before market release to ensure compliance with or exceeding relevant laws, regulations, and standards. Additionally, United Imaging Healthcare places high importance on product quality and safety testing environments. The safety and electromagnetic compatibility (EMC) laboratories for its full product line are recognized as Customer Test Facility (CTF-1) by TÜV SÜD and TÜV Rheinland, and as CTF-2 by SGS. These laboratories undergo annual audits by TÜV SÜD, TÜV Rheinland, and SGS, with qualifications covering all IEC safety and EMC standards related to the product lines, meeting all on-site witness testing requirements.

3. Design Validation and Clinical Evaluation

For the design aspects of product interaction, image quality, and workflow, experts with a clinical medical background evaluate the product. Through continuous iteration and optimization, they ensure the product's functionalities become more professional, refined, and intelligent, better meeting the clinical needs of a wide range of users. The company requires that the prototype for design validation must be the initial production unit or an equivalent. Any issues or defects identified during the design validation process must be resolved before approval, with both test execution rate and pass rate required to reach 100%.

During product development and before market launch, external customer evaluations are also required. The evaluation may target the entire system, product software, or specific functions or applications within the product to supplement customer input on product requirements. The evaluation covers: whether the product's customer experience meets expected levels; whether the product's workflow, interface interactions, customer preferences, default settings, labels, and other usability-related features align with customer needs; and whether the product's serviceability satisfies customers. For products utilizing new technologies, the company selects qualified medical institutions in accordance with the regulatory requirements of the *Norms on the Quality Management for the Clinical Trials of Medical Devices* to conduct trials or validations under normal use conditions, evaluating whether they meet the expected safety and efficacy. The company consistently focuses on clinical needs, actively seeking methods to address clinical pain points and provide high-quality medical services.

In the first half of 2025, the company cumulatively executed approximately 8.24 million tests, covering over 270 components and more than 150 systems, achieving a testing case coverage rate of 100%. Additionally, to meet the product registration and safety compliance requirements across multiple regions, the company has obtained third-party testing reports for the full range of commercially available products, including MR, CT, XR, PET/CT, PET/MR, RT, and software post-processing applications, in accordance with domestic and international standards such as GB 9706.1 and its series, as well as the IEC 60601 series.

4. Product Reliability Laboratory and Reliability Testing Status

The company integrates product reliability management throughout the entire product development lifecycle. Based on the *Reliability Activity Guidelines*, reliability activities are summarized at each project stage, covering reliability planning, determination and decomposition of reliability indicators, reliability design and analysis, reliability test planning and execution, and the output of a series of comprehensive reliability technical reports on key raw materials, modules, components, and complete machines.

The company has established a laboratory dedicated to in-house testing and evaluating product reliability. This lab is primarily used to verify product performance and durability under various environmental conditions, ensuring product reliability and stability, thereby enhancing user satisfaction and trust. The reliability laboratory is equipped with various testing devices and technologies, enabling it to conduct a range of environmental tests, vibration/impact tests, drop tests, mechanical durability/life tests, road driving tests, reliability growth tests, ESS tests, and more.

In accordance with the requirements of a series of testing standards, including the *Reliability Testing Specification Guidelines*, United Imaging Healthcare implements reliability measures throughout all stages of product design and development, verification and validation, and manufacturing to ensure product quality and reliability.

In the first half of 2025, the company conducted a cumulative total of 21,524 reliability tests, covering 272 critical components and 21,500 test cases, achieving a 100% test case coverage rate. The scope of reliability testing encompassed the entire product line and components, including MR, PET/CT, CT, RT, XR, and others, involving products and components such as ceiling-mounted DSA, Mobile C-arm X-ray System, large-bore slide guide CT, SPECT CT, 3T PET MR, MR spectrometer, PET detector, PET CT control hardware, CT X-ray tube, CT detector, CT main bearing, CT imaging chain electronic components, radiotherapy electron gun, radiotherapy accelerator tube, magnetron, radiotherapy high-voltage module, beam defining head control unit, Smart Sky Eye camera, vital signal module, digital intercom unit, human machine interface controller, and others. The tests included HALT, environmental stress testing, storage and transportation testing, high-temperature aging, mechanical durability, and fatigue life testing.

In addition, the company completed vibration durability tests simulating 160,000 kilometers and domestic road driving tests for vehicle-mounted imaging equipment, covering standard road conditions, harsh road conditions, and emergency start-stop scenarios. The harsh road conditions included washboard roads, bumpy roads, uphill and downhill roads, and gravel roads. By the end of the reporting period, the company had completed reliability tests simulating 7 vehicle-mounted imaging products. Reliability testing effectively supports product optimization design, completes the design and verification loop, and enhances the reliability levels of components and the entire system.

5. Environmental Protection and Product Environmental Regulation Testing

The company strictly adheres to the system document *Environmental Regulation Requirements for Products* at every stage, including product initiation, R&D, incoming materials, production, and market launch, ensuring that every component of all products continuously complies with environmental regulations throughout their entire lifecycle.

Based on the alert notifications from the EU Rapid Alert System for Dangerous Non-Food Products (RAPEX), and considering the different materials used in the company's products, the company not only tests the compliance of hazardous substances in materials from the supply side but also commissions third-party laboratories to test the content of hazardous substances in materials, ensuring that all products are covered by the tests. In the first half of 2025, the company tested a total of 18,184 homogeneous materials to ensure that the products meet environmental standards and regulatory requirements.

6. Production Testing and Quality Control Process

The company has established a comprehensive production quality management system, covering core process documents such as the *Design Transfer Process*, the *Process Development Procedure*, the *Production Control Procedure*, the *Incoming Inspection Control Procedure*, the *Process and Final Quality Control Procedure*, the *Equipment Management Procedure*, and the *Environmental Control Procedure*. Through a systematic management mechanism, the company ensures that the design output of products can be accurately translated into production specifications, achieving full-process quality control from raw material management, process development, production manufacturing to finished product inspection.

In terms of raw material control, the company relies on the *Incoming Inspection Control Procedure* to establish and operate a supplier material risk assessment system. This system deeply integrates risk assessment results with the tiered management of incoming inspections, forming a quality control mechanism at the source. The raw material inspection items comprehensively cover accompanying documents (certificates of compliance), physical characteristics (packaging integrity, appearance, dimensions, etc.), functional parameters (power-on testing, material composition analysis, etc.), and identification management (label information, material version control). The company ensures the compliance of raw materials in terms of quality, safety, and regulatory requirements through multi-dimensional and comprehensive inspection standards.

In terms of process development and validation, the company systematically conducts FMEA analysis based on the *Process Development Procedure*, comprehensively identifying potential failure modes, quantitatively assessing risk levels (severity/occurrence/detection), and formulating targeted control and preventive measures. The company implements full-process management of key process characteristics,

clearly defines critical procedures and special processes, strictly enforces process validation and process confirmation, scientifically sets and solidifies parameter control limits to ensure the stability and repeatability of the manufacturing process. At the same time, the company integrates risk management concepts throughout the entire process of process design, validation, and continuous improvement, continuously enhancing product quality consistency and production operation compliance.

In terms of production process control, the company has established a multi-dimensional, full-process monitoring system based on the 5M1E management framework (Man, Machine, Material, Method, Environment, Measurement). Specific measures include: personnel qualification management and training certification, standardized procedures for equipment inspection and maintenance, periodic calibration and traceability of measuring instruments, full-process data traceability via MES systems, real-time monitoring of environmental parameters, automated inspection systems and data analysis platforms, as well as finished product and process sampling inspections. The company integrates preventive controls with real-time monitoring to form a traceable, quantifiable, and improvable closed-loop quality management mechanism, ensuring stable and controlled production processes and further solidifying its competitiveness in the global market.

7. Final Product Testing and Inspection

The company strictly adheres to the medical device quality management system and relevant regulatory requirements, implementing 100% testing and inspection on all products to ensure their safety, efficacy, and regulatory compliance. Testing and inspection cover multiple categories, including protective earth resistance, withstand voltage, noise, system functionality, images, among others, totaling over 17,700 items, comprehensively addressing the product's functional performance, electrical safety, and other key technical indicators. United Imaging Healthcare has established a long-term data preservation and traceability mechanism, retaining testing and inspection records for 30 years to ensure traceable management throughout the product's entire lifecycle.

iii. Product Safety and Quality Training

United Imaging Healthcare places high importance on employee quality and safety training. Through comprehensive and systematic training programs and courses, the company ensures that all employees thoroughly understand regulatory and standard requirements, consistently adhere to corporate procedural demands, continuously enhance their skill levels and quality safety awareness, and guarantee the high quality and safety of products.

To ensure employees fully understand and fulfill their job responsibilities, United Imaging Healthcare conducts comprehensive quality and safety training for all employees, including interns and outsourced personnel. As of the end of the reporting period, a total of 130,349.24 hours of product quality and safety-related training had been conducted company-wide, reaching 242,289 employee participations.

The company has designed diversified training themes based on different training targets and levels, such as onboarding training and quality and safety awareness promotion training for new employees, retrospective training and advanced training for employees, as well as quality and safety awareness enhancement training and quality and safety habit-building training. Additionally, the company has implemented diverse training formats, including traditional text- or video-based classroom training, self-directed learning, periodic remote online courses, electronic system online training, and educational content via self-media subscription accounts.

1. Quality and Safety Awareness Training

To enhance the quality and safety awareness of all employees, strengthen their sense of responsibility, and improve product and service quality, the company has conducted quality and safety awareness training for all staff. Specifically, for all new employees, quality and safety awareness promotion is carried out, including training on the *Quality Management System* and the *EHS Environment and Health Safety*. For long-tenured employees, enhanced training on quality and safety awareness is conducted, including the study of the *Quality Policy*, the *Quality Manual*, and the *EHS Management Manual*, as well as the

organization of “Quality Month” activities. Additionally, quality and safety activities, including “Quality Regulations Update” and “EHS Journal”, are disseminated through the “QM Broadcasting Station”.

2. Training on Regulatory Standards

To enhance employees' compliance awareness and ensure high standards of quality management in the global market, United Imaging Healthcare has conducted regulatory standards training for managers, R&D personnel, and quality management personnel. The training covers China's *Guidelines for the Review of Usability Engineering Registration of Medical Devices*, the EU's *2017/745 MDR Regulation*, the U.S. *21 CFR 820*, and the international standard *ISO 14064-1:2018 Specification with Guidance at the Organization Level for Quantification and Reporting of Greenhouse Gas Emissions and Removals*, enabling employees to deeply understand and implement regulatory requirements, ensuring product quality and safety in their work.

3. Training on Control Procedures and Standardized Processes

To prevent non-conformities, improve work efficiency, foster teamwork, and enhance quality awareness, United Imaging Healthcare has conducted process and procedure training for all employees involved in quality and safety, including top management, R&D personnel, process personnel, production personnel, sales personnel, installation personnel, service personnel, quality management personnel, administrative personnel, HR personnel, and IT staff. The training content includes the *Quality Manual*, the *Product Development Process*, the *Production Control Process*, the *Marking Control Procedure*, the *Service Management Procedure*, the *Complaint Handling Procedure*, the *Customer Satisfaction Procedure*, and other related procedures, ensuring that every employee strictly adheres to the company's established processes and standards in their respective positions.

4. Product Knowledge and Technical Training

To ensure the safety and effectiveness of products designed and developed by the company, as well as to enhance communication efficiency between departments and customer satisfaction, United Imaging Healthcare has conducted product knowledge training for R&D personnel, process personnel, sales personnel, installation personnel, service personnel, and quality management personnel. The training content covers the *MR Product Basics*, the *CT Product Basics*, the *PET/CT Product Basics*, the *RT Product Basics*, the *XR Product Basics*, and the *Software Product Basics*, ensuring that every employee gains an in-depth understanding of product features and applications.

In addition, the company has conducted multiple theoretical knowledge training sessions for R&D personnel, including the *Basic Principles of MRI Sequences*, the *Principles of PET/CT*, the *Monte Carlo Method & Alias Method Sampling Algorithms*, *The Development of AI and Introduction to Large Models*, the *CT Spectral Technology*, and the *Theories and Methods of Automated Testing*, aiming to strengthen employees' professional knowledge reserves and ensure the company maintains a leading position in the technological field.

5. Practical Operation Training

To ensure that employees, in their respective positions, “perform their roles diligently and take full responsibility”, United Imaging Healthcare has conducted practical training for R&D personnel, process personnel, production personnel, sales personnel, installation personnel, service personnel, and quality management personnel. The training content includes the *Software Development Skills Training*, the *Interface Testing Training*, the *After-Sales Product Knowledge Training*, the *Welding Fixture Design Training*, the *Six Sigma Training and Coaching Camp*, the *Work Instructions*, and the *Inspection Skills*, aiming to enhance employees' practical skills and job adaptability, ensuring efficient and high-quality work outcomes.

6. Environmental and Occupational Health and Safety Training

To ensure that employees understand and comply with laws, regulations, policies, and procedures related to environmental protection, employee health, and production safety, the company conducts

Environmental and Occupational Health and Safety Training for all staff. The training content includes the *Safety Training for Resuming Work and Production*, the *Waste Management Training*, the *Emergency Rescue Knowledge Training*, the *Environmental Management System & Occupational Health and Safety Management System Training*, the *Organizational-Level Greenhouse Gas Inventory—Standard Interpretation and Practical Guide Training*, the *Radiation Safety Training*, the *Occupational Health and Safety Training*, and the *Traffic Safety Training*, aimed at enhancing employees' awareness of environmental protection and knowledge of occupational safety and health.

iv. Supply Chain Management

In the global supply chain system, supplier management and auditing are core components to ensure product quality, safety, and compliance. United Imaging Healthcare implements rigorous supplier management procedures, integrating quality and compliance requirements throughout the entire process of supplier qualification, performance evaluation, periodic audits, and continuous improvement, which not only ensures the stability and reliability of the supply chain but also drives collaborative enhancement in quality, management, and technical capabilities among partners. The company relies on a systematic supplier certification, audit, and training mechanism to strengthen supply chain resilience, promote green procurement and responsible supply chain development, and is committed to building a high-quality, sustainable global medical device ecosystem, collectively shaping a world-class quality and brand image.

1. Supplier Certification and Audit Management

United Imaging Healthcare has integrated supply chain management into the core of the company’s global strategy, ensuring product quality, safety, compliance, and supply chain sustainability through a rigorous system of supplier qualification, evaluation, and reviewing.

In accordance with the *Supplier Management Procedure* and the *Supplier Audit Procedure*, the company conducts systematic evaluation, auditing, or qualification verification for all new Tier 1, Tier 2, and Tier 3 suppliers. The evaluation criteria cover multi-dimensional indicators such as technical support, business support, quality data, control of environmentally hazardous materials, and employee occupational health and safety; the focus of audits or qualification verification is to validate the supplier's quality system and third-party system certifications. As of the end of the reporting period, 98.3% of the company's Tier 1, Tier 2, and Tier 3 suppliers have obtained third-party system certifications, establishing a high-standard supply chain access system.

The company has established a tiered evaluation and audit mechanism for suppliers at different levels to ensure the dynamic optimization and continuous improvement of the supply chain quality system:

1) Tier 1 and Tier 2 suppliers: Conduct an annual business evaluation and a biennial system review, covering quality systems, product quality, and environmental management requirements. Suppliers are required to develop and implement corrective measures for issues identified during reviews to ensure the ongoing compliance of quality and environmental systems.
2) Tier 3 suppliers: Conduct a business evaluation every two years, and perform a comprehensive inspection and archiving of qualification certificates such as agency qualifications and quality system certifications to ensure all certificates remain valid. For suppliers that fail to meet requirements, the company will drive their rectification and, if necessary, implement an elimination mechanism to maintain the overall stability, reliability, and strategic competitiveness of the supply chain.

In terms of supplier risk management, the company incorporates evaluation and review results into the supplier risk rating system and implements differentiated management strategies based on risk levels:

1) Define assessment indicators or dimensions for different suppliers, including technical capability, delivery capability, quality performance, environmental management, occupational health and safety, and business ethics (such as anti-bribery, prohibition of child labor or forced labor), etc.
2) Based on the review results, suppliers are classified into risk levels, and differentiated evaluation, review, and management measures are implemented to enhance supply chain resilience, risk control capabilities, and sustainable development capabilities.

United Imaging Healthcare has established a comprehensive information-based supplier data management

and monitoring system, systematically integrating and regularly updating supplier evaluation, review, and rectification data to achieve full-chain traceability management. The procurement contracts and quality agreements specify environmental and social responsibility requirements, stipulating that all purchased materials must comply with green and regulatory standards. The company comprehensively manages the environmental requirements of purchased materials through the GPM (Green Product Management) platform. The review methods are diversified, including questionnaires, third-party reviews, and on-site inspections, with flexible adjustments to the review frequency based on business development. Continuous follow-up on supplier improvement outcomes is also conducted to promote the overall sustainability of the supply chain.

As of the end of the reporting period, all 12 newly added suppliers have passed evaluation and review, and were successfully included in the qualified supplier list. Out of the 128 suppliers planned for annual review (68 planned for Q1/Q2), 68 were actually completed, with all review results passing and no major anomalies. The evaluation and review results indicate that the company's suppliers continue to meet company standards in technical capabilities, delivery, quality management, and social-environmental responsibility (ESG), among other aspects. The overall supply chain remains stable and controllable, providing solid support for the company's global business expansion.

Through the aforementioned measures, United Imaging Healthcare has established a closed-loop management system covering supplier qualification, evaluation, review, rectification, and continuous monitoring, deeply integrating quality, safety, environmental, and social responsibility into the entire supply chain process. Building on this foundation, the company will continue to advance the digitization and intelligent management of the supply chain, deepen the assessment of ESG metrics in supply chain management, strengthen suppliers' continuous improvement capabilities, and further build a high-quality, sustainable global supply chain ecosystem, which will provide solid support and long-term assurance for the steady implementation of future internationalization strategies, the enhancement of global market competitiveness, and the sustainable development of the healthcare industry.

2. Supplier Product and Quality Training

United Imaging Healthcare places great emphasis on supplier quality management and capability building, incorporating supplier training into the company's strategic system as a key initiative to drive overall quality improvement and sustainable development of the supply chain. The company conducts supplier training in accordance with the *Supplier Training System*. The training system specifies the training requirements, topics, content, frequency, and assessment criteria. Training methods include offline centralized training and online learning, while establishing training records and assessment archives to ensure the standardization and traceability of supplier training. During the reporting period, the company continued to optimize and improve supplier training to ensure coverage of all suppliers and promote continuous improvement.

United Imaging Healthcare plans and implements annual routine training for all Tier 1, Tier 2, and Tier 3 suppliers each year, while conducting flexible specialized training based on business needs and quality management priorities. Supplier training takes various forms, including online knowledge sharing, official account promotions, quality meetings, procurement technology exchange sessions, and customized training. The training content covers quality system standards and requirements, United Imaging Healthcare's quality standards, applicable quality and environmental regulations, as well as ESG-related management requirements such as labor safety and environmental management. After the annual training, the company conducts assessment exams for supplier quality representatives. The exam content includes quality requirements and related compliance standards. Those who pass the exam will receive JQE (Joint Quality Engineer) certification to encourage suppliers to continuously improve their quality and compliance management capabilities.

The company conducts annual training on quality for all suppliers each year. The 2025 annual quality training is scheduled to take place in September and will last for two days. The training is divided into two main modules: First, a session for sharing and exchanging best practices, where suppliers with outstanding performance in quality management and social responsibility are invited to share their practical experiences, and United Imaging Healthcare's SCM process experts are invited to introduce production

processes and address suppliers' concerns about manufacturing workflows. Second, a systematic training course covering key topics such as quality standards, regulatory compliance, hazardous material management, and carbon emissions management.

In addition to annual training, United Imaging Healthcare conducts specialized training through various formats such as quality meetings, technical exchange sessions, and the JQE Club. For example, for suppliers showing an exceeding trend in quality targets during Q1 and Q2, the company collaborated with R&D teams to conduct specialized inspections and guidance for 62 suppliers, analyzing root causes and driving the implementation of improvement measures to enhance their quality management and process control capabilities. Meanwhile, the company regularly conducts quality meetings with key suppliers. As of the end of the reporting period, the company has held over 100 meetings with suppliers, accumulating more than 120 hours of training for them. The company also conducted 64 online GPM training sessions for 64 suppliers to ensure they fully understood environmental regulatory requirements and collaborated with the company in managing hazardous materials.

Through systematic annual and specialized training, the introduction of high-quality internal and external resources, a training feedback mechanism, and practical application tracking, United Imaging Healthcare linked supplier training content with grading, evaluation, and review s, continuously driving improvements in supplier quality and ESG management capabilities. Training covers all suppliers to ensure the company's quality standards and social responsibility requirements are effectively implemented across all aspects of the supply chain, thereby building a high-quality, sustainable global supply chain system that provides strategic support for the steady advancement of the company's internationalization strategy and global market competitiveness.

3. Collaborative Supply Chain Development

United Imaging Healthcare actively participates in industry supply chain associations and related activities, proactively strengthening communication and collaboration within and beyond the industry to promote the co-creation of a high-quality, sustainable supply chain ecosystem, while continuously enhancing the company’s own supply chain risk management capabilities and resilience. The company has engaged in industry organizations and major events such as the China Medical Equipment Association, the Medical Enterprise Supply Chain Association of the China Federation of Logistics & Purchasing, the Medical Device Supply Chain Annual Conference, and the China International Import Expo. Through systematic analysis and adoption of industry best practices and advanced management experiences, the company continuously optimizes upstream and downstream collaboration models and strengthens supply chain synergies.

In this process, United Imaging Healthcare has made supply chain stability, reliability, and compliance core management objectives. By integrating environmental, social, and governance (ESG) standards, the company promotes supplier capabilities in quality management, environmental protection, labor safety, and social responsibility, achieving sustainable development across the entire supply chain. Through continuous participation in industry exchanges and practices, the company has not only enhanced supply chain risk response capabilities but also strengthened the resilience in the face of market volatility and uncertainty, providing strategic support for the steady development of global business.

v. Responsible Marketing Management

1. Responsible Marketing System

In the global medical device industry, responsible marketing practices are not only a core requirement for corporate compliance but also a crucial measure to protect patient rights and maintain market credibility. The company fully recognizes the significant impact of marketing activities on society, the environment, and stakeholders. The company has established the *Responsible Marketing Policy*[2], which is simultaneously published on the corporate website to ensure that the marketing activities of the company, subsidiaries and branches worldwide are always legal, compliant, honest, and ethical. The *Responsible*

[2] *Responsible Sales and Marketing Policy:* https://global.united-imaging.com/-/media/uih/pdf/investor/20240823/responsible-sales-and-marketing-policy_en.pdf

Marketing Policy applies to the company, subsidiaries and branches. Third-party organizations such as distributors and service providers that represent the company or participate in business-related activities (collectively referred to as "third parties") must also comply with this policy. Additionally, all marketing personnel, including but not limited to directors, supervisors, senior executives, full-time employees, contract personnel, part-time personnel, temporary workers, consultants, and other relevant personnel must strictly adhere to this policy.

1) Basic Principles

The company requires all marketing activities to ensure legality, fairness, honesty, and truthfulness. All marketing activities must comply with the laws, regulations, industry standards, and regulatory requirements of the respective jurisdictions, including medical device regulatory laws, anti-unfair competition laws, advertising laws, and anti-monopoly laws. The company requires ensuring compliance with laws and regulations related to data security, cybersecurity, and personal information protection in marketing activities, safeguarding the trade secrets and information security of partners and customers. Meanwhile, the company adheres to high ethical standards, guided by the principle of creating and delivering value, and strictly prohibits any form of corruption or bribery in marketing activities.

Throughout the entire marketing process, the company requires strict compliance with the universally accepted principles of fair competition in the business sector. Marketing activities must not contain any content that violates public order and good customs in relevant countries and cultures, nor should they abuse customer trust or exploit the inexperience of patients. For factors that may affect the interests of patients, the company requires timely consideration and appropriate action. All marketing content must be truthful and accurate, and must not mislead customers or patients in any way.

2) Promotion and publicity requirements

The company requires strict compliance with laws and regulations regarding the promotion and advertising of medical devices, ensuring that all promotional content clearly, accurately, objectively, and truthfully describes the functions, quality, uses, and other information of products and services, and aligns with the latest and valid scientific research, test data, and clinical practices. The company mandates that the content of marketing materials must be consistent with the product registration certificates or filing documents and must not include or imply any functions the device does not possess or performance parameters it cannot achieve. For products or features that have not obtained marketing authorization or registration, the company requires that their safety and efficacy not be promoted, and their authorization or registration status must be clearly indicated in marketing materials. Promotional materials involving scientific research results, statistical data, survey findings, abstracts, data, or quotations must be truthful and accurate, with complete citations, and must clearly indicate the source and time frame (if applicable). If promotional activities require approval under local advertising laws and regulations, the company will ensure that the relevant administrative approvals are obtained.

3) Review and control of promotional materials

The company has established and continuously improved a strict review mechanism for promotional materials and a control process for marketing documents to ensure that the preparation, review, release, and archiving of all external promotional materials comply with regulations. The company requires that marketing documents intended for external promotion must undergo the processes of preparation, review, release, and archiving, in accordance with the company's *Marketing Document Control Process*. All promotional materials must undergo review and approval by the relevant departments before official release. Meanwhile, the Legal Compliance Department has compiled the *Promotional Compliance Self-Checklist*, which serves as a guide for compliant promotion. It includes common promotional compliance review comments for reference and learning by relevant business departments when creating promotional materials.

The company has also established a series of compliance systems and documents, including the *Business Conduct Guidelines*, the *Anti-Bribery and Anti-Corruption Policy*, the *Supplier Code of Conduct*, and the *Distributor Code of Conduct*, which clearly define the business conduct standards for all employees, marketing personnel, and relevant partners in activities such as sales, promotion, and supply chain management. To ensure that distributors and suppliers are familiar with and understand United Imaging

Healthcare's compliance policies and fulfill their business conduct in compliance, the company requires distributors to sign and adhere to the *Distributor Code of Conduct* and suppliers to sign and comply with the *Supplier Code of Conduct*. These compliance policies and documents not only provide clear behavioral guidelines for employees and partners but also lay a solid foundation for the company's overall compliance management system.

2. Responsible Marketing Training

United Imaging Healthcare consistently upholds the mission of “To Bring Equal Healthcare for All” by strictly managing promotional content, channel networks, market and bidding activities. The company actively conducts responsible marketing training for all employees to ensure that the information conveyed by employees and received by clients accurately reflects the features of the company's products and services, guaranteeing that marketing information is transparent, accurate, and understandable, thereby achieving fair and just transactions.

The *Responsible Marketing Policy* outlines the requirements for responsible marketing training, driving United Imaging Healthcare to continuously provide education and training on responsible marketing for employees, ensuring that the awareness of responsible marketing is propagated to all marketing employees, key employees involved in external communications, and third-party personnel. The company requires employees of United Imaging Healthcare and third-party personnel to implement specific responsible marketing requirements in all business activities, comprehensively enhancing employees' awareness of responsible marketing and ensuring the compliance and transparency of marketing activities.

Meanwhile, United Imaging Healthcare conducts annual training on responsible marketing policies for all employees. This year, the company has conducted business ethics compliance training for all employees, as well as compliance training for all marketing personnel, to communicate and emphasize the compliance requirements highlighted in the *Responsible Marketing Policy*, including business ethics and promotional practices. The training participants included managers, full-time employees, interns, part-time and outsourced personnel. Additionally, the company requires all marketing personnel to sign compliance confirmation forms to further clarify the compliance requirements for employee duties and responsible marketing awareness. This approach helps employees better understand company policies, fully comprehend and familiarize themselves with responsible marketing requirements, ensuring the comprehensive implementation of the responsible marketing system.

3. Responsible Marketing Audit

United Imaging Healthcare continuously strengthens the supervision and management of responsible marketing, conducting annual responsible marketing audits and compliance reviews to ensure that global marketing activities comply with legal and regulatory requirements, effectively implementing responsible marketing initiatives and fulfilling the company's commitment to social responsibility. The company has established an independent and efficient audit and supervision system, bringing together an internal audit team with extensive experience and professional expertise to ensure the high independence and impartiality of audit work. Based on the risk management strategy, the audit department annually develops a comprehensive and systematic audit plan, clarifying objectives, scope, methods, and responsibilities. It continuously conducts full-coverage compliance audits on the marketing activities of United Imaging Healthcare and the company’s agents, focusing on core aspects such as risk control, regulatory compliance, authenticity of information disclosure, and privacy protection, firmly upholding the concept of responsible marketing and strictly preventing risks of misleading and false advertising.

Simultaneously, the company innovatively advances a “routine + key + special” tripartite audit model, deeply identifying potential risks and management loopholes in business processes, and driving the dynamic optimization and upgrading of the internal control system. The company issued the *Internal Audit Practice Guidelines: Responsible Marketing Audit*, establishing a unannounced-inspection mechanism for marketing activities to empower various functional departments in implementing standardized compliance operations. These measures comprehensively strengthen the compliance governance capabilities for market, advertising, and marketing activities, solidifying the strategic foundation for the company's sustainable and compliant development. As a new initiative for 2025, unannounced inspections will be

conducted 1-2 times per month based on the annual activity plan and activity application forms. These checks will monitor the compliance execution of marketing activities in real-time, covering core aspects such as promotional activities across all operational entities, dealer conduct standards, employee training, and customer privacy protection, which ensures the full implementation of responsible marketing policies across all business processes. Meanwhile, the company conducts annual specialized audits on responsible marketing, implementing a three-year comprehensive audit plan that covers all domestic and international operational entities, employees, and commercial partners (including third parties such as distributors), ensuring thorough and gap-free audits. By combining annual risk assessments, sampling reviews, and marketing whistleblower checks, the company continuously monitors the policy implementation effectiveness of business personnel and third-party partners.

1) Responsible Marketing Audit Scope

To fully implement the responsible marketing policy, United Imaging Healthcare has systematically reviewed and continuously advanced the audit work for all aspects of marketing activities. The audit scope covers key areas such as marketing expense management, conference and academic promotion, product information disclosure, conflict of interest prevention, agent management, third-party products, and after-sales maintenance, ensuring effective control of compliance risks in each segment.

In specific implementation, the company defines audit frequency and coverage for different audit items:

- **Marketing Expense Audit:** Regularly review the compliance of marketing personnel expenses to prevent risks of improper spending and ensure that expenses align with company policies and relevant regulatory requirements.
- **Conference and Academic Promotion Audit:** Through sampling checks and special audits, oversee the standardized execution of meetings and promotional activities, strictly control potential compliance risks.
- **Product Lifecycle Management Audits:** Focus on reviewing compliance with product promotion and service information dissemination to ensure the accuracy and truthfulness of product information, meeting responsible marketing requirements.
- **Marketing Personnel Management Audits:** Monitor behavioral standards and conflict of interest prevention to uphold the company's integrity and compliance culture.

2) Functional Departments and Responsibilities for Responsible Marketing

The responsible marketing audit at United Imaging Healthcare is jointly advanced by multiple functional bodies, forming a three-line defense system that covers the entire process:

a) First line of defense: Business departments

Business departments serve as the first line of defense in responsible marketing compliance management, primarily responsible for identifying and controlling marketing compliance risks in daily operations. The business departments of United Imaging Healthcare include, but are not limited to, the Sales and Marketing Department, Commercial Operations Department, Product R&D Department, and Customer Service Department. These departments bear direct compliance management responsibilities within their respective business areas, ensuring all employees understand and strictly adhere to the company's responsible marketing policies and relevant compliance requirements.

The business department has established clear operational procedures and internal control mechanisms in various aspects of marketing activities, such as advertising, customer relationship management, and contract management. Department heads regularly conduct self-inspections to identify and report potential compliance risks, and take necessary preventive measures based on the assessment results. These measures may include adjusting processes, enhancing training, or introducing new controls to ensure the legality and transparency of marketing activities.

b) Second line of defense: Legal Compliance Department, Financial Control Department, and Business Compliance Committees

The Legal Compliance Department and the Financial Control Department, as the company's second line of defense, are responsible for formulating, implementing, and overseeing the execution of responsible marketing policies across the company. The Financial Control Department particularly focuses on financial compliance and internal control management in marketing activities, ensuring all financial

processes adhere to company policies and relevant regulations to prevent financial risks in marketing campaigns.

The Financial Control Department plays a key role in budget management, financial management, and fund flow for marketing activities, identifying and assessing potential financial compliance risks through regular financial analysis and reporting. At the same time, the Financial Control Department works closely with business departments to ensure the lawful and compliant use of marketing expenses and provides support for major financial decisions.

The Legal Compliance Department and the Financial Control Department also coordinate with various business compliance committees to ensure policies are consistently implemented company-wide. The company has established several specialized business compliance committees, which oversee and guide the execution of responsible marketing practices within their respective domains, including:

i. Marketing Compliance Committee: Oversees the company's compliance in marketing and sales activities, ensuring that advertising, promotions, and customer relationship management adhere to company policies and legal regulations. The committee reviews compliance reports on marketing activities, assesses potential risks, and provides improvement recommendations.
ii. Information Security and Privacy Protection Committee: Responsible for formulating and overseeing the company's compliance policies in the fields of information security and privacy protection, ensuring that data processing, storage, and transmission comply with relevant legal requirements. The committee regularly reviews data privacy risk reports and promptly responds to and handles information security incidents.
iii. Quality and Compliance Management Committee: Responsible for overseeing the quality of company products and compliance management, ensuring all products meet industry standards and regulatory requirements. The committee conducts pre-review of new product compliance to ensure all regulatory requirements are met before product launch.
iv. Anti-Corruption and Data Compliance Team: Responsible for reviewing internal and external data transactions and financial records of the company to ensure no violations of anti-bribery, anti-corruption, or other compliance requirements. The team conducts in-depth supervision and review of compliance in relevant areas through regular meetings.

c) The third line of defense: Audit Department

As the third line of defense in risk management, the Audit Department is responsible for conducting independent audits of responsible marketing activities. The work of the Audit Department includes reviewing the risk assessment of marketing activities, compliance with laws and regulations, implementation of business ethics, accuracy of information disclosure, privacy protection measures, compliance of promotional activities, as well as training and supervision of employees and third parties.

3) Audit Process and Implementation of Responsible Marketing Activities

United Imaging Healthcare's responsible audit scope covers employees and business partners across all global operational locations, ensuring the comprehensive implementation of responsible marketing policies in practical work. The audit focuses include:

a) Marketing Campaign Risk Assessment

The Audit Department conducts systematic risk assessments to identify and analyze various risks that may affect the achievement of marketing campaign objectives, and ensures the effective implementation of risk response measures. Focus on reviewing the compliance of key aspects such as sales strategies, market forecasts, and channel management.

b) Internal Compliance Review

The audit department reviews whether the company's marketing activities comply with relevant laws, regulations, and internal policies and procedures, particularly in areas such as anti-unfair competition, advertising compliance, data security, and privacy protection.

c) Information Disclosure and Business Ethics Focus

Ensure that the information disclosed in marketing activities is true and accurate, and prevent false or misleading advertising. At the same time, the audit also checks for any violations of business ethics, such

as improper benefits provision.

d) Internal Supervision and Rectification Tracking
The Audit Department of United Imaging Healthcare works closely with the Compliance Committee, the Disciplinary Committee, and the Marketing Committee to supervise and inspect the compliance of marketing activities, and conducts regular rectification tracking to ensure timely and effective resolution of identified issues.

4) Review and Corrective Actions
To ensure the effective implementation of the responsible marketing policy, United Imaging Healthcare has implemented comprehensive review and corrective measures. The company conducts responsible marketing audit risk assessments for business departments worldwide on an annual basis to identify and address potential compliance risks. Based on the assessment results, the company develops an annual monitoring plan, conducts sampling reviews of marketing activities for end users and customers, and examines supporting documents related to the market sales process to evaluate and review the compliance of business personnel and third-party representatives with company policies.

5) Employee Responsibilities and Whistleblowing/Protection Mechanisms
In addition to responsible marketing audits, United Imaging Healthcare has established a comprehensive set of systematic control procedures to enhance the enforcement and coverage of responsible marketing policies. The company's Audit Department has established a dedicated reporting channel (email: internalaudit@unitedimaging.com), open to all employees, suppliers, distributors, and other stakeholders, accepting both real-name and anonymous reports. All reported information is subject to strict confidentiality measures and will be promptly investigated and verified by the Audit Department. For confirmed violations, accountability will be enforced in accordance with the group’s policies and applicable laws and regulations to ensure thorough rectification and appropriate consequences. This mechanism establishes a routine, all-staff-participating compliance prevention and control network beyond audit supervision, effectively enhancing the execution and transparency of responsible marketing efforts.

6) Responsible Marketing Audit Results
During the reporting period, United Imaging Healthcare comprehensively strengthened the construction of a responsible marketing supervision system by combining unannounced inspections with regular audits. Special audits and monitoring were conducted, focusing on key compliance issues such as the legality of product promotion, the authenticity of marketing activities, and anti-bribery and anti-corruption measures.

In response to issues identified during the audit, the company has established a closed-loop management mechanism to promptly communicate rectification requirements to relevant business departments, issue formal audit reports, and track the progress of rectification. After summarizing the issues, they are publicly reported at the quarterly marketing management committee meeting. Collaboration with functional departments such as finance and legal ensures the implementation of rectification measures, effectively enhancing the overall compliance level of the enterprise.

Looking ahead, United Imaging Healthcare will advance the construction of a dynamic and intelligent risk control system in phases within the internal control and audit system framework for responsible marketing. The company plans to leverage real-time risk assessment mechanisms and advanced digital control tools to build an intelligent internal audit platform, deeply embedded in core business processes, achieving precision and efficiency in audit activities. By closely linking audit rectification results with operational performance, United Imaging Healthcare will achieve continuous monitoring and early warning of risks throughout the entire process, enhancing risk response speed and governance standards. This leading governance model not only meets current compliance requirements but also possesses forward-looking risk identification and management capabilities, providing solid compliance assurance and support for the group's global business expansion, and driving the company toward sustainable and steady development.

IX Corporate Governance

United Imaging Healthcare continuously strengthens corporate governance, striving to enhance

management capabilities. The company closely monitors key factors in sustainable development, such as diversity, independence, equality, and inclusion, while improving executive compensation management mechanisms and reinforcing performance constraints related to sustainability. The company has prioritized the identification of business ethics-related matters, improved the construction of the business ethics management system, extensively conducted training and capacity building, and established a comprehensive audit and supervision mechanism for business ethics, comprehensively promoting the implementation of corporate governance measures and the enhancement of quality and efficiency.

i. Strengthen the protection of shareholder rights to promote a fair and efficient governance structure

United Imaging Healthcare consistently upholds the improvement of corporate governance systems, strengthens the protection of shareholder rights, and promotes fairness, transparency, and efficiency in governance structures. Voting rights are the core rights for shareholders to participate in corporate management. To safeguard the interests of all shareholders, especially minority shareholders, the company continuously refines mechanisms such as cumulative voting, separate vote counting, proxy solicitation, and online voting. These mechanisms are implemented in the voting on proposals such as director elections and compensation plans to enhance governance standards.

According to Article 87 of *the Articles of Association of United Imaging Healthcare*, the company adopts a cumulative voting system in the election of directors. This system applies to the competitive election of directors, and the eligibility of candidates is determined by the number of votes they receive. The *Company Law* clearly stipulates: ”The cumulative voting system referred to in this Law means that in the election of directors or supervisors at a shareholders' meeting, each share carries the same number of voting rights as the number of directors or supervisors to be elected, and the voting rights held by shareholders may be concentrated for use.” The implementation of cumulative voting helps enhance the voting influence of minority shareholders in director elections. Compared to the traditional simple majority voting system (where shareholders vote separately for each director based on their shareholding), cumulative voting grants shareholders greater flexibility in allocating their voting rights according to their interests. This mechanism effectively mitigates the disadvantages of minority shareholders in director elections, enhances their actual influence on corporate governance, and avoids underrepresentation caused by dispersed shareholding.

To ensure the fairness and transparency of director elections, the company strictly complies with the requirements of laws and regulations such as the *Company Law*, fully discloses the resumes and basic information of candidates, and ensures shareholders can make informed voting decisions. In addition, the company strictly implements the cumulative voting system and separate vote counting mechanism. For major matters involving the rights and interests of minority shareholders (such as director compensation proposals), the voting results of minority shareholders are disclosed separately to enhance their decision-making influence and ensure the fairness of the election process. On August 30, 2023, the company held the second extraordinary general meeting of shareholders in 2023, electing directors for the second board of directors and non-employee representative supervisors for the second board of supervisors, with a term of three years.

United Imaging Healthcare places great emphasis on the reasonableness and transparency of director compensation, and reviews relevant compensation plans at the annual shareholders' meeting each year to ensure the compensation policy aligns with shareholder interests. Article 83 of *the Articles of Association of United Imaging Healthcare* stipulates that when deliberating on major matters involving the interests of minority shareholders (such as director compensation), the company implements a separate voting mechanism for minority shareholders. The vote counting results must be disclosed separately, enhancing the decision-making influence of minority shareholders and ensuring their rights and interests are fully protected.

On June 30, 2025, the company held the 2024 Annual General Meeting, where the *Proposal on Director Remuneration for 2025* was reviewed and approved. The proposal included separate vote counting for minority investors, further demonstrating the company's respect and protection for the rights and interests of minority shareholders.

The company is committed to enhancing shareholder engagement and decision-making transparency, continuously optimizing various mechanisms to ensure the fairness and openness of the governance structure. Looking ahead, the company will further refine procedures related to shareholder voting rights, strengthen the fairness of director elections, optimize the compensation governance system, and align with international advanced governance standards to improve corporate governance levels and market recognition.

ii. Board diversity

The second board of directors of United Imaging Healthcare consists of 9 members, including 3 executive directors, 1 employee director, and 5 non-executive directors, among which 3 are independent directors. During the reporting period, the company held 3 board meetings and 1 general shareholders' meeting. All directors attended the aforementioned meetings, actively fulfilled their duties, and promoted the stable operation of corporate governance. There were no instances of absence or delegation of attendance by other directors at the board meetings and general shareholders' meetings. Meanwhile, all directors conducted comprehensive investigations and understanding of the matters under review. They fully utilized their professional knowledge and practical experience to provide reasonable suggestions to the company, exercised their rights as independent directors objectively and independently, actively promoted the objectivity and standardization of board decisions, and effectively safeguarded the legitimate interests of the company and all shareholders.

To further improve the corporate governance structure and strengthen the role of independent directors in the governance system, the company strictly adheres to the relevant provisions of the *Company Law* and the *Articles of Association*, and complies with regulatory requirements such as the *Measures for the Administration of Independent Directors of Listed Companies* and the *Shanghai Stock Exchange Science and Technology Innovation Board Listed Companies Self-Regulatory Guidelines No. 1—Standard Operation*. The company has established the Audit Committee, Nomination Committee, Remuneration and Appraisal Committee, and Strategy and Social Responsibility Committee under the Board of Directors. Each committee is responsible for supervision and review in specific areas and performs decision-making duties within the scope of its authorization. Among them, the Audit Committee and the Remuneration and Appraisal Committee are composed of 3 independent directors to ensure the independence, impartiality, and professionalism of supervision and decision-making. During the reporting period, the company's Board of Directors' Remuneration and Appraisal Committee held 2 meetings, the Audit Committee held 1 meeting, the Strategy and Social Responsibility Committee held 1 meeting in total, and the Nomination Committee held 1 meeting in total.

United Imaging Healthcare deeply recognizes that board diversity and professionalism are crucial for the sustainable development and good governance of the enterprise. The company continuously promotes the construction of a diverse and inclusive board in terms of gender, age, cultural background, and professional experience, leveraging the board’s multi-dimensional perspectives and rich experience to enhance the comprehensiveness of complex decision-making and strategic formulation. The board members of United Imaging Healthcare possess diverse nationalities and cultural backgrounds, with expertise spanning multiple disciplines such as biomedical engineering, physics, law, and financial management. They also have professional experience from globally leading enterprises and academic institutions. This diverse and professional background enables the board to ensure the group's policies align with international standards and best practices, while more effectively overseeing and guiding management to improve governance quality and transparency. The company also prioritizes advancing gender diversity, with several female executives already in the management team, fully implementing gender-diverse management.

The company also places high importance on the professional composition and independence of the audit committee to ensure the committee’s effective performance in financial oversight, compliance management, and risk control. The second Audit Committee of the company's board of directors consists of 2 independent directors and 1 non-executive director. The three members have backgrounds as financial experts, industry experts, and legal experts, respectively. All members possess professional knowledge and experience in financial management, audit supervision, legal compliance, and the pharmaceutical and biotechnology industry, forming a multi-dimensional professional support system to ensure the robust

operation of the Audit Committee in core functions such as financial reporting quality, internal control, legal compliance, and risk management.

Among them, Mr. Wang Shaofei, a financial and risk management expert and the lead independent director, serves as the Chairman of the Audit Committee. Mr. Wang Shaofei possesses a solid professional background in accounting and financial management, with profound theoretical knowledge and practical experience in financial supervision, accounting standards, corporate financial management, and capital market operations. Industry expert Mr. Shen Siyu, as a member of the Audit Committee, has over ten years of experience in the management and investment fields of the pharmaceutical and biotechnology industry. With deep expertise in these areas, he is well-versed in the investment and financing operations, financial governance, and capital market regulatory requirements of the healthcare industry. He can provide professional support for the company's financial supervision, internal control, and risk management, tailored to industry characteristics, thereby enhancing the industry-specific adaptability of audit oversight. Mr. Sheng Leiming, a legal and risk management expert, also serves as a member of the Audit Committee. With a profound legal professional background, he has long focused on areas such as corporate governance, securities legal compliance, and risk management, providing professional support to the Audit Committee in optimizing corporate governance structures, ensuring compliant operations, and managing legal risks.

The company also places high importance on the diversity and capability building of the directors, actively encouraging board members to participate in various professional skill enhancement and compliance training programs. These cover national policies, securities market laws and regulations, operational mechanisms, corporate systems, as well as topics related to environmental and social responsibilities (such as climate change). Through these training sessions, the compliance awareness and performance capabilities of the board members have been effectively enhanced. In 2024, the company's board members participated in two annual training sessions, one of which focused on business ethics compliance, emphasizing the latest anti-corruption and anti-bribery regulations and compliance requirements. Another training session focused on United Imaging Healthcare's carbon reduction project, delving into the company's carbon reduction goals, carbon neutrality pathways, and zero-carbon management practices. It covered core topics such as climate change response, carbon emission management, and product responsibility, further enhancing the board members' professional capabilities in sustainable governance.

iii. Director independence

United Imaging Healthcare places high importance on the independence of directors, striving to ensure and continuously improve the quality of decision-making and the effectiveness of supervision. To fully leverage the positive role of independent directors in corporate governance, United Imaging Healthcare continuously refines the working mechanisms for independent directors, promotes the establishment of a Lead Independent Director, and organizes, coordinates, and leads independent directors to fully fulfill their functions in decision-making participation, checks and balances, and professional consultation. These measures effectively standardize the conduct of independent directors, safeguards the overall interests of the listed company, and protects the legitimate rights and interests of shareholders. As of the end of the reporting period, the number of independent directors on the board was 3, accounting for one-third of the total number of directors.

During the reporting period, the company held 1 special meeting for independent directors, who prudently assessed the company's related-party transactions. The implementation of this system has further strengthened the independence and supervisory functions of independent directors, ensuring the fairness and scientificity of board decisions, and effectively safeguarding the legitimate rights and interests of shareholders.

In addition to performing the duties of an independent director, the lead independent director is also responsible for the following functions:

- Convene and preside over special meetings of independent directors;
- Solicit suggestions from all independent directors on matters to be reviewed by the board and the meeting agenda, and communicate with senior management such as the board secretary;
- Provide recommendations to the convener of the board's specialized committee regarding the preparation of the committee's agenda;

- Conduct research on policies related to independent directors and propose revisions, and organize on-site work sessions for independent directors at the company.

For details, please refer to the *Independent Director Work System* disclosed on the Shanghai Stock Exchange website (www.sse.com.cn).

During the reporting period, all independent directors of the company adhered to a responsible attitude towards the company and all shareholders, strictly complied with the requirements of various laws and regulations, faithfully and diligently performed their duties as independent directors, participated in the decision-making of major company matters, independently and impartially expressed opinions and exercised voting rights, fully leveraged the supervisory role and independence of independent directors, and made due efforts to safeguard the overall interests of the company and the rights and interests of all shareholders.

iv. Compensation Management

1. Linking Compensation to Sustainable Development

The company deeply recognizes the intrinsic connection between corporate success and social responsibility as well as sustainable development. As an industry leader, the company is not only committed to achieving commercial excellence but also actively seeks effective solutions to social and environmental issues through innovation and professional services. The company's ESG strategy is the core driver of long-term sustainable development, profoundly influencing decision-making and daily operational practices.

To ensure the leadership team remains highly aligned with the company's sustainable development vision and strategic goals, the company has specifically elevated the importance of sustainability in compensation policies. As of the end of the reporting period, the company has formally incorporated sustainability goals into the individual performance evaluation system for members of the Management Committee. Specifically, 5% of the performance evaluation weight for members of the Executive Management Committee is directly linked to “improvement in ESG rating performance.” This not only reinforces the company's commitment to ESG performance but also incentivizes continuous optimization and enhancement in the ESG field, thereby ensuring the creation and maintenance of long-term value for all stakeholders. Through this innovative incentive mechanism, the company aims to drive positive change in key areas such as environment, society, and governance, achieving a harmonious coexistence of corporate and social value.

2. 2025 Semi-Annual Director Compensation

Unit: RMB

Name	Allowance	Paid compensation	Employer contributions for various social insurances and housing provident funds	Pre-tax total
Zhang Qiang	-	1,575,000	99,862	1,674,862
GUOSHENG	-	1,312,000	24,836	1,336,836
JUN BAO	-	1,286,250	32,826	1,319,076
TAO CAI	-	945,000	22,262	967,262
Ding Jun	-	-	-	-
Shen Siyu	-	-	-	-
Sheng Leiming	100,000	-	-	100,000
Wang Shaofei	100,000	-	-	100,000
JIA HONG GAO	100,000	-	-	100,000

v. Business ethics

1. Business Ethics Management System

1) Overview of Compliance Governance System: Comprehensive business compliance coverage under the leadership of the board of directors

As a globally leading medical technology company, United Imaging Healthcare regards business ethics and compliance management as the cornerstone of operations. Establishing a rigorous compliance system ensures the highest standards of business ethics are upheld in all business activities. At the same time, the company firmly opposes any form of corruption and bribery, which are contrary to United Imaging Healthcare's corporate culture. The company maintains a "zero-tolerance" policy toward any acts of corruption or bribery.

a) Business Ethics Management System

The company is committed to establishing and continuously maintaining a comprehensive business ethics compliance system to ensure all business activities strictly adhere to relevant laws, regulations, and the highest ethical standards.

The business ethics compliance system of United Imaging Healthcare is directly managed by the company's board of directors, with the Strategy and Social Responsibility Committee and the Audit Committee under the board ensuring the effective implementation of high standards in business ethics. The Legal Compliance Department, Financial Control Department, Internal Audit, and various specialized committees are responsible for the specific execution and implementation of this system. This system covers multiple key areas, including anti-bribery and anti-corruption (ABAC), conflict of interest management, business conduct guidelines, information security and privacy protection, data compliance, responsible marketing, anti-monopoly, anti-unfair competition, data security, export controls, and economic sanctions.

i. **Responsibilities of the Strategy and Social Responsibility Committee:** According to the *Working Rules of the Strategy and Social Responsibility Committee of United Imaging Healthcare*, the board's Strategy and Social Responsibility Committee bears significant management responsibilities in business ethics. The committee is responsible for setting the company's long-term goals in the field of business ethics and ensuring these goals are fully reflected in the company's daily operations and strategic planning. The committee regularly oversees the implementation of the company's policies in areas such as anti-corruption and anti-fraud, ensuring all business conduct complies with the company's ethical standards. At the same time, the committee is also responsible for assessing commercial ethics risks, proposing improvement suggestions, and driving the company's continuous progress in areas such as social responsibility and environmental protection. Through these efforts, the Strategy and Social Responsibility Committee ensures that every step the company takes in the market is grounded in solid ethical foundations, further enhancing the company's sense of social responsibility and industry reputation.

ii. **Responsibilities of the Audit Committee:** According to the *Working Rules of the Audit Committee of United Imaging Healthcare*, the board's Audit Committee is primarily responsible for overseeing and reviewing the company's financial information and related disclosure, ensuring the authenticity, accuracy, and completeness of financial reports, and preventing any actions that may harm the company's business ethics. The Audit Committee regularly evaluates the effectiveness of the company's internal audit procedures and the independence of external audit institutions to ensure that audit reports objectively and fairly reflect the company's financial status. Through the oversight of internal controls and external audits, the Audit Committee ensures that the company consistently adheres to high standards of business ethics in all operational activities.

b) Business Ethics Performance

The Board Audit Committee regularly conducts rigorous reviews of the company's financial reports and the financial information in periodic reports to ensure the truthfulness, accuracy, and completeness of information disclosure, preventing financial fraud or misconduct that could affect the company's business ethics, thereby strongly safeguarding the transparency and compliance of the company's financial information. In addition, the Audit Committee also oversees and evaluates the work of the company's internal audit department to ensure the effectiveness and independence of its procedures. At the same time, it reviews the independence and professionalism of external audit institutions to ensure their reports

objectively and fairly reflect the company's financial status and operational results.

Subsequently, the Audit Committee will hold regular meetings to collectively review and vote on matters related to business ethics audits, ensuring the comprehensive implementation of relevant work. Committee members diligently prepare and rigorously review proposals to ensure each topic is thoroughly discussed. During the audit execution process, the committee paid special attention to the implementation of business ethics audits and provided guidance on identified key focus areas to ensure all issues were promptly addressed and reported to the board of directors, providing a solid foundation for the company's sustainable and healthy development.

During the reporting period, the audit committee regularly reviewed reports from the audit department, overseeing the independence and effectiveness of internal audits to ensure compliance with the board's requirements. This year, we conducted routine audits in key areas according to the audit rotation plan and implemented special audits and assessed the health of the anti-corruption system based on business risks. At the implementation level, we focused on reviewing the compliance of business collaborations with healthcare professionals and conducted unannounced inspections on market conference activities to ensure adherence to regulations and company policies, effectively preventing and controlling corruption risks. Meanwhile, we conducted follow-up reviews on high-risk areas identified in previous audits and continued to advance the three-year full coverage plan to ensure business ethics audits encompass all global operating entities. During the issue confirmation phase, a “two-way communication” mechanism was adopted, combining written material verification with on-site interviews to ensure audit findings were thoroughly validated. When finalizing the audit report, responsible departments were simultaneously required to develop actionable rectification plans, with audits continuously tracking progress to achieve closed-loop issue resolution.

The Strategy and Social Responsibility Committee plays a pivotal role in the strategic planning and execution of business ethics. The Strategy and Social Responsibility Committee ensures the implementation of the company's business ethics objectives in daily operations and long-term strategies by setting and overseeing these goals. Secondly, the Strategy and Social Responsibility Committee regularly reviews the company's measures in areas such as anti-corruption and anti-fraud to ensure their effective implementation, and assesses and addresses potential business ethics risks.

On August 29, 2024, the second meeting of the second board of directors' Strategy and Social Responsibility Committee in 2024 reviewed and approved the *Anti-Bribery and Anti-Corruption Policy*, the *Whistleblower Protection Policy* and the *Responsible Marketing Policy*. The 11th meeting of the second board of directors was briefed on the content of these resolutions. For details, please refer to the *Announcement on the Resolution of the 11th Meeting of the Second Board of Directors of United Imaging Healthcare* disclosed on the Shanghai Stock Exchange website (www.sse.com.cn). The company's business ethics compliance system applies to all employees and global business partners.

c) Business ethics system and training overview

During the reporting period, the company continued to improve the construction of the business ethics system, having reviewed and publicly disclosed the *Anti-Bribery and Anti-Corruption Policy*[3] on the company website. This policy applies to all employees of United Imaging Healthcare, clearly stipulating that the board of directors provides guidance and management on anti-bribery and anti-corruption matters. It identifies compliance with anti-corruption and anti-bribery laws applicable in China and other global jurisdictions where the company operates, including but not limited to the *Anti-Unfair Competition Law of the People's Republic of China* (AUCL), the U.S. *Foreign Corrupt Practices Act* (FCPA), and the UK *Bribery Act* (UKBA). The policy reinforces the principles of integrity, transparency, compliance, and accountability, as well as defines the scope of bribery and corrupt practices. It specifically outlines the anti-bribery and anti-corruption compliance requirements for United Imaging Healthcare employees, clients, suppliers, distributors, and other relevant parties.

At the same time, the policy specifically outlines the scope, frequency, and topics of anti-bribery and anti-

[3] *Anti-Bribery and Anti-Corruption Policy*: https://global.united-imaging.com/-/media/uih/pdf/investor/20240823/anti-bribery-and-anti-corruption-policy_en.pdf

corruption training for United Imaging Healthcare employees and business partners: For all employees, United Imaging Healthcare will provide anti-bribery and anti-corruption training upon onboarding, followed by annual sessions thereafter; for employees in key positions, the company will conduct regular and ad-hoc multi-topic training sessions throughout the year. For business partners, the company requires distributors in each region to participate in at least one United Imaging Healthcare compliance training session annually and obligates them to sign necessary documents committing to anti-bribery and anti-corruption compliance. In addition, the policy clearly defines the reporting channels for anti-bribery and anti-corruption matters and the disciplinary handling provisions.

d) Reporting management system
The company is committed to optimizing the complaint and reporting investigation mechanism, integrating the mechanism with routine internal supervision and inspections, and continuously conducting systematic evaluations and oversight of the completeness and effectiveness of the internal control system. At the same time, the company will focus on the accuracy and completeness of financial information to ensure the authenticity and reliability of financial reports.

The company is committed to continuously improving the whistleblowing management system, encouraging all employees to actively participate in the supervision and feedback of misconduct, and building a more open and transparent compliance oversight platform. The company will take all received whistleblowing leads seriously and promptly initiate investigations to ensure that disciplinary actions against violations and related personnel are compliant and reasonable. During the reporting period, the company has reviewed and publicly disclosed the Chinese and English versions of the *Whistleblower Protection Policy*, clarifying the requirements for whistleblower protection and strictly prohibiting any form of retaliation, striving to create a safe and reliable reporting environment.

The company has publicly disclosed reporting channels such as email and hotline through internal policies and emails to ensure whistleblowers can effectively report issues. United Imaging Healthcare encourages whistleblowers to provide valid contact information when submitting reports, enabling the company to better understand, verify, and investigate the relevant matters. At the same time, the company respects and protects the right of whistleblowers to remain anonymous for personal safety considerations. The specific reporting channels are as follows:
Reporting email: UIH_Compliance@united-imaging.com
Report hotline: 021-67076619

2) Three Lines of Defense: Establishing a robust compliance management and control mechanism
To ensure the comprehensiveness and effectiveness of the business ethics compliance system, United Imaging Healthcare has established a three-line defense control program to strengthen internal management and risk prevention, ensure the legality and compliance of business operations, and safeguard the rights and interests of the company and all stakeholders.

a) First line of defense: Business departments
Each business department serves as the first line of defense in commercial ethics compliance management, primarily responsible for identifying and controlling compliance risks in daily operations. United Imaging Healthcare's business departments include, but are not limited to, the Sales and Marketing Department, Procurement Department, Supply Chain Management Department, R&D Department, and Customer Service Department. These departments bear direct compliance management responsibilities within their respective business areas, ensuring that all employees understand and strictly adhere to the company's business ethics compliance policies and other relevant compliance requirements.

Each business department must establish clear operational procedures and internal control mechanisms in high-risk areas such as contract management, procurement processes, product development, supply chain management, and customer interactions. Department heads must regularly organize self-inspections to identify and report potential compliance risks, and take necessary preventive measures based on the assessment results. These preventive measures may include adjusting processes, enhancing training, or introducing new control measures to ensure the legality and transparency of business activities.

b) Second line of defense: Legal Compliance Department, Financial Control Department, and

various business compliance committees

As the second line of defense for the company, the Legal Compliance Department and Financial Control Department bear the important responsibility of formulating, implementing, and overseeing the execution of business ethics compliance policies company-wide.

The Legal Compliance Department plays a crucial regulatory role within the company, primarily responsible for formulating and updating compliance policies to ensure the company adheres to legal and regulatory requirements in all business activities. The department works closely with other business departments to identify and prevent potential legal risks, provides compliance guidance, and oversees and rectifies any actions that may violate laws and regulations. The Legal Compliance Department is also responsible for conducting regular compliance training for all employees to ensure they understand and adhere to the company's compliance policies.

The responsibilities of the Financial Control Department include strict supervision and management of the company's financial processes, particularly in high-risk areas such as contract management, procurement, sales, and fund flows, ensuring all financial operations comply with laws, regulations, and company policies to avoid potential financial risks. The Financial Control Department is also responsible for coordinating collaboration with other functional departments, ensuring the transparency and accuracy of financial reports, and supporting business departments in maintaining compliance in financial decision-making.

At the same time, the Financial Control Department regularly conducts audits and risk assessments of financial activities across business departments, identifies and addresses potential compliance risks, and provides improvement suggestions and preventive measures based on audit findings.

In addition to the Legal Compliance Department and the Financial Control Department, United Imaging Healthcare has established several specialized business compliance committees. These committees oversee and guide the implementation of compliance matters within their respective fields, including:

i. Marketing Compliance Committee: Oversees the company's compliance in marketing and sales activities, ensuring that advertising, promotions, and customer relationship management adhere to company policies and legal regulations. The committee will also review compliance reports on marketing activities, assess potential risks, and provide improvement recommendations.
ii. Information Security and Privacy Protection Committee: Responsible for formulating and overseeing the company's compliance policies in the fields of information security and privacy protection, ensuring that data processing, storage, and transmission comply with relevant legal requirements. The committee regularly reviews data privacy risk reports and promptly responds to and handles information security incidents. During the reporting period, the committee confirmed the full implementation of the company's data privacy protection measures, with no information leakage incidents identified.
iii. Quality and Compliance Management Committee: Responsible for overseeing the quality and compliance management of company products, ensuring all products meet industry standards and regulatory requirements. The committee also conducts preliminary review of the compliance of new products to ensure all regulatory requirements are met before product launch. During the reporting period, there were no incidents of non-compliance with quality standards.
iv. Anti-Corruption and Data Compliance Team: Responsible for reviewing internal and external data transactions and financial records to ensure no violations of ABAC policies or other compliance requirements. Regular meetings are held to conduct in-depth supervision and review in the areas of anti-bribery, anti-corruption, and data compliance. During the reporting period, the company did not identify any instances of bribery or corruption.

Meanwhile, the relevant meetings implement archiving and document management mechanisms including but not limited to the following: reviewing the minutes of the previous meeting, examining the latest compliance report, assessing newly identified risks, discussing and approving relevant policy changes, and formulating improvement measures. The decisions and recommendations of each committee will be formally recorded after each meeting and submitted to the Legal Compliance Department and the company's senior management for further review and implementation.

c) The Third Line of Defense: Audit Department

As the company's third line of defense, the Audit Department operates independently from business departments, Legal & Compliance, and Financial Control, focusing on evaluating the overall effectiveness of the company's compliance management system. The Audit Department conducts an annual independent review of the company's business activities, with a particular focus on high-risk areas such as bribery, corruption, conflicts of interest, and improper marketing practices.

Audit activities, while covering the company's internal business processes, have been extended to interactions with external partners, such as assessing the compliance status of suppliers and distributors. The audit results are reported directly to the board of directors and provide critical decision-making support to the company's senior management. Through audit results, the company can identify potential compliance gaps, take corrective actions, and continuously optimize and improve its compliance management system.

During the reporting period, the Audit Department completed a comprehensive review of the company's main business areas and conducted compliance assessments of key external partners. The audit report indicated that all reviewed businesses and partners complied with the company's compliance policies and legal requirements, with no significant violations identified. In addition, internal audit collaborates with external audit institutions to conduct regular independent reviews, ensuring that United Imaging Healthcare's compliance management system not only meets internal company standards but also aligns with international best practices and legal requirements.

The company also expects all business partners (including customers, suppliers, agents, and distributors) to uphold high business ethics and work with United Imaging Healthcare to foster an honest and compliant business environment.

2. Business Ethics Training

United Imaging Healthcare is committed to strengthening compliance culture and deepening education and training on business ethics. The training content comprehensively covers the requirements of policies and systems such as the *Business Conduct Guidelines*, the *Anti-Bribery and Anti-Corruption Policy*, the *Responsible Marketing Policy*, the *Conflict of Interest Policy*, the *Trade Secret Management System*, the *Internal Investigation System*, and the *Whistleblower Protection Policy*. A multi-channel, diversified, and multi-level comprehensive training system has been established, with annual regular business ethics and compliance training provided to all employees (including full-time employees, interns, part-time employees, outsourced employees, and labor dispatch personnel), aiming to strengthen the business ethics and compliance awareness of all employees. United Imaging Healthcare conducts extensive business ethics and compliance training through diversified formats, combining online and offline methods, and utilizing various forms such as slides, video tutorials, and case discussions to ensure all employees can participate in the training in the most suitable way. To further consolidate the training outcomes, the company has also established a rigorous assessment mechanism to evaluate and provide feedback on employees' learning achievements.

1) General Business Ethics Training

United Imaging Healthcare provides systematic business ethics and compliance training for all employees annually, covering topics such as business conduct guidelines, promotion and responsible marketing, anti-bribery and anti-corruption, anti-fraud, conflict of interest, trade secret protection, internal investigations, and whistleblower protection. These general training programs aim to establish a solid compliance foundation for every employee, enhancing their ability to identify and mitigate business ethics risks in their work.

During the reporting period, the company has released the annual business ethics compliance training course to all employees. The company published both Chinese and English versions of the video training materials on the internal learning platform, requiring all employees to complete the training, achieving 100% training coverage with 15,709 participant attendances. Additionally, the course remains open for new hires to participate in the training, ensuring all employees fully understand the company's business ethics standards, compliance systems, and policy content.

2) Specialized Training for Key Positions

In addition to general business ethics and compliance training for all employees, the company also provides specialized and targeted training for key positions such as the marketing and sales departments.

For key positions involving external communication and business development, such as marketing and sales departments, the company has designed more in-depth and professional training modules. The specialized training not only covers fundamental business ethics but also delves into how to effectively prevent corruption and fraud risks in specific business scenarios, such as market promotion, advertising, and customer relationship management, tailored to industry characteristics and departmental functions. In relevant training, employees are guided through case analysis and scenario simulations to develop the ability to make compliant decisions in high-risk environments.

In marketing activities, the training details how to follow company policies regarding business etiquette, client reception, and event organization to avoid legal and reputational risks caused by improper conduct. The professional training for the marketing department focuses on the compliance of advertising content, the authenticity of product promotion, and transparency in communication with customers and partners.

By combining general training with professional training, United Imaging Healthcare continuously optimizes a multi-level and diversified training system to ensure that employees at every level and in every department receive training content tailored to their job requirements. This approach effectively enhances the entire company's awareness of the importance of business ethics and compliance, further strengthening the ability to implement compliance requirements in practical operations.

During the reporting period, the company has completed compliance training for specific business departments, key positions, and personnel. The total number of training participants exceeded 3,000.

For department-specific training, the company has conducted business ethics and compliance training for all sales and marketing personnel, combining both online and offline methods, which has covered all sales and marketing staff. The training content focuses on business ethics and conduct standards, anti-bribery and anti-corruption, responsible marketing and promotion, conflict of interest, and trade secret protection. Meanwhile, the company conducts specialized compliance training for newly hired sales and marketing personnel every quarter to ensure they promptly understand the company's compliance requirements. At the same time, the company requires all sales and marketing personnel to sign a compliance acknowledgment, clearly understanding the business ethics and compliance standards in their duties.

For key positions and personnel, the company has conducted specialized commercial ethics and compliance training for procurement personnel, requiring them to sign integrity and self-discipline commitment letters to clarify the requirements for clean performance of duties. The training content covers key areas such as commercial ethics in procurement, anti-bribery and anti-corruption, anti-fraud, trade secret protection, and conflict of interest. Meanwhile, the company has provided supplementary learning resources for personnel with managerial functions, specifically conducting a specialized legal compliance training to help managers further deepen their understanding of the legal and compliance aspects of business conduct and performance management.

Looking ahead, the company will continue to deepen business ethics and compliance management, strengthening the awareness of compliance among all employees. The Legal Compliance Department of United Imaging Healthcare will further optimize and expand its multi-level training system. Through innovative learning methods and more personalized training content, it ensures that every employee can consistently uphold high standards of professional ethics and compliant behavior in the ever-changing industry environment. Meanwhile, the company also plans to enhance training and supervision for partners, establishing a more transparent and fair cooperation mechanism to promote mutual growth and long-term development between the company and its partners. The company will steadfastly fulfill social responsibilities and set a strong example of business ethics for the industry.

3. Business Ethics Audit

To proactively manage compliance risks and deeply integrate business ethics into the core operations of the enterprise, United Imaging Healthcare strategically deployed a risk-oriented dynamic audit system, which is regarded as a strategic cornerstone of corporate governance. The core of this system lies in a continuously evolving risk assessment mechanism, which forms comprehensive risk insights through systematic integration and analysis of relevant laws and regulations, operational data, and historical audit records. This insight provides a decision-making basis for the strategic allocation of audit resources, enabling the company to precisely focus on high-risk areas that significantly impact corporate value, such as anti-bribery, anti-fraud, and conflicts of interest.

United Imaging Healthcare has established a comprehensive internal audit management and institutional system to guide the implementation of various audit activities, ensuring full coverage and effective execution of internal audits. To standardize the audit process, the company has established and implemented the *Internal Audit System* along with 21 supporting practice guidelines to clarify the audit standards for business ethics. Among them, the *Internal Audit Practice Guide: Business Ethics Audits* further defines the audit scope and operational procedures in the field of business ethics compliance, ensuring adherence in key areas such as anti-corruption, anti-fraud, employee behavior management, and responsible marketing. We have established a ”three-year coverage” audit plan for the business ethics domain to ensure comprehensive business ethics audits are conducted across all operational entities within three years.

1) Business Ethics Audit System

The company's business ethics audit system is directly led by the board of directors to ensure the legality and compliance of operations. At the execution level, the audit department not only conducts thorough reviews of key areas but also ensures the root causes of issues are fully revealed through in-depth communication and verification with business departments. Ultimately, through mandatory rectification requirements and continuous progress tracking, a dynamic supervision loop was formed, encompassing risk warning, precise response, and rectification optimization. This system not only ensures the effective resolution of issues but also strengthens the company's compliance resilience, providing a solid foundation for sustainable development.

To ensure the effective transformation of business ethics audit results into organizational capability enhancement, United Imaging Healthcare has established a closed-loop management system encompassing high-level oversight, cross-departmental communication, responsibility implementation, and continuous tracking. Under this system, audit reporting follows a clear hierarchy with supervisory functions. The Audit Department is required to report regularly to the company's Audit Committee, which oversees the independence and effectiveness of internal audits to ensure compliance with the governance requirements of the board of directors. Before finalizing the audit conclusions, the company initiates a “two-way communication” mechanism. The audit team verifies findings through written materials and on-site interviews, thoroughly validating audit discoveries with the audited department to establish a solid consensus foundation for subsequent improvement efforts.

While issuing the final audit report, the company simultaneously requires the responsible department to develop specific and actionable rectification plans, seamlessly connecting issue identification with corrective actions. To ensure the thoroughness of the rectification and prevent the recurrence of issues, a systematic follow-up supervision mechanism was promptly initiated. On one hand, the audit department will continuously monitor the progress of each issue's rectification until closed-loop resolution is achieved; on the other hand, it will also conduct regular follow-up reviews of high-risk areas identified in previous audits. This dual-supervision model, which combines real-time issue tracking with long-term risk reviews, complements the company's three-year comprehensive audit plan, systematically strengthening the business ethics and compliance resilience of global operations, providing a solid foundation for sustainable corporate development.

2） Business Ethics Audit Matters

United Imaging Healthcare's business ethics audit covers key areas such as anti-corruption, anti-fraud, employee conduct management, and responsible marketing. Based on risk assessment results, the audit department focuses on reviewing high-risk key areas related to business ethics.

The company has detailed regulations for various audit matters through the *Internal Audit Practice Guide: Business Ethics Audits*:

a) Anti-corruption audit: Assess bribery risks by analyzing historical cases, Transparency International's Corruption Perceptions Index, and other data, and develop an annual audit plan targeting high-risk areas. Based on comprehensive risk ratings, the company annually selects specific subsidiaries and business areas for auditing and establishes a three-year rotation plan to ensure full coverage of all global operations and business departments.
b) Anti-fraud audit: Focus on examining internal fraud risks, including fabricated reimbursements, inflated expenses, forged contracts, and other misconduct. The company has established comprehensive procedures to ensure all financial operations and contract executions comply with legal and corporate policy requirements.
c) Employee Conduct Management: The audit covers employee conduct standards, with particular attention to the management of conflicts of interest and the enforcement of confidentiality agreements for employees in key positions.
d) Responsible Marketing Audit: Reviews the marketing activities of the company and associated agents to ensure compliance with responsible marketing requirements, eliminating misleading or false advertising. The concurrently released *Internal Audit Practice Guide: Responsible Marketing Audits* clarifies the responsibilities of various functional bodies, systematically guides responsible marketing audits and key focus areas, ensuring the company's compliance in market, advertising, and marketing activities.

3) Business Ethics Audit Procedures and Mechanisms

In terms of audit procedures and mechanisms, United Imaging Healthcare dynamically identifies and focuses on key audit areas based on risk assessment results. The audit process begins with a comprehensive assessment of potential risks, testing the effectiveness of control measures through methods such as “compliance testing”. The company's audit department regularly collaborates closely with various business and functional departments, such as the Legal Compliance Department and the Financial Control Department, to ensure all policies and procedures are fully implemented. Audit reports are submitted directly to the Audit Committee, and corresponding rectification plans are formulated based on audit findings to ensure the company's compliance with ethical standards and continuous improvement. Additionally, the Audit Department has established a dedicated whistleblowing email (internalaudit@united-imaging.com), enabling all employees and relevant parties to anonymously report potential violations, thereby further strengthening the company's internal oversight mechanisms.

Specific audit procedures include:

a) Preliminary Preparation and Risk Assessment: Adhere to the risk-oriented principle, collect relevant laws and regulations, institutional processes, and historical audit records to conduct a rigorous preliminary assessment of the compliance of business activities, and develop a detailed audit plan covering the global operational network. The plan sets a strategic goal of achieving full coverage within three years, ensuring the audit scope seamlessly extends to all employees, organizations, and third-party partners (such as distributors, suppliers, etc.) both domestically and internationally.
b) Audit Execution: The Audit Department, based on risk assessment results, focuses on reviewing high-risk areas, including in-depth audits of key areas such as anti-bribery, anti-fraud, conflicts of interest, and responsible marketing. The audit process involves detailed inspections of relevant documents, financial records, contracts, and transaction procedures to ensure all operations comply with the company's compliance standards.
c) Preliminary Audit Results and Verification: After conducting the audit, the Audit Department verifies the preliminary audit findings with the audited department through on-site interviews and document reviews to ensure all identified issues are fully explained and resolved.
d) Audit Report and Rectification Tracking: Upon completion of the verification phase, the Audit Department prepares a detailed audit report, listing the identified issues and recommendations. The report is submitted to the Audit Committee for review, and corrective measures are formulated based on the audit results. The Audit Department will continue to track the progress of rectification to ensure all issues are effectively resolved.

Through the above execution procedures, United Imaging Healthcare integrates risk assessment, on-site

inspections, preliminary verification, rectification tracking, and closed-loop management to ensure business ethics audits are implemented efficiently and in a controlled manner worldwide, providing solid support for the company's stable international operations and sustainable development.

4) The "Three-Year Coverage" Plan for Business Ethics Audits

For the "Three-Year Coverage" plan of business ethics audits, the Audit Department of United Imaging Healthcare formulates a detailed annual audit plan and implements institutional rotation arrangements to ensure all operational entities are covered within every three years. The 2025 internal audit plan includes focused audits on emerging markets and high-risk areas to dynamically respond to the evolving business environment. In the first half of 2025, the company completed audits of several key business areas and plans to further expand audit coverage in the second half of the year to ensure comprehensive risk management and ethical compliance. The specific progress of the work is as follows:

a) First half of 2025: The company's Audit Department conducted systematic business ethics audits on United Imaging Healthcare's domestic operational entities and branches in Australia and New Zealand, with a focus on anti-bribery, anti-fraud, and compliance management. The audit scope covered high-risk areas such as contract management, procurement processes, expense reimbursement, after-sales maintenance, and third-party product control, completing over ten audit projects in total. Through systematic auditing, the company strengthened internal control mechanisms in key areas, further fortifying compliance defenses to ensure stable business development.

b) Second half of 2025: Based on the work achievements of the first half and dynamic adjustments in risk assessment, the company's Audit Department has established a clear strategic direction and execution plan for the commercial ethics audit work in the second half of the year and the entire year. The core work direction is to continue and expand the global audit coverage. Geographically, the focus of audit work in the second half of the year will strategically expand to branches in Southeast Asia and Europe. This move is a key step toward achieving the goal of comprehensive global operational audit coverage, aimed at ensuring the company's unified business ethics and compliance standards are implemented across all markets. In terms of audit content, the company will continue to combine systematic routine audits, special audits, and anti-corruption system health assessments to deepen supervision over high-risk areas.

c) Rotation arrangement for institutions: In the annual audit plan, the company conducts rotating audits for different institutions and business departments to ensure the independence and comprehensiveness of audits. The overall rotation arrangement for the business ethics audit "Three-Year Coverage" is as follows: the first year focuses on headquarters, the second year on domestic subsidiaries, and the third year on overseas subsidiaries. At the same time, more frequent reviews are conducted for high-risk areas to address market changes and new compliance challenges.

5) Summary and enhancement of risk assessment, reporting, and audit results

During the reporting period, United Imaging Healthcare identified and summarized several key focus areas in risk assessment and audit results, and implemented a series of improvement measures based on the audit findings. During the implementation of commercial compliance audits, the company identified and addressed potential risk points through on-site interviews, contract reviews, and the examination of compliance training records. For markets identified as high-risk, the company has implemented stricter control measures and intensified audit efforts to ensure strict adherence to anti-corruption and anti-bribery policies by employees and business partners. In terms of conflict of interest management, the audit revealed that some employees failed to update conflict of interest information in a timely manner. The company has initiated a re-examination and established a periodic review mechanism for key positions to ensure the accuracy and timely updating of conflict of interest information.

The Audit Committee regularly listens to work reports from the Audit Department, oversees the independence and effectiveness of internal audit work, and ensures that internal audit activities meet the requirements of the board of directors. During the year, the company conducted routine audits in key areas in accordance with the audit rotation plan, and implemented special audits and anti-corruption system health assessments based on business risks. At the implementation level, the company focused on reviewing the compliance of business collaborations with healthcare professionals, and conducted unannounced inspections on market meetings and activities to ensure strict adherence to regulations and company policies, effectively preventing and controlling corruption risks. Meanwhile, the company conducts follow-up reviews on high-risk areas identified in previous audits, continuously advancing the

“three-year full coverage” plan to ensure business ethics audits cover all global operations.

In the issue confirmation phase, the company employs a “two-way communication” mechanism, combining written material verification with on-site interviews to ensure audit findings are thoroughly validated. After the audit report is finalized, the responsible department is simultaneously required to develop an actionable rectification plan and continuously track the progress of rectification to achieve closed-loop management of issues. Through the audit work during the reporting period, United Imaging Healthcare has completed the first phase of audit tasks and implemented effective rectifications and improvements in relevant areas, ensuring more compliant and transparent future business collaborations. Strategic assurance is thereby provided for the steady development of global operations and sustainable corporate governance.

6) Outlook and Planning

United Imaging Healthcare will continue to implement the risk-oriented internal audit strategy of “prevention, management, and control”, further strengthening internal control and compliance management. For any internal control issues or deficiencies identified during the audit process, the Audit Department will promptly provide improvement recommendations to the relevant management and follow up on the implementation of corrective actions. Through these measures, United Imaging Healthcare is committed to continuously enhancing the efficiency and effectiveness of internal controls, ensuring the legality and compliance of business operations, thereby maintaining and strengthening the company's strong reputation in the industry.

Looking ahead, United Imaging Healthcare's internal audit work will continue to adhere to a risk-oriented approach, constantly enhancing the depth and breadth of commercial ethics internal audits. The company will introduce more advanced audit technologies and tools to further strengthen risk identification and monitoring in key business areas, ensuring the continuous optimization and improvement of the internal control system. Meanwhile, the company will enhance the professional competence of the audit team through systematic training and practice, improving the team's audit capabilities and acumen to cope with the complex and ever-changing market environment and regulatory requirements. Through efficient and independent internal audit work, we ensure the compliance and effectiveness of all business activities, safeguarding the company's sustainable development.

Section III Changes in Shares and Shareholders

I Shareholder information

i. Total number of shareholders:

Total number of common shareholders at the end of the reporting period (households)	16,502
Total number of preferred shareholders with voting rights restored at the end of the reporting period (households)	/
Total number of shareholders holding special voting rights shares at the end of the reporting period (households)	/

ii. Table of the Top 10 Shareholders and Top 10 Shareholders with Unrestricted Shares as of the Reporting Period End

Cases Where the Top 10 Shareholders Hold Shares Through Both Ordinary Securities Accounts and Securities Company Customer Credit Trading Collateral Securities Accounts

Shanghai Yiduan holds 21,024,363 shares through ordinary securities accounts and 5,087,688 shares through investor margin securities accounts.

Unit: shares

Top 10 Shareholders' Shareholding Status (Excluding Shares Lent Out Through Securities Lending)								
Shareholder Name (Full Name)	Increase/Decrease During the Reporting Period	Number of shares held at the end of the period	Percentage (%)	Number of shares with restricted sale conditions held	Number of restricted shares including those lent out through securities lending	Pledge, tagging, or freezing status		Shareholder Nature
						Shares Status	Quantity	

United Imaging Healthcare Technology Group Co., Ltd.	-	167,550,968	20.33	167,550,968	167,550,968	None	-	Domestic Non-State-Owned Legal Entity
Shanghai Alliance Investment Co Ltd	-	134,959,614	16.38	-	-	None	-	State-Owned Legal Entity
Shanghai Yingsheng Investment Partnership (Limited Partnership)	-	60,204,628	7.30	60,204,628	60,204,628	None	-	Other
China Merchants Bank Co., Ltd. - Huaxia SSE STAR Market 50 Constituents ETF	478,747	26,544,624	3.22	-	-	None	-	Unknown
Shanghai Yiduan Investment Co., Ltd.	-281,635	26,112,051	3.17	-	-	None	-	Domestic Non-State-Owned Legal Entity
Shanghai Zhongke Daofu Investment Partnership (Limited Partnership)	-17,157,000	24,306,858	2.95	-	-	None	-	Other
Hong Kong Securities Clearing Company Limited	7,669,955	22,016,540	2.67	-	-	None	-	Unknown
Yan Quanliang	-	20,685,304	2.51	-	-	None	-	Domestic natural person

Industrial and Commercial Bank of China Limited - E Fund SSE STAR Market 50 Index ETF	3,225,025	20,469,875	2.48	-	-	None	-	Unknown
Shanghai Beiyuan Investment Partnership (Limited Partnership)	-11,929,400	16,900,961	2.05	-	-	None	-	Other

Top 10 shareholders with unrestricted sale conditions (excluding shares lent through securities lending)			
Shareholder name	Number of tradable shares held	Types and quantities of shares	
		Type	Quantity
Shanghai Alliance Investment Co Ltd.	134,959,614	Renminbi ordinary shares	134,959,614
China Merchants Bank Co., Ltd. - Huaxia SSE STAR Market 50 Constituents Exchange Traded Open-End Index Securities Investment Fund	26,544,624	Renminbi ordinary shares	26,544,624
Shanghai Yiduan Investment Co., Ltd.	26,112,051	RMB ordinary shares	26,112,051
Shanghai Zhongke Daofu Investment Partnership (Limited Partnership)	24,306,858	RMB ordinary shares	24,306,858
Hong Kong Securities Clearing Company Limited	22,016,540	RMB ordinary shares	22,016,540
Yan Quanliang	20,685,304	RMB ordinary shares	20,685,304
Industrial and Commercial Bank of China Limited - E Fund SSE STAR Market 50 Index ETF	20,469,875	RMB ordinary shares	20,469,875
Shanghai Beiyuan Investment Partnership (Limited Partnership)	16,900,961	Renminbi ordinary shares	16,900,961
Bank of China Limited - Huabao CSI Healthcare Sector Trading Open-End Index Securities Investment Fund	16,389,896	RMB ordinary shares	16,389,896
Ningbo Meishan Free Trade Port Zone Yingli Investment Management Partnership (Limited Partnership)	12,411,182	Renminbi ordinary shares	12,411,182
Ningbo Meishan Free Trade Port Zone Yingkang Investment Management Partnership (Limited Partnership)	12,411,182	Renminbi ordinary shares	12,411,182
Ningbo Meishan Free Trade Port Zone Yingjian Investment Management Partnership (Limited Partnership)	12,411,182	RMB ordinary shares	12,411,182
Explanation of the repurchase special accounts among the top ten shareholders	Not applicable		

Explanation of the above-mentioned shareholders' entrusted voting rights, delegated voting rights, and waived voting rights	Not applicable
Explanation of the relationship or concerted action among the aforementioned shareholders	1. United Imaging Group and Shanghai Yingsheng are enterprises controlled by Xue Min, the actual controller of the company. 2. Zhongke Daofu and Shanghai Beiyuan are both private investment funds managed by Shanghai Daofu Yuantong Equity Investment Management Co., Ltd. as the private fund manager. 3. Ningbo Yingli, Ningbo Yingkang, and Ningbo Yingjian are all employee stock ownership platforms of the company, with Zhang Qiang serving as the executive partner for each. 4. Apart from this, the company has not received any declarations from other shareholders regarding the existence of affiliated relationships or concerted action agreements, and it is unknown whether any such relationships or agreements exist among other shareholders.
Explanation of the restoration of voting rights for preferred shareholders and the number of shares held	Not applicable

Note: Among the shareholders with unrestricted sale conditions, Ningbo Yingli, Ningbo Yingkang, and Ningbo Yingjian are tied for tenth place.

Top 10 shareholders with restricted shares and their restrictions

Unit: share

Serial Number	Name of Shareholder with Restricted Sale Conditions	Number of restricted shares held	Trading status of restricted shares		Sales restrictions
			Tradable date	Newly added tradable shares	
1	United Imaging Healthcare Technology Group Co., Ltd.	167,550,968	2025.8.22	-	36 months from the date of listing
2	Shanghai Yingsheng Investment Partnership (Limited Partnership)	60,204,628	2025.8.22		36 months from the date of listing
3	Shanghai Yingzhi Investment Partnership (Limited Partnership)	3,103,416	2025.8.22	-	36 months from the date of listing
Explanation of the relationship or concerted action among the aforementioned shareholders		United Imaging Group, Shanghai Yingsheng, and Shanghai Yingzhi are enterprises controlled by Xue Min, the actual controller of the company.			

Section IVFinancial report

Consolidated Balance Sheet

June 30, 2025

Prepared by: Shanghai United Imaging Healthcare Co., Ltd.

Unit: Yuan Currency: RMB

Project	June 30, 2025	December 31, 2024
Current assets:		
Cash and cash equivalents	6,565,796,074.82	8,399,997,063.38
Settlement Provision		
Funds lent		
Financial assets held for trading	2,035,980,163.64	1,705,986,636.59
Derivative financial assets	-	489,944.97
Notes receivable	26,496,454.24	1,056,048.00
Accounts receivable	5,080,080,731.16	4,358,808,221.15
Financing receivables		
Prepayments	335,576,410.88	195,777,640.89
Premium receivable		
Reinsurance receivables		
Reinsurance contract reserve		
Other receivables	168,865,064.18	137,492,774.23
Including: Interest receivable		
Dividends receivable		
Financial assets purchased under resale agreements		
Inventories	5,962,281,307.39	5,528,382,408.16
Including: Data Resources		
Contract Assets	69,456,937.34	50,253,819.13
Assets held for sale		
Non-current assets due within one year	385,099,880.04	290,564,565.05

Other current assets	169,734,970.45	225,032,196.91
Total current assets	20,799,367,994.14	20,893,841,318.46
Non-current assets:		
Loans and advances		
Debt investments		
Other debt investments		
Long-term receivables	41,001,381.52	114,605,452.67
Long-term equity investments	186,725,969.65	187,799,803.53
Investments in other equity instruments		
Other non-current financial assets	138,370,307.25	82,366,375.73
Investment property		
Fixed assets	3,145,113,459.37	2,944,033,041.66
Construction in progress	2,041,634,560.74	1,770,074,723.58
Productive biological assets		
Oil and gas assets		
Right-of-use assets	68,517,372.30	82,847,128.12
Intangible assets	1,071,105,861.30	1,004,333,811.10
Including: Data Resources		
Development costs	564,909,459.25	329,169,118.87
Including: Data Resources		
Goodwill	22,104,603.13	22,104,603.13
Long-term deferred expenses	63,760,731.99	67,946,154.27
Deferred income tax assets	453,295,427.17	439,339,625.67
Other non-current assets	83,152,161.64	97,227,715.69
Total non-current assets	7,879,691,295.31	7,141,847,554.02
Total Assets	28,679,059,289.45	28,035,688,872.48
Current liabilities:		
Short-term borrowings	76,287,236.84	557,489,368.89
Borrowings from the central bank		

Borrowed funds		
Trading financial liabilities		
Derivative financial liabilities		
Notes payable	353,273,520.59	520,013,867.50
Accounts payable	2,201,425,281.12	2,087,816,659.14
Advance receipts		
Contract liabilities	2,463,244,541.28	2,139,304,950.07
Funds from repurchase agreements		
Deposits and placements from banks and other financial institutions		
Funds for securities trading on behalf of clients		
Funds for securities underwriting on behalf of clients		
Employee benefits payable	517,343,652.80	578,225,593.32
Taxes payable	410,114,365.05	326,702,443.76
Other payables	582,397,335.28	677,339,798.99
Including: Interest payable		
Dividends payable	65,601,909.76	
Fees and commissions payable		
Reinsurance accounts payable		
Liabilities held for sale		
Non-current liabilities due within one year	36,950,384.05	54,499,168.71
Other current liabilities	133,602,563.75	134,355,301.68
Total current liabilities	6,774,638,880.76	7,075,747,152.06
Non-current liabilities:		
Insurance contract reserves		
Long-term loans		
Bonds payable		
Including: Preferred shares		
Perpetual bond		

Lease liabilities	77,049,569.56	83,997,441.38
Long-term payables		
Long-term employee benefits payable	3,171,240.43	5,642,483.55
Estimated liabilities		
Deferred income	470,127,561.22	461,427,326.26
Deferred tax liabilities	11,179,586.43	12,179,906.91
Other non-current liabilities	556,100,672.36	490,453,489.65
Total non-current liabilities	1,117,628,630.00	1,053,700,647.75
Total liabilities	7,892,267,510.76	8,129,447,799.81
Share capital	824,157,988.00	824,157,988.00
Other equity instruments		
Including: preferred shares		
Perpetual bonds		
Capital reserve	13,909,050,564.95	13,947,476,239.79
Less: Treasury stock	449,839,312.68	449,839,312.68
Other comprehensive income	-17,645,013.00	-14,329,564.58
Special reserve		
Surplus reserve	412,078,994.00	412,078,994.00
General risk reserve		
Undistributed profits	6,116,037,227.36	5,183,621,073.00
Total equity attributable to owners of the parent company	20,793,840,448.63	19,903,165,417.53
Minority interests	-7,048,669.94	3,075,655.14
Total shareholders' equity	20,786,791,778.69	19,906,241,072.67
Total liabilities and shareholders' equity	28,679,059,289.45	28,035,688,872.48

Company Representative: Zhang Qiang Chief Accounting Officer: Wang Jianbao Head of Accounting Department: Li Ping

Consolidated Income Statement

January–June 2025

Unit: Yuan Currency: RMB

Item	First half of 2025	First Half of 2024
I. Total Revenue	6,015,901,402.16	5,333,486,253.17
Including: revenue	6,015,901,402.16	5,333,486,253.17
Interest income		
Earned premiums		
Fee and commission income		
II. Total costs	5,075,101,040.91	4,564,826,089.38
Including: Cost of sales	3,132,664,301.76	2,708,826,710.47
Interest expense		
Fees and commissions expense		
Surrender value		
Net claims paid		
Net withdrawal of insurance liability reserves		
Policy dividend expenses		
Reinsurance expenses		
Taxes and surcharges	30,107,015.65	27,173,585.08
Sales expenses	938,304,878.27	829,404,472.35
Administrative expenses	257,182,484.27	238,744,275.50
R&D expenses	766,458,924.01	826,022,924.17
Finance expenses	-49,616,563.05	-65,345,878.19
Including: Interest expense	5,292,016.92	3,420,713.91
Interest income	-44,496,516.79	-70,968,434.57
Add: Other income	215,480,112.85	252,502,221.60
Investment income ("-" for loss)	39,841,032.04	45,034,348.30
Including: Investment income from associates and joint ventures	-1,073,833.88	-6,808,793.44
Gain on derecognition of financial assets measured at amortized cost ("-" for loss)		
Exchange gain ("-" for loss)		
Net open hedging gains ("-" for loss)		
Fair value change gains ("-" for loss)	-45,441,421.76	7,410,470.99

Credit impairment loss ("-" for loss)	-72,911,342.79	-73,491,375.32
Asset impairment loss ("-" for loss)	-197,713.08	39,520,280.84
Gains on disposal of assets ("-" for loss)	-640,729.77	622,909.34
3. Operating profit ("-" for loss)	1,076,930,298.74	1,040,259,019.54
Add: Non-operating income	2,148,497.13	1,551,981.76
Less: Non-operating expenses	6,106,665.13	2,013,184.16
IV. Total profit before tax ("-" for total loss)	1,072,972,130.74	1,039,797,817.14
Less: Income tax expense	85,076,398.44	95,232,490.90
V. Net profit ("-" for net loss)	987,895,732.30	944,565,326.24
(1) Classification by Business Continuity		
1. Net profit from continuing operations ("-" for net loss)	987,895,732.30	944,565,326.24
2. Net profit from discontinued operations ("-" for net loss)		
1. Net profit attributable to shareholders of the parent company ("-" for net loss)	998,018,064.12	950,211,921.88
2. Net profit attributable to minority interests	-10,122,331.82	-5,646,595.64
VI. Other comprehensive income, net of tax	-3,315,448.42	2,233,137.29
(1) Other comprehensive income, net of tax, attributable to shareholders of the parent company	-3,315,448.42	2,233,137.29
1. Other comprehensive income that cannot be reclassified to profit or loss		
(1) Remeasurement of defined benefit plans		
(2) Other comprehensive income that cannot be reclassified to profit or loss under the equity method		
(3) Fair value changes in other equity instrument investments		
(4) Changes in fair value due to the entity's own credit risk		
2. Other comprehensive income to be reclassified to profit or loss	-3,315,448.42	2,233,137.29
(1) Other comprehensive income under the equity method that can be transferred to profit or loss		
(2) Fair value changes of other debt investments		
(3) Amount of financial assets reclassified to other comprehensive income		

(4) Credit impairment provision for other debt investments		
(5) Cash flow hedge reserve		
(6) Differences on translation of foreign currency ¬financial statements	-3,315,448.42	2,233,137.29
(7) Others		
(2) Net amount of other comprehensive income attributable to minority shareholders after tax		
VII. Total comprehensive income	984,580,283.88	946,798,463.53
(1) Total comprehensive income attributable to owners of the parent company	994,702,615.70	952,445,059.17
(2) Total comprehensive income attributable to minority shareholders	-10,122,331.82	-5,646,595.64
8. Earnings per share:		
(1) Basic earnings per share (RMB/share)	1.21	1.16
(II) Diluted earnings per share (RMB/share)	1.21	1.16

Company Representative: Zhang Qiang Person in Charge of Accounting Work: Wang Jianbao Person in Charge of Accounting Department: Li Ping

Consolidated Cash Flow Statement

January–June 2025

Unit: Yuan Currency: CNY

Project	First half of 2025	First half of 2024
I. Cash flows from operating activities:		
Cash received from sales of goods and rendering of services	6,178,837,680.41	4,341,238,639.46
Net increase in customer deposits and interbank deposits		
Net increase in borrowings from central bank		
Net increase in funds borrowed from other financial institutions		
Cash received from premiums of original insurance contracts		
Net cash received from reinsurance business		
Net increase in policyholder deposits and investment funds		
Cash received from interest, fees, and commissions		

Net increase in funds borrowed		
Net increase in funds from repurchase agreements		
Net cash received from securities brokerage		
Refund of taxes	324,863,010.51	163,707,378.23
Cash received from other operating activities	158,711,457.91	212,489,469.85
Sub-total of cash inflows from operating activities	6,662,412,148.83	4,717,435,487.54
Cash paid for goods and services	3,873,800,637.00	2,753,183,224.42
Net increase in customer loans and advances		
Net increase in deposits with central banks and interbank funds		
Cash paid for claims under original insurance contracts		
Net increase in funds lent		
Cash paid for interest, fees, and commissions		
Cash paid for policy dividends		
Cash paid to and on behalf of employees	1,637,468,936.03	1,511,817,347.06
Payments of taxes	425,196,601.60	531,678,653.41
Cash paid relating to other operating activities	677,186,174.43	545,348,680.82
Sub-total of cash outflows from operating activities	6,613,652,349.06	5,342,027,905.71
Net cash flow from operating activities	48,759,799.77	-624,592,418.17
2. Cash flows from investing activities:		
Cash received from disposal of investments	20,191,246,227.11	8,377,695,000.00
Cash received from returns on investments	44,402,082.08	54,895,927.01
Net cash received from disposal of fixed assets, intangible assets, and other long-term assets	65,400.00	-
Net cash received from disposal of subsidiaries and other business units		
Cash received from other investment-related activities	-	-
Subtotal of cash inflows from investing activities	20,235,713,709.19	8,432,590,927.01
Cash paid to acquire fixed assets, intangible assets and other long-term assets	1,077,380,818.06	977,258,938.74
Cash paid to acquire investments	18,675,232,199.99	7,417,678,901.93

Net increase in pledged loans		
Net cash received from subsidiaries and other business units	-	10,354,444.15
Cash paid for other activities related to investments	-	-
Sub-total of cash outflows from investing activities	19,752,613,018.05	8,405,292,284.82
Net cash flows from investing activities	483,100,691.14	27,298,642.19
III. Cash flows from financing activities:		
Cash received from investments	-	7,800,000.00
Including: Cash received from minority shareholders' investments in subsidiaries	-	7,800,000.00
Cash received from borrowings	71,749,911.33	-
Cash received related to other financing activities		
Sub-total of cash inflows from financing activities	71,749,911.33	7,800,000.00
Cash repayments of borrowings	552,984,320.94	3,455,172.40
Cash payments for distribution of dividends, profits or interest expenses	127,366.72	138,955.57
Including: Dividends and profits paid to minority shareholders by subsidiaries		
Cash paid relating to other financing activities	40,391,520.69	118,287,542.59
Sub-total of cash outflows from financing activities	593,503,208.35	121,881,670.56
Net cash flows from financing activities	-521,753,297.02	-114,081,670.56
IV. Effect of Exchange Rate Changes on Cash and Cash Equivalents	-717,683.65	-5,046,195.91
V. Net (decrease)/increase in cash and cash and cash equivalents	9,389,510.24	-716,421,642.45
Add: Cash and cash equivalents at the beginning of the year	5,867,855,094.11	7,530,632,407.17
VI. Cash and cash equivalents at the end of the year	5,877,244,604.35	6,814,210,764.72

Company Representative: Zhang Qiang Chief Accounting Officer: Wang Jianbao Head of Accounting Department: Li Ping